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ABSTRACT 
 
Myostatin is a negative regulator of muscle mass, and several strategies are 
being developed to knock down the expression of the myostatin gene as a means to 
bring about improvements in muscle wasting conditions, including Duchenne muscular 
dystrophy (DMD). Improved muscle regeneration in the absence of myostatin has been 
demonstrated in mdx mice by crossing them with myostatin null mice. Increased muscle 
strength and improved dystrophic pathophysiology has been found in the mdx mice 
treated with myostatin antibodies, purified myostatin propeptide (natural binding 
partner of myostatin) with a mouse fusion protein and AAV-mediated transfer of 
propeptide. Virus-based strategies have the major drawbacks of uncontrolled insertion 
into the target genome and undesirable immune response; whereas, injecting binding 
partners to the target tissue might have low sustainability over a longer period of time.  
In this study the design and use of antisense oligonucleotides (AOs) to 
manipulate myostatin pre-mRNA splicing and knockdown myostatin has been 
described. AOs of both 2‟O-methyl RNA (2‟OMePS-with a phosphorothioate 
backbone) and phosphorodiamidate morpholino (PMO) chemistries were designed 
using different bioinformatics algorithms. Efficiency of destructive myostatin exon 
skipping was then demonstrated and evaluated comparatively by oligomer transfection 
of cultured muscle cells, and RT-PCR and bioactivity analyses. Sustained and high 
levels of destructive exon skipping of the myostatin mRNA, and increases in skeletal 
muscle mass and fibre sizes was observed up to 2 months following a single injection of 
Vivo-PMO (PMO conjugated to a cell-penetrating octa-guanidine moiety) into the 
tibialis anterior muscle in normal mice. The efficiency of Vivo-PMO was also 
compared to a PMO conjugated to a cell penetrating peptide moiety (B-PMO) by single 
intra muscular treatment of wild type mice. Weekly intravenous injections of Vivo-
PMO in normal mice also lead to myostatin exon skipping in selected skeletal muscles, 
and associated increases in tissue mass, cross-sectional area, and average fibre diameter. 
Dual exon skipping of myostatin and dystrophin was also carried out successfully in 
mdx mice. These studies indicate that (i) antisense-mediated destructive exon skipping 
can be induced in the myostatin RNA, (ii) antisense AO treatment reduces myostatin 
bioactivity and enhances muscle mass in vivo, and (iii) AO-induced myostatin exon-
skipping may be a potential therapeutic strategy to counter muscular dystrophy, 
muscular atrophy, cachexia and sarcopenia.  
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CHAPTER 1 
INTRODUCTION 
 
1.1 General structure and physiology of skeletal muscle 
Skeletal muscle carries out all the voluntary movements of the body. 
Differentiated skeletal muscle cells, or myofibres are multinucleated cells formed as a 
result of fusion of various uninucleate cells called myoblasts. Depending upon the 
whole length of the muscle, individual myofibres vary in length ranging from a few mm 
to over 10 cm (Davies et al., 2001). The diameter of myofibres also varies ranging from 
10-100µm. Each myofibre is composed of myofibrils which are the contractile 
functional units of striated muscle. Myofibrils are surrounded by cytoplasm known as 
sarcoplasm. Myofibres are surrounded by a cell membrane called the sarcolemma to 
which a layer of external connective tissue called the endomysium is attached. Bundles 
of myofibres are further surrounded by another connective tissue layer called the 
perimysium. The whole muscle tissue composed of a series of myofibre bundles is 
covered by a tougher connective tissue layer known as the epimysium (Keynes & 
Aidley, 2001; Marieb, 2009). These connective tissues structures continue beyond the 
length of the muscle tissue and culminate into a tendon which attaches to cartilage or a 
bone as shown in Figure 1.1.  
Skeletal myofibres are striated due to specific arrangement of contractile 
proteins present in myofibrils such as actin and myosin that give them an alternate light 
and dark banded appearance. The so-called A-bands are highly refractile and appear 
dark, whereas I-bands are less refractile and appear lighter. In the middle of the I-band 
there is a dark line called the Z-line (or disc) and in the middle of the dark A-band there 
is a lighter zone called the H-zone with a central darker line called the M-line. The unit 
of length between two Z-lines is called a sarcomere. From either side of the Z-line, the 
I-band extends to the beginning of A-band which is made up of thick myosin filaments 
as shown in Figure 1.1. Myosin filaments are surrounded by actin filaments outside the 
H-zone and these are held in place by the M-line (Davson et al., 1970). The myofibrils 
have been demonstrated to be arranged in groups from four fibrils to twenty fibrils or 
more. These „muscle columns‟ are separated by a 0.2µm-0.5µm sarcoplasmic layer. The 
cross-linking connections between actin and myosin filaments are called crossbridges 
(Davson et al., 1970). 
17 
 
 The A-band does not undergo any change in length either during muscle 
stretching or shortening.  The contraction is brought about by sliding of thin filaments 
(actin-based) between the thick filaments (myosin-based). A series of reactions between 
active sites on actin filaments and projections on myosin filaments take place. The 
projections on myosin filaments attach themselves with actin filaments to form a cross 
bridge and then pull on them, eventually releasing them and moving back to attach to 
another site further along the actin filament (Green, 1968).  
The myosin filaments are composed of around 100 myosin molecules that have 
a golf club like appearance with double heads. Half of these heads point in one direction 
while the rest in opposite direction. These heads have ATPase activity that can release 
energy from ATP and facilitate binding to the actin molecule‟s active site. Between two 
actin strands are laid two strands of tropomyosin that controls the binding of actin 
strands to myosin. The tropomyosin strands alternate with molecules of troponin. At 
rest, tropomyosin and calcium-binding troponin prevent contact between actin and 
myosin filaments. When stimulation takes place, calcium is released that activates 
troponin and leads to comformational changes in tropomyosin facilitating interaction 
between actin and myosin. This results in ATP hydrolysis by myosin heads giving 
energy to myosin to attach to and push along actin filaments. Actin and myosin 
filaments come apart when ADP is re-substituted for ATP (Keynes & Aidley, 2001)  
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Figure 1.1 
                    
 
 
 
 
 
 
 
 
 
Figure 1.1: Diagrammatic representation of the framework of skeletal muscle showing (a) 
various connective tissue layers surrounding the muscle and myofibres within a muscle and (b) 
structure of a myofibril with myosin and actin filaments (Reprinted from Seeley et al., 2006). 
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1.2 Control of skeletal muscle mass in health and disease 
As skeletal muscle is the most abundant tissue in human body, maintenance of 
its mass is very important for strength, posture balance and some very basic and vital 
functions like locomotion and respiration. Muscle fibres are responsible for generating 
mechanical strength. Following an inflammatory, degenerative or traumatic injury, 
muscle progenitor cells transform into active myoblasts which proliferate and fuse into 
myotubes. These myotubes further differentiate into mature muscle myofibres (Wiendl 
et al., 2005).  
Sarcopenia is an unintentional degenerative loss of muscle mass and strength 
related to ageing. Histologically, sarcopenia is characterized by a decrease in myofibre 
number and size (Carmeli et al., 2002). Cachexia, on the other hand, is a metabolic 
syndrome characterized by loss of muscle mass associated with underlying chronic 
diseases such as cancer,  heart failure, kidney failure, AIDS and chronic obstructive 
pulmonary disease (COPD) etc (Evans et al., 2008; Matsakas et al., 2009). There is a 
very tightly regulated balance between skeletal muscle protein breakdown and synthesis 
via a network of signalling pathways. In case of sarcopenia, cachexia and several 
inherited and inflammatory myopathies, this balance between protein synthesis and 
breakdown is disturbed.  
Factors leading to loss of muscle mass and function in sarcopenia have not been 
precisely understood (Cruz-Jentoft et al., 2010). It has been shown by dual-emission X-
ray absorptiometry that the incidence of sarcopenia in humans aged 65-69 years is 14% 
and in those aged 80 years or above is more than 50% (Baumgartner et al., 1998). In 
case of limb muscles, the extent of muscle mass loss may reach up to about 20-30% and 
for the trunk muscles; it may reach up to nearly 40% between the age of 68 and 100 
years (Baumgartner et al., 1998). Key features of age-related skeletal muscle mass 
changes include myofibre atrophy, changes in extracellular matrix composition, 
disruption of contractile apparatus, and neuromuscular junction (NMJ) deterioration 
resulting in denervation of ageing muscle (Chai et al., 2011). Neuromuscular changes 
(including loss or diminished function of neurons in brain and spinal cord, progressive 
degeneration of NMJs and demyelination of nerves) that contribute to denervation of 
myofibre take place within peripheral and central nervous system as well as within 
skeletal muscle (Flood & Coleman, 1988; Luff, 1998). 
It has been reported that the following changes take place during ageing: (a) loss 
of number of motoneurons in the central nervous system (Tomlinson & Irving, 1977), 
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(b) axon demyelination (Knox et al., 1989), (c) nerve terminal withdrawal from NMJs 
(Valdez et al., 2010) and (d) re-innervation of denervated myofibres by the surviving 
motoneurons (Auld & Robitaille, 2003). It is however, not known if the initial myofibre 
denervation results from deleterious changes in neurons or muscle cells or both. It is 
likely that a healthy state of myofibres and motoneurons is the key in the maintenance 
of NMJs (McLennan & Koishi, 2002; Naguib et al., 2002). 
There are also a range of metabolic and signalling factors and pathways 
responsible for controlling skeletal muscle growth and accounting for muscle wasting 
which are described below. 
1.2.1. Protein anabolism and catabolism 
In the autophagic/lysosomal pathway, cell organelles and cytoplasm are 
sequestered into autophagosomes which then fuse with lysosomes, and proteins are 
digested (Lum et al., 2005). Forkhead box O (FoxO) transcriptional factors normally 
inactivated by phosphorylation via PI3K/Akt (Phosphatidyl inositol-3 kinase/ protein 
kinase B, PKB or Akt) pathway (Figure 1.2 (d)) (detailed later) translocate into nucleus 
and induce transcription of skeletal muscle-specific E3 ubiquitin ligases namely MuRF1 
and MAFbx or atrogin 1 (Sandri et al., 2004) as well as some autophagy-related genes, 
LC3 and Bnip3 (Mammucari et al., 2007). In contrast, insulin-like growth factor-1 (IGF-
1) counteracts muscle atrophy by inhibiting autophagy and the ubiquitin-proteasome 
system (UPS) and also induces protein synthesis via the Akt-mTOR (mammalian target 
of rapamycin)-p70
S6K
 (P70-S6k kinase) pathway (Glass, 2003). 
There is conflicting data on the contribution to muscle wasting by the UPS in 
ageing (Bardag-Gorce et al., 1999; Clavel et al., 2006). Therefore, at least in sarcopenia, 
UPS may not be a major pathway leading to muscle loss. Involvement of calcium-
dependent cysteine proteases, calpains, has been reported to be involved in muscle loss 
in ageing rats (Dargelos et al., 2007). In transgenic mice over expressing IGF-1, it was 
evident that sarcopenia was partly prevented (Musaro et al., 2001).  Also, post-
maturational ageing is associated with reduced concentration of serum IGF-1 (Dennis et 
al., 2008). In case of cachexia however, UPS has been reported to be the major 
systemically-activated proteolytic machinery involved. The mRNA levels of ubiquitin 
were found to be two to four times higher in muscles from cancer patients than in 
muscles from control patients (Williams et al., 1999). 
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When Foxo-1 was targeted and reduced in a cancer cachexia mouse model using 
an antisense oligonucleotide, there was also found to be an increase in levels of the 
muscle differentiation transcriptional regulator, MyoD, and a decrease in concentration 
of negative regulator of muscle mass, myostatin (Liu et al., 2007). Besides increased 
catabolism, decreased anabolism has been shown by demonstrating downregulation of 
IGF-1 in animal models of cachexia (Costelli et al., 2006).  
1.2.2. Oxidative stress 
In C2C12 cells, oxidative stress has been shown to induce expression of the E3 
ubiquitin ligase (Li et al., 2003) resulting in an increase in ubiquitin-conjugation and 
proteasome activity, and a decrease in myosin protein levels (Gomes-Marcondes & 
Tisdale, 2002). The chronic state of oxidative stress that exists even under normal 
conditions in muscle is increased with ageing because of an imbalance between 
generation and detoxification of reactive oxygen species (Sohal & Weindruch, 1996). 
Reactive oxygen species are regarded as a crucial factor increasing muscle protein 
catabolism by stimulation of UPS in both cachexia and sarcopenia (Gomes-Marcondes 
& Tisdale, 2002). Also, in both conditions there is an increase in reactive oxygen 
species due to lower activity of antioxidant enzymes (Mantovani et al., 2003).  
1.2.3. Regenerative capacity 
Differentiation of myogenic cells is under the control of myogenic factors 
including MyoD, myogenin and Myf5 (Olson & Klein, 1994). When satellite cells are 
in their quiescent state, MyoD expression is absent but as soon as they become active, 
they start to proliferate and there are high levels of MyoD in their nucleus (Megeney et 
al., 1996). MyoD is however ubiquitinated by atrophy-associated E3 ubiquitin ligase 
and thus degraded by the UPS (Tintignac et al., 2005). In case of muscle atrophy along 
with MuRF1/MAFbx upregulation and increased oxidative stress, the regenerative 
capacity of satellite cells is also impaired (Zaccagnini et al., 2007). 
1.2.4. Steroids 
Testosterone and its derivatives are steroid hormones that bind to cytosolic 
receptors and result in protein synthesis and increase in muscle mass (Bassel-Duby & 
Olson, 2006). This increase in muscle mass is hypertrophic as there is an increase in 
myofibre cross-sectional area of both type I and type II fibres but no change in number 
of fibres (Sinha-Hikim et al., 2002). Ageing-related deficiency in anabolic hormones 
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promotes catabolism, occurring relatively abruptly in the case of estrogen in women at 
menopause, and relatively gradually in the case of testosterone in men. Hormone 
replacement therapy has been studied and resulted in conflicting outcomes for changes 
in lean mass and grip strength (Kenny et al., 2001; Sih et al., 1997). There is a relative 
deficiency of anabolic hormones in cachectic state. A reduced testosterone level might 
lead to reduced muscle strength and bone mass (Zitzmann & Nieschlag, 2000).  
1.2.5. Inflammation 
High levels of inflammatory markers are associated with physical decline in 
older persons (Schaap et al., 2009) and induction of cancer-related muscle wasting 
(Argiles & Lopez-Soriano, 1999). Tumor necrosis factor-α (TNF-α) either in 
combination with other cytokines or on its own can induce mature myotube breakdown 
(Guttridge et al., 2000). In cell culture, TNF-α has been shown to be a potent stimulator 
of MuRF1 and MAFbx expression (Adams et al., 2007b; Li et al., 2005). In some 
animal studies it has been shown that MuRF1 is essential for TNF-α induced reduction 
in muscle function (Adams et al., 2008). When myocytes are exposed to TNF-α, it 
activates a transcription factor NF-κB (Nuclear factor „kappa light chain enhancer‟ of 
activated B-cells) which in turn suppresses MyoD synthesis and inhibits muscle cell 
differentiation (Megeney et al., 1996). Once activated, NF-κB also up-regulates 
cytokine synthesis which could result in further myofibre breakdown (Tisdale, 2000).  
1.2.6. Genetic defect 
Muscular dystrophies are a group of diseases with clinical and molecular 
heterogeneity characterized by skeletal muscle wasting that compromises the mobility 
of a patient. Mostly the mutations affecting the proteins that link the cytoskeleton to the 
basal lamina result in muscular dystrophies. Absence of such proteins cause 
disassembly of the entire multi protein complex and results in sarcolemma fragility in 
particular during intense contractile activity causing damage to the fibres (Blake et al., 
2002). The dystrophinopathies include muscle disease caused by mutations in 
dystrophin gene which links the muscle cytoskeleton with the extracellular matrix. The 
phenotype ranges from asymptomatic increase in serum creatine kinase level and 
muscle cramps to progressive muscle diseases including Duchenne or Becker muscular 
dystrophy (where skeletal muscle is primarily affected) and dystrophin-associated 
dilated cardiomyopathy (DCM), where heart is primarily affected. Whereas mutations in 
the dystrophin gene lead to Duchenne muscular dystrophy (DMD) and Becker muscular 
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dystrophy (BMD), mutations in the genes encoding sarcoglycan complex result in limb 
girdle muscular dystrophies (LGMD) (Swaggart et al., 2011). LGMD patients generally 
show muscle weakness restricted to limb musculature (greater proximal than distal) 
(van der Kooi et al., 1994). In congenital muscular dystrophy (CMD), there is severe 
muscle hypotonia at birth or within first few months of life. Symptoms also include 
generalised muscle weakness and contractures of variable severity. CMD is caused in 
approximately 50% of the cases by deficiency of an extracellular matrix protein, the α2 
chain of laminin-2 (merosin). There are also other types of CMDs that are related to 
collagen VI or abnormal glycosylation of α-dystroglycan or integrin deficiency (Reed, 
2009). Facioscapulohumeral muscular dystrophy (FSHD) is present typically before the 
age of 20 and results in marked weakness of facial muscles and stabilizers of scapula or 
dorsiflexors of foot. Weakness is slowly progressive and about 20% of the patients are 
restricted to wheelchair.  In 95% of affected FSHD patients, a deletion of integral copies 
of 3.3kb DNA repeat motif called D4Z4 is detected. Oculopharyngeal muscular 
dystrophy (OPMD) usually has a late-onset (after the age of 45 years) and it is 
characterized by eyelid drooping and swallowing difficulties. As the disease progresses, 
limb and facial muscle weakness is also observed. It is caused by a defect in exon 1 of 
polyadenylate binding protein nuclear 1 (PABN1) encoding gene. PABN1 is 
responsible for efficient and progressive polymerisation and size control of poly (A) 
tails on the 3‟ ends of eukaryotic genes. A normal allele contains ten GCG trinucleotide 
repeats, whereas autosomal dominant allele ranges in size from 12-17 GCN repeats and 
autosomal recessive allele has eleven GCN repeats (Robinson et al., 2006). 
In DMD, weakness of respiratory and cardiac muscles due to lack of dystrophin 
protein causing respiratory or/and cardiac failure and subsequent premature death 
(Emery, 2002). Dystrophic satellite cells also have the same molecular defect and they 
produce fibres susceptible to degeneration.  The satellite cell population is exhausted 
with time and there is progressive replacement of muscle tissue with adipose and 
connective tissue (Blake et al., 2002).   
Hereditary neuropathies are neurological conditions that are characterized by 
progressive loss of motor and/or sensory function and muscular atrophy. Motor axons 
are responsible for conduction of action potential from brain and spinal cord to skeletal 
muscles, whereas sensory axons conduct in the opposite direction. Peripheral nerves 
connect the brain and spinal cord to the rest of the body (Scherer, 2011). Functional 
damage to the peripheral nerves results in peripheral neuropathy. Hereditary peripheral 
24 
 
neuropathies are known as Charcot-Marie-Tooth (CMT) disease after the names of the 
physicians who described them first. The classification of CMT is based on severity of 
clinical symptoms and the type of primarily affected cells [myelin sheath (CMT1) or 
axon (CMT2)] (Vance, 1991). It is also classified based on whether sensory, motor 
and/or autonomic peripheral neurons are affected (Vance, 1991). In the case of inherited 
demyelinated neuropathies, although demyelination is a primary pathology, axon 
degeneration is a long-term consequence. Some patients have minimal symptoms while 
others may become wheelchair-dependent. In an inherited axonal neuropathy, 
demyelination takes place as a secondary symptom to axonal degeneration (Scherer & 
Wrabetz, 2008).  
Familial amyotrophic lateral sclerosis (FALS), also known as Lou Gehrig‟s 
disease, is a fatal neurodegenerative disease of upper and lower motor neurons resulting 
in gradual degeneration and death of motor neurons (Siddique & Ajroud-Driss, 2011). 
Superoxide dismutase 1 (SOD1) is an enzyme that is responsible for destroying free 
superoxide radicals in the body. Mutations in this gene have been linked with FALS 
(Rosen, 1993). A4V (Alanine at codon 4 changed to valine) and H46R (Histidine at 
codon 46 changed to Arginine) mutations have been shown to be the most common 
FALS-causing mutations in American and Japanese population respectively. At least ten 
other genes have been linked to FALS (Cudkowicz et al., 1997). 
Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular 
disorder resulting from loss of function of survival of motor neuron 1 gene (Lefebvre et 
al., 1995).  SMA is characterized by progressive loss of α-motor neurons in the anterior 
of the spinal cord resulting in trunk and limb paralysis along with atrophy of voluntary 
muscles (Munsat & Davies, 1992).  Spinal and bulbar muscular atrophy (SBMA) or 
Kennedy‟s disease is an X-linked neurodegenerative disease caused by trinucleotide 
(CAG) repeat expansion in the androgen receptor gene resulting in toxic gain of 
function in mutant protein (Finsterer, 2009). SBMA pathology includes loss of primary 
motor neurons in the brain stem and spinal cord (Beitel et al., 2005). Muscle cramps, 
arm and leg weakness, difficulty with swallowing and speech are some of the symptoms 
of SBMA apart from androgen sensitivity including reduced fertility and breast 
enlargement (Rhodes et al., 2009). Huntington‟s disease is another inherited 
neurodegenerative disease in which there is a CAG repeat expansion which results in to 
a polyglutamine stretch translation in exon 1 of huntingtin gene. It affects muscle 
coordination and causes cognitive decline and dementia (Khoshnan & Patterson, 2011).  
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1.3 Negative growth regulation of skeletal muscle mass: Role of myostatin 
Although there have been immense advances in the knowledge of various 
molecules and strategies that are active in cell proliferation and differentiation, a lot is 
still to be investigated regarding tissue size control. It was proposed decades ago that 
there exist certain negative growth regulators (or chalones) secreted by individual 
tissues which act to restrict the growth of the tissue that produces them (Bullough, 1962; 
1965). Due to lack of sufficient evidence in support of the existence of such molecules 
with the characteristics of a „negative growth regulator‟, this hypothesis was initially 
discarded. However, over the last decade or so, research in the field of skeletal muscle 
structure and function strongly suggests that this tissue does control its own mass 
through a regulatory mechanism that involves an endogenous negative muscle mass 
regulator called myostatin or GDF 8 (growth and differentiation factor 8) (Lee, 2004). 
In particular the study of natural and transgenic mutations in the myostatin gene have 
been shown to lead to major increases in muscle mass in cattle, mice and dogs as well 
as humans, and based on this various approaches have been explored to develop 
myostatin-targeted strategies that would lead to recovery of muscle mass and function 
in various muscle wasting conditions. Myostatin-null mice were also reported to have 
significantly lower fat accumulation and propensity to insulin resistance, suggesting that 
inhibiting the myostatin pathway could be a potential therapy for obesity as well as type 
II diabetes (Lin et al., 2002; McPherron & Lee, 2002). 
Initially myostatin was thought to be expressed predominantly in developing 
muscle. However, recent studies have demonstrated myostatin expression in adult tissue 
in different animal species (Ji et al., 1998; Ostbye et al., 2001; Rodgers et al., 2001). 
Myostatin is first expressed in the myotome compartment of somites on 9.5
th
 day of 
embryonic development in mice. The expression is observed from there on throughout 
embryogenesis in skeletal muscles (Lee, 2004). Myostatin is expressed in adult tissue 
predominantly in skeletal muscles with adipose tissue also expressing detectable levels 
of myostatin RNA. The level of myostatin in different skeletal muscles varies from 
muscle to muscle (Lee, 2004).  
The myostatin gene has a simple molecular arrangement. It has three exons 
separated by two intervening introns (Gonzalez-Cadavid et al., 1998) as shown in 
Figure 1.2. The myostatin protein sequence has an N-terminal propeptide domain 
(~38kDa and also known as latency associated protein or LAP-fragment) with a small 
signal sequence, and a C-terminal receptor-binding domain (12kDa) that gives rise to 
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active peptide. Myostatin gene sequences are highly conserved among various 
mammalian species including humans, pigs, mice, rats as well as in chickens as 
determined by genomic southern analysis (Maccatrozzo et al., 2001; McPherron et al., 
1997; Ostbye et al., 2001; Rescan et al., 2001; Roberts & Goetz, 2001). Myostatin 
sequence conservation in various species proposes that mutation of this gene would also 
then have a similar effect on its function across these species. Mice with a deletion of a 
part of the myostatin gene encoding C-terminal domain have been demonstrated to have 
individual muscles weighing up to twice as much as the wild type mice as shown in 
Figure 1.3 (McPherron et al., 1997). This increase in muscle mass was attributed to 
both an increase in number (hyperplasia) as well as size (hypertrophy) of myofibres. 
Homozygous mutant mice weighed ~100% more, whereas the heterozygotes  weighed 
~25% more than their wild type counterparts (McPherron & Lee, 2002). A natural 
myostatin mutation has been identified in cattle, which is related to increased skeletal 
muscle mass (McPherron et al., 1997). The myostatin sequence of a breed of cattle 
called the Belgian Blue has a deletion of 11 nucleotides in the third exon resulting in a 
frame shift mutation and eventual loss of the entire active mature region of the 
myostatin protein. Another cattle breed called Piedmontese carries a missense mutation 
in the third exon of myostatin (McPherron & Lee, 1997). A mutation in myostatin gene 
in whippet dogs has been described to result into double muscling, the phenotype being 
typically called „bully‟ whippet (Mosher et al., 2007) (Figure 1.4 A). In these dogs 
there is a 2bp deletion in the third exon of the myostatin gene that leads to a premature 
stop codon and thereby, removal of 63 amino acids from the C-terminal domain of the 
protein. Heterozygous”bully” whippets with one copy of the mutant gene have 
increased muscle size and enhanced athletic performance compared to the normal 
whippets. However, homozygous”bully” whippets with two copies of mutant allele 
have a double muscling phenotype similar to double-muscled cattle with myostatin 
deficiency (Mosher et al., 2007).  Schuelke et al. were the first to identify a natural 
myostatin mutation in a human child in 2004 (Schuelke et al., 2004) (Figure 1.4 B). All 
the exons and flanking intron regions of the patient‟s and his mother‟s gene were 
sequenced. There was a ga transition in intron 1 of both the alleles of the patient and 
in one allele of his mother. Two PCR products were detected from the RNA of mutant 
construct by an RT-PCR across the boundary between exon 1 and exon 2. One band 
was equivalent in size to the full length band obtained for wild type construct whereas 
the second band contained an insertion of 108 bp of intron 1 that resulted from 
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activation of a cryptic splice site within intron 1. Quantification of band intensities 
showed that nearly 68% of myostatin mRNA from the mutant construct was misspliced 
(Schuelke et al., 2004). 
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Figure 1.2 (a) 
                                                                                                                                                                                                                                                                   
 
 
 
Figure 1.2 (a): Structural organization of myostatin gene. Myostatin gene is composed of 3 
exons and two introns. Pre-mRNA splicing removes the intervening introns and translation 
takes place that results in the formation of latent myostatin that is attached to its natural binding 
partner called propeptide. The numbers above and below boxes in the figure indicate the amino 
acid residue positions in human gene. SS represent the signal sequence. Position of mutations in 
Belgium blue and Piedmontese cattle breed are roughly indicated by „B‟ and „P‟ respectively 
(Figure adapted from (Patel & Amthor, 2005)). At the bottom, an arrangement and sizes of 
exons and introns for other species (mouse, chicken and rat) are also shown for comparison 
(Figure adapted from (Rodgers & Garikipati, 2008)). 
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Figure 1.2 (b) 
Figure 1.2 (b): Myostatin protein processing. Synthesized as a precursor, myostatin 
undergoes two proteolytic cleavage events. (A) One cleavage removes the N-terminal signal 
sequence and second cleavage generates a C-terminal fragment with receptor-binding activity. 
(B) Propeptide and C-terminal dimer remain non-covalently bound, until (C, D) myostatin is 
activated by cleavage of propeptide by BMP-1/tolloid family of metalloproteinases.Figure 
adapted from (Lee, 2004) 
 
Figure 1.2 (c) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 (c): A general overview of pathways activated by myostatin. Myostatin activates 
its receptors on binding them and results in decrease in muscle growth and differentiation. 
Various antagonists like propeptide, follistatin, FLRG etc. block myostatin activation and 
therefore inhibit its function (Figure adapted from (Elkina et al., 2011)). 
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Figure 1.2 (d) 
 
 
Figure 1.2 (d): Myostatin signalling pathway: In response to IGF signalling, Akt/mTOR 
pathway is activated and results in phosphorylation of Akt which further inhibits FOXO nuclear 
entry thereby preventing induction of gene expression of muscle atrophy mediators. Activated 
Akt is also responsible for increased protein synthesis resulting from activation of its 
downstream targets mTOR and P70
S6K
. Mature myostatin binds to AcRII (type B to higher 
extent than type A) which activates AcRI. This further activates Smad 2/3 which form a 
complex with co-smad 4. This smad complex then translocates into the nucleus where it initiates 
the gene transcription. Myostatin inhibits Akt activation and therefore favours protein 
degradation. MAPK activation by myostatin results in blockade of genes responsible for 
myogenesis (Figure adapted from (Elkina et al., 2011)). 
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Figure 1.3 
                                                  
 
Figure 1.3: Myostatin null mice with increased muscle mass compared to normal mouse as 
shown in the upper limb (reprinted from McPherron et al., 1997)  
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Figure 1.4 
 
(A) 
 
 
                    
 (B) 
                                                   
(C) 
 
 
 
 
 
 
 
Figure 1.4: Natural Myostatin mutations in dog and a human child: (A). Comparative 
images of whippets with wild type genotype; with one normal and one mutant allele; and with 
two copies of mutant alleles. (B). A child pictured at 6 days and 7 months of age with a 
mutation in myostatin gene shown to have protruding calf and thigh muscles.(Reprinted (A): 
Mosher, 2007; (B): Schuelke, 2004). (C). Comparison of human myostatin protein sequence to 
other species for degree of conservation.  
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1.4 Myostatin signalling pathway 
Myostatin is synthesized as a pre-propeptide that undergoes proteolytic 
processing to produce biologically active myostatin. Depending upon post-translational 
modifications, myostatin can exist in either active or inactive states (Hill et al., 2002; 
Thies et al., 2001). Proteolytic processing involves removal of the N-terminal signal 
peptide and generation of mature domain capable of binding to its receptor (Wakefield 
et al., 1989). After proteolytic processing, the propeptide and disulphide-linked C-
terminal dimer remains bound to each other non-covalently. Further cleavage of 
propeptide by members of BMP1 (Bone morphogenetic protein 1)/Tolloid family of 
metalloproteinases is required to allow the dissociation of propeptide and mature region 
(McPherron et al., 1997) (Figure 1.2 (b)). It has been shown that propeptide region of 
TGF-β family members can also form disulphide linkages with latent TGF-β proteins 
(LTBP), a class of polypeptides. These latent proteins are responsible for increasing the 
rate of TGF-β secretion. When the complex consisting of mature region, propeptide 
region and the LTBP is secreted, non-covalent links are formed by the LTBP with the 
extra cellular matrix (ECM) components allowing large quantities of TGF-β to be stored 
in the ECM in an inactive form (Taipale et al., 1994). Myostatin is present in the serum 
in its inactive form (Hill et al., 2002) but there is inconsistency in the data regarding 
active myostatin detection in serum (Gonzalez-Cadavid et al., 1998; Zimmers et al., 
2002) which is likely to be due to different antibodies used for myostatin detection with 
different specificities. 
A majority of TGF-β superfamily members induce a signalling cascade through 
heterodimeric complexes of serine/threonine kinase receptors of type I and type II (also 
known as activin receptors type I and II). The TGF-β members bind to the activin 
receptor II (ActRIIB to a greater extent than ActRIIA) first and then to the receptor I 
(ActRI) thereby leading to phosphorylation of type I receptor kinases by type II receptor 
kinases (Chen et al., 1998). Type I receptor kinases then in turn phosphorylate and 
activate Smad proteins which are a cluster of transcription factor molecules downstream 
of the TGF-β receptors acting as signal transducers. Upon activation, Smad2 and Smad3 
form heterodimers with co-Smad, Smad4. This activated complex then moves from 
cytoplasm to nucleus where the target gene transcription is regulated (Langley et al., 
2002a; Shi & Massague, 2003).  
Double muscling cattle with natural myostatin mutation have increased 
formation of type IIB fibres (fast glycolytic fibres) in their biceps (Stavaux et al., 1994).  
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Myostatin null mice have increased type IIB but decreased type I and type IIA fibres in 
tibialis anterior (TA) and biceps. A decrease in fatigue resistance of the myostatin null 
biceps demonstrated by functional electrical stimulation supports the increase in type 
IIB fibre content (Girgenrath et al., 2005). Myocyte enhancer factor 2 (MEF2) has an 
important role in the formation of oxidative type I fibres and therefore myostatin null 
muscle has been reported to have reduced levels of MEF2 and that of downstream genes 
like calcineurin (Wu et al., 2000). Fast fibres have high levels of early muscle 
differentiation marker, MyoD and therefore myostatin null muscle were revealed to 
have increased levels of MyoD (Hennebry et al., 2009). Transcriptional regulators of 
myogenic cell proliferation, Pax-3 and Myf-5 and correspondingly MyoD are 
downregulated in response to myostatin (Devitt et al., 1997). 
Myoblast differentiation and myotube hypertrophy are known to be mediated by 
the Akt/mTOR/p70S6 pathway. Induction of hypertrophy in adult skeletal muscle has 
been shown to be accompanied by increase in level of IGF-1 (DeVol et al., 1990). IGF-
1 binds to its receptor and leads to activation of phosphatidyl-inositol-3-kinase (PI3K) 
along with various other intracellular kinases. A membrane phospholipid, phosphatidyl-
inositol-4,5-bisphosphate is then phosphorylated by PI3K into phosphatidyl-inositol-
3,4,5-trisphosphate, which results in creation of a lipid-binding site for Akt on cell 
membrane. This in turn facilitates phosphorylation and activation of Akt by a kinase 
called PDK-1 (Vivanco & Sawyers, 2002). Various downstream targets of Akt include 
key regulatory proteins like mTOR and p70
S6K 
involved in protein synthesis and 
translation (Cross et al., 1995; Nave et al., 1999). Myostatin has been shown to inhibit 
the IGF-1/PI3K/Akt pathway by mediating hypophosphorylation of Akt and thus 
reduces the muscle growth (Trendelenburg et al., 2009). Hypophosphorylation of Akt 
leads to reduced levels of phosphorylation of FoxO1 and therefore an increase in levels 
of the atrophy mediator, atrogin-1 or MaFbx which activates ubiquitin E3 ligase 
(Langley et al., 2002a). Therefore, myostatin is understood to inhibit the myotube 
hypertrophy which is induced by IGF-I and the activation of Akt (Morissette et al., 
2009) (See Figure 1.2 (d)). 
Myostatin has been shown to mediate polyubiquitination of cyclin D1, thereby 
inhibiting G1 to S phase progression (Yang et al., 2007). Myostatin also activates TGF-
β-activated kinase 1 (TAK-1) which further activates p38 mitogen-activated protein 
kinase (MAPK). This is followed by an increase in levels of cyclin dependent kinase 
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inhibitor, p21 and thereby, a change in retinoblastoma protein phosphorylation status 
which blocks the G1 to S-phase progression (Philip et al., 2005). 
Myostatin has been demonstrated to also have a key regulatory role in skeletal 
muscle fibrosis. Expression of myostatin and its receptor ActRIIB on muscle fibroblasts 
and induction of fibroblast proliferation along with ECM protein synthesis has been 
reported both in vitro and in vivo. This muscle fibroblast proliferation involves the 
Smad, p38 MAPK and PI3K/Akt/mTOR signalling pathways (Li et al., 2008).  
1.5 Natural and therapeutic mechanisms of myostatin inhibition 
The following strategies have been studied with an aim to inhibit the expression of 
myostatin gene. 
1.5.1. Myostatin propeptide 
Regulation of myostatin signalling has been extensively studied by recognizing 
various different inhibitors of myostatin that could be important in muscle growth 
promotion. Studies have shown that if myostatin is bound to its natural binding partner, 
the myostatin propeptide, it leads to myostatin inhibition due to its unavailability to bind 
to ActRIIB. Systemic administration of Adeno-associated virus-8 (AAV8) vector 
expressing mutated myostatin propeptide (AAV8ProMyo) to healthy mice led to 
myofibre hypertrophy which resulted in increase in muscle mass of the TA, extensor 
digitorum longus (EDL), gastrocnemius and rectus femoris muscles (Matsakas et al., 
2009). Another interesting study on systemic administration of AAV8ProMyo has 
shown that an increase in slow (soleus) muscle mass resulted in increased force output 
but the same was not observed in the fast (EDL) muscle mass. Therefore, it has been 
suggested that myostatin inhibition  might have muscle- or fibre-type specific effects in 
terms of remodelling muscle mass and strength (Foster et al., 2009). 
         A dominant negative myostatin transgene (dnMstat) has been reportedly 
synthesized by deleting C-terminal region of isolated myostatin gene and introducing a 
mutation to produce a peptide that is resistant to proteolytic activation (Morine et al., 
2010). This transgene was cloned into an AAV vector along with a liver specific 
promoter and then injected into mdx mice. This treatment resulted in increased skeletal 
muscle mass which was comparable to the increase obtained with other approaches such 
as use of myostatin propeptide and neutralizing antibodies to knockdown myostatin 
(Morine et al., 2010). 
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1.5.2. Follistatin and related proteins 
First isolated from the ovary, follistatin suppresses the follicle stimulating 
hormone (FSH). However, follistatin has also been shown to be a myostatin antagonist 
that binds to myostatin and blocks its association with the ActRIIB. Therefore, 
follistatin can lead to inhibition of myostatin activity, but as a potential therapeutic 
approach invokes serious concerns about adverse effects on reproductive capabilities 
(Lee et al., 2004). However, a strategy using AAV based delivery system to deliver a 
form of alternatively spliced follistatin has been reported to increase muscle mass and 
size, largely bypassing adverse off-target side-effects (Rodino-Klapac et al., 2009). 
Follistatin-related gene (FLRG) and growth and differentiation factor association 
protein (GASP-1) are two other proteins that are found associated with mature 
myostatin in human as well as mouse blood. They both bind to the C-terminal dimers 
and have been shown to inhibit the activity of myostatin in signalling assays (Hill et al., 
2002; Hill et al., 2003).  
1.5.3. Activin Receptor type IIB (ActRIIB) 
Transgenic mice have been produced overexpressing a truncated form of the 
ActRIIB receptor, as the dominant negative form, capable of binding and sequestering 
myostatin but unable to initiate the signalling pathway. In these animals muscle 
hyperplasia as well as hypertrophy leads to significant increases in muscle mass (Lee & 
McPherron, 2001). Furthermore as a potential recombinant therapeutic protein, an 
ActRIIB-Fc fusion protein has been generated by fusing the human IgG1 Fc domain to 
the extracellular domain of ActRIIB lacking the intracellular kinase domain (Lee et al., 
2005).  The extracellular domain is responsible for the TGF-β binding whereas the Fc 
domain of human IgG1 helps in homodimer formation which allows high receptor 
affinity for myostatin. The ActRIIB-Fc fusion protein was shown to inhibit myostatin 
signalling in A204 cells via a pGL3-(CAGA)12-luciferase reporter system (Lee et al., 
2005). The ActRIIB-Fc fusion protein was also tested in mice that were treated with 
intraperitoneal injections leading to 30-60% dose-dependent increases in body weight 
(Lee et al., 2005).  
Acceleron has reported a single-dose and repeated doses sub-cutaneous studies 
of ACE-031 (a soluble form of ActRIIB) in healthy volunteers 
(http://www.acceleronpharma.com/products/ace-031/). And a phase 2 study in patients 
with Duchenne muscular dystrophy (ACE-031) has been conducted in Canada.  The 
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main purpose of the studies was to determine if ACE-031 is safe and well-tolerated in 
children with DMD.  Another purpose of the study was to obtain preliminary 
information regarding the effects of ACE-031 on muscle size, strength and function in 
patients with DMD.  In all of the clinical trials conducted to date, increases in muscle 
mass were reported with ACE-031 treatment.   During the course of clinical trials in 
healthy adults and in DMD boys, some participants experienced minor nosebleeds, gum 
bleeding and/or small dilated blood vessels within the skin.  The majority of these 
events resolved fully upon discontinuation of treatment.  By themselves, the minor 
bleeding events and dilated blood vessels were not considered to be a serious safety 
concern for study subjects.   However, based on review of these preliminary safety data 
with the FDA and Health Canada, Acceleron ended the DMD trial and the follow-on 
extension studies. Acceleron reports that they intend to resume studies of ACE 031 in 
DMD as soon as possible pending further analysis of safety data and following 
discussions with regulatory agencies. 
1.5.4. BMP-1 (Bone morphogenetic protein-1)/Tolloid family of metalloproteins 
BMP-1/Tolloid family of metalloproteins and related proteinases like mTLL-1, 
mTLL-2 and mTLD cleave and release the mature myostatin fragment from its natural 
binding partner (myostatin propeptide) and allow the activation of activin receptors 
(Wolfman et al., 2003). Therefore, proteases that are modified structurally in such a 
way that despite being able to bind to myostatin, they are unable to cleave it from 
propeptide, can restrict the activation of ActRIIB and eventually the myostatin effect on 
the muscle function. 
1.5.5. Antibodies against myostatin 
The mouse anti-myostatin monoclonal blocking antibody, JA16 was raised 
against recombinant myostatin to inhibit myostatin binding to its receptor ActRIIB. 
Intraperitoneal injections of JA16 for twelve weeks have been reported to lead to an 
increase in body weight, muscle mass and absolute muscle strength along with decrease 
in levels of serum creatine kinase and muscle degeneration in mdx mouse, a model of 
Duchenne muscular dystrophy (Bogdanovich et al., 2002). A phase I/II clinical safety 
trial conducted for another myostatin neutralizing antibody, MYO-029 showed good 
tolerability and safety profiles (Wagner et al., 2008).  
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1.6 Other RNA-based therapy for gene expression modulation  
Regulation of pre-mRNA processing in a specific and precise manner is very 
crucial in directing gene expression (Sharp, 2009). This process known as pre-mRNA 
splicing includes removal of the introns to produce a mature mRNA transcript 
containing a single open reading frame coding regions. This mature mRNA is then 
translated into a functional protein (Crick, 1979). Alternative splicing contributes to 
proteomic diversity (Schmucker & Flanagan, 2004) and defects in alternative splicing 
have been demonstrated to be the cause of various disorders (Licatalosi et al., 2008).  
1.6.1. Pre-mRNA splicing 
The removal of introns in a precise fashion is a key event in the expression of 
genes. This RNA splicing machinery has a very crucial role in the recognition and 
elimination of introns, and the fusion of exons in a very specific manner. In the case of 
alternative splicing, different isoforms of proteins perhaps having diverse functions can 
be generated through regulated splicing mechanism and spice site and exon recognition 
(Collins & Guthrie, 2000). Splice sites are specific sequences that are present at 
intron/exon boundaries and play an important role in directing the omission of introns 
and fusion of exons in mRNA. The 5‟-end of the intron has a 5‟-splice site at the 
junction of intron and exon with consensus sequence and a GU dinucleotide at the 
intronic end. The 3‟ end of the intron also has a consensus 3‟-splice site which is 
characterized by conserved sequences including a terminal AG right at the 3‟ end, a 
polypyrimidine tract in the middle, and a branch point (Black, 2003). 
Five different small nuclear ribonucleoproteins (snRNPs) namely, U1, U2, U4, 
U5 and U6 along with several other non-snRNPs form the spliceosome complex as 
shown in Figure 1.5 (Collins & Guthrie, 2000) which is responsible for specific  
recognition of exons and introns, and for carrying out the two transesterification steps 
involved in the splicing process. The snRNA of U1 snRNP base pairs with and binds to 
the 5‟-splice site. SF1, a branch point binding protein, then binds the components of the 
3‟splice site. U2 auxillary factor (U2AF) is a dimer composed of two subunits that are 
65kDa and 35kDA in size. The 65kDA subunit of U2AF binds to the polypyrimidine 
tract whereas in some cases the smaller subunit of U2AF binds to the terminal AG at 3‟ 
splice site. U1 and U2AF attached to either end of the intron constitute the early (E) 
spliceosome complex, also known as the commitment complex. U2 snRNA binds to this 
E-complex via base pairing with the branch point, thereby forming the A-complex. This 
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A-complex is then joined by U4/U5/U6 to form the B-complex which then undergoes 
reorganization to replace U1 snRNP with U6 snRNP and remove U1 and U4 snRNPs, 
and thus form a C-complex (Black, 2003; Nilsen, 1996; 2002).  The C-complex then 
catalyzes the two chemical reactions of splicing (Figure 1.6).  
First of all, the phosphate at the 5‟ splice site is attacked by the 2‟-OH group of a 
specific branch point A residue. This results in cleavage of the exon at 5‟ end and fusion 
of 2‟-OH group with the 5‟ end of the intron. Two intermediate products are formed as 
an outcome of this reaction which are, (i) the 5‟ exon released from the mRNA and (ii) a 
5‟ intron and 3‟ exon fragment. This is followed by an attack by the 3‟-OH of the 
released exon on the phosphate group at the 3‟ end of the intron resulting in fusion of 
the two exons and elimination of the intron which is in a lariat conformation (Black, 
2003).  
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Figure 1.5 
 
 
 
Figure 1.5: Spliceosomal assembly before transesterfication reactions for splicing. The 
small nuclear ribonucleoprotein (snRNP), U1 binds to the 5‟ splice site at the 5‟end of the 
intron/exon boundary which is followed by SF1 binding to the 3‟ splice site and U2 auxillary 
factor (U2AF) binding to the 3‟ splice site of the intron. A 65kDa subunit of U2AF binds to the 
polypyrimidine tract in the middle, whereas a smaller subunit of U2AF binds to 3‟ terminal AG. 
Binding of these two snRNPs to the intron results in the formation of a complex namely E 
complex (or early complex). The E complex is then joined by U2 snRNA resulting in the 
formation of the A complex. This complex is then bound by U4/U5/U6 (forming B complex) 
which is followed by re-arrangement involving replacement of U1 with U6 and then removal of 
U1 and U4. The resulting complex is known as C complex. (Diagram modified from Black, 
2003) 
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Figure 1.6 
                                               
 
 
 
 
 
 
Figure 1.6: Transesterification reactions involved in splicing. A 2‟-OH group on a specific 
A- residue at the branch point attacks the phosphate group at 5‟ splice site of the intron. This 
leads to release of exon at 5‟ end and fusion of 2‟-OH group on the residue A to the 5‟ end of 
the intron. This is followed by an attack on the phosphate group of the 3‟ end of the intron by 
the 3‟-OH of the released exon. The final product therefore is two exons fused together with the 
removal of intron in a lariat conformation. (Diagram modified from Black, 2003) 
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Targeting the defects in the pre-mRNA splicing as in the case of various genetic 
disorders by RNA modulation or splice correction overcomes the following flaws of 
conventional gene replacement therapies, (a) transgene size limitations, (b) low gene 
transfer efficiency, (c) insertion into the host genome and (d) immunological response 
to the vector components (Wood et al., 2007). RNA modulation can therefore be used in 
removal of the target mRNA, mRNA repair or in alteration of the final mRNA product 
(Aartsma-Rus & van Ommen, 2007). Modulation of pre-mRNA splicing has been 
investigated as a potential treatment for various disease conditions.  
1.6.2. RNA interference 
RNA interference (RNAi) is a mechanism of double stranded RNA (dsRNA)-
mediated mRNA silencing that can regulate endogenous gene expression. The double 
stranded RNA molecule is degraded by an endogenous ribonuclease (Dicer) into smaller 
fragments which are about 21-23 nucleotide long and are called small interfering RNAs 
(siRNAs) (Grishok et al., 2000; Zamore et al., 2000). A protein complex known as 
RNA-induced silencing complex (RISC) is then bound by the siRNAs. The RISC has a 
helicase as well as endonuclease activity. The two strands of the siRNA molecules are 
unwound by the helicase activity of RISC so that the antisense strands are facilitated to 
bind the targeted RNA molecule (Sharp & Zamore, 2000). The target RNA molecule is 
then hydrolyzed at the point of contact with the antisense strand by the endonuclease 
activity (Hutvagner & Zamore, 2002; Schwarz et al., 2002). It is possible to induce 
RNAi exogenously by expression of duplexes of microRNA (miRNA) and short hairpin 
RNA (shRNA) with the viral vectors or by incorporating synthetic siRNA (de 
Fougerolles et al., 2007; Liu et al., 2008; Sledz & Williams, 2005). 
Activation of exogenous siRNA-induced RNAi has a very promising therapeutic 
potential. Apart from knocking down the expression of genes that implicate a specific 
disease-related pathogenesis, RNAi has also been shown to allow specific knockdown 
of the alternatively spliced isoforms (Wood et al., 2007). Almost 70% of the human 
genes with multiple exons are known to generate different transcripts through 
alternative splicing (Stamm et al., 2005). Defects in this process can lead to various 
genetic disorders. RNAi targeted at specific sequences within or at the boundaries of the 
alternatively spliced exons can knockdown the expression of disease-related isoforms 
(Celotto & Graveley, 2002). However, the use of RNAi to target endogenous splicing 
factors needs to be monitored very precisely as it can possibly lead to substantial off-
43 
 
target effects.  Therefore, in the case of dominant genetic disorders where a mutant 
allele needs to be targeted but the normal allele has to stay intact as it might be crucial 
in certain important functions in the body, a very precise discrimination between the 
two alleles is required for RNAi applicability (Denovan-Wright & Davidson, 2006; 
Rodriguez-Lebron & Paulson, 2006). Some in vitro studies on allele-specific RNAi 
have been reported for spinocerebellar ataxia (Xia et al., 2004), osteogenesis imperfecta 
(Millington-Ward et al., 2004) and sickle cell anaemia (Dykxhoorn et al., 2006). A 
combined study to inhibit myostatin using RNAi against ActRIIB and restore quasi 
dystrophin by U7 exon skipping has been reported recently to improve muscle 
physiology (Dumonceaux et al., 2010).  
Chemically synthesised siRNAs are short-lived and result in only transient 
inhibition of gene expression. Delivery of synthetic siRNAs requires a lot of emphasis 
on stabilization of the siRNAs as well as development of methods for targeting the 
siRNAs in an effective way. Viral vector based system has safety concerns. Although 
various viral vectors have been clinically tested in phase I safety trials, a complete 
assessment of efficacy, specificity and risks still needs to be done (Weinstein & Peer, 
2010). Unmodified naked siRNAs when injected intravenously are recognized by Toll 
like receptors (TLRs) that stimulate the immune system and provoke an interferon 
response as well as cytokine induction and coagulation cascades (Szulc et al., 2006). 
Another problem with RNAi lies in the off-target effects that are likely to be induced by 
this technology (Pei & Tuschl, 2006).  
1.7. Some examples of disorders resulting from defective mRNA splicing 
1.7.1. Phenylketonurea 
  Deficiency of phenylalanine hydroxylase (PAH) leads to an autosomal recessive 
genetic disorder, phenylketonurea (PKU) in humans. Human hepatic PAH is 
responsible for hydroxylation of phenylalanine to tyrosine, therefore its deficiency leads 
to abnormalities related to PAH metabolism that include severe brain damage (Scriver 
& Clow, 1980a; b). When a PKU carrier‟s PAH mutant cDNA clones were isolated, an 
internal deletion corresponding to exon 12 of the human PAH gene was revealed that 
resulted in production of a truncated protein. When the expression studies were carried 
out, it was found that this internal deletion led to termination of PAH activity resulting 
from instability of the protein (Woo et al., 1986). Further investigation to find out about 
the molecular mechanism and basis of this activity demonstrated that there was a 
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GTAT substitution at the donor splice site of intron 12 that consequently led to the 
skipping of exon 12 (DiLella et al., 1986; Marvit et al., 1987).  
1.7.2. Ornithine transcarbamylase (OTC) deficiency 
Deficiency of a liver specific X-linked enzyme, ornithine transcarbamylase 
(OTC) can lead to early death due to ammonia intoxication. OTC catalyzes the second 
step in urea cycle which involves production of citrulline by condensation of carbamyl 
phosphate and ornithine (Hata et al., 1986; Horwich et al., 1984). When cDNA samples 
from patients‟ liver were amplified using PCR, no full length product was observed, 
neither did western blot analysis of protein extracted from patient liver show any cross 
reacting material (Carstens et al., 1991).  Three of the seven samples showed PCR 
products smaller than the normal which upon sequencing revealed that two of the 
samples had no exon 7 of the gene and the third had a few base pairs of exon 5 missing. 
One of the mutants with missing exon 7 had a TC substitution in the 5‟ splice donor 
site of intron 7 while the other one with missing exon 7 had an AG substitution in the 
intron 7. An AT change was found at the end of exon 4 in the 3‟ splice acceptor site 
of third mutant (Carstens et al., 1991).  
1.7.3. The Menkes disease 
Defects in a copper-transporting ATPase gene (ATP7A) lead to a 
neurodegenerative disorder, the Menkes disease. In severe cases of Menkes disease, 
connective tissue abnormalities, distinctive „kinky hair‟ and ultimate death in early 
childhood are observed. Approximately 22% of the ATP7A mutations are splice site 
mutations and over 60 splice mutations have been studied (Kaler et al., 1996; Skjorringe 
et al., 2011). 
1.7.4. β-Thalassemia 
β-Thalassemia is a serious genetic blood disorder in which production of a 
subunit of haemoglobin, β-globin is either partially or completely ablated by mutations 
in the β-globin gene. This defect results in decreased oxygen-carrying capacity of red 
blood cells causing compensatory bone marrow expansion and if untreated, fatal iron 
overload (Sazani & Kole, 2003). Splicing defect mutations are quite common in 
thalassemic patients. Mutations causing splicing defects, for instance, in intron 2 of β-
globin gene lead to activation of a cryptic 3‟ splice site along with the production of an 
aberrant 5‟ splice site. This eventually leads to the inclusion of a part of the intron into 
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the spliced mRNA resulting in creation of an in-frame stop codon (Dominski & Kole, 
1993; Lacerra et al., 2000; Sazani & Kole, 2003; Suwanmanee et al., 2002).  
1.7.5. Cystic Fibrosis 
  Cystic fibrosis is a recessive genetic disease affecting lungs, pancreas, liver and 
intestine characterized by abnormal chloride and sodium transport across epithelium 
resulting in thick viscous secretions (Yankaskas et al., 2004). About 14% of deleterious 
cystic fibrosis mutations result from defects in mRNA splicing of cystic fibrosis 
transmembrane conductance regulator (CFTR) gene. Nearly 2% of these mutations 
occur due to aberrant splicing resulting from a mutation in intron 19 of this gene that 
activates a cryptic 3‟ splice site and produces an aberrant 5‟ splice site (Friedman et al., 
1999; Tsui, 1992). 
1.7.6. Cancer 
 In case of tumours that are noncompliant to apoptosis, maintenance of the 
correct ratio of antiapoptotic proteins to proapoptotic proteins is very crucial. The bcl-x 
gene can be spliced alternatively to result in the production of two isoforms that have 
proapoptotic function (bcl-xS) and antiapoptotic function (bcl-xL). Both the forms are 
required for normal functioning but in case of many cancers including prostate cancer, 
bcl-xL is over-represented (Krajewska et al., 1996). Therefore, blocking the bcl-xL 5‟ 
splice site should increase the ratio of bcl-xS to bcl-xL, and simultaneously increase the 
proapoptotic signals and decrease the antiapoptotic signals, resulting in inhibition of 
growth or death of cancer cells.  
1.7.7. Ataxia-Telangiectasia 
 A progressive autosomal recessive neurodegenerative disorder called ataxia-
telangiectasia (A-T) is caused by a splicing mutation in ataxia-telangiectasia mutated 
(ATM) gene leading to activation of a cryptic 5‟ splice site; or a cryptic 3‟ splice site; or 
activation of a downstream 5‟ splice site leading to the inclusion of an intron within the 
spliced mRNA (Perlman et al., 2003). PMO-based AOs targeted to these aberrant splice 
sites led to successful mRNA level restoration of normal splicing of ATM protein and 
also resulted in translation of full length product in three different cell lines for up to 84 
hours (Du et al., 2007). 
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1.7.8. Inflammatory diseases 
 Several proinflammatory factors are known to initiate signalling through 
myeloid differentiation factor 88 (MyD88) which further results in activation of 
Interleukin-1 receptor (IL-1R) -associated kinase known as IRAK-1. The activation of 
IRAK-1 via phosphorylation eventually leads to the activation of nuclear factor kappa-
light-chain-enhancer of activated B-cells (NF-κB). There is a splice variant of MyD88, 
known as MyD88S which does not possess the capacity to bind to NF-κB (Janssens et 
al., 2002). AOs of 2‟OMePS chemistry, targeted at donor sites of MyD88 exon 3 
resulted in an alteration of splicing ratio of MyD88 to MyD88S, thereby leading to 
decreased proinflammatory signalling in vitro as well as in vivo (Vickers et al., 2006). 
1.8. Duchenne muscular dystrophy (DMD) and experimental treatment strategies 
The largest gene of the human genome by far is the X-linked dystrophin gene 
which has 79 exons (Tennyson et al., 1995). Dystrophin acts as a linker between muscle 
cytoskeleton and extracellular matrix via dystrophin-glycoprotein complex (DGC). 
There are four main domains of dystrophin protein, namely, the N-terminal region, a 
central domain (with spectrin-like repeats), a cysteine-rich domain and a C-terminal 
domain. The N-terminal region of dystrophin interacts with cytoskeletal actin. β-
dystroglycan is bound by cysteine-rich domain of dystrophin protein. The C-terminal of 
dystrophin interacts with syntrophins and dystrobrevins as shown in Figure 1.7. 
Premature termination of the synthesis process of the dystrophin gene may occur as a 
result of certain mutations that disrupt the dystrophin transcript reading frame. 
Deficiency of dystrophin thus makes the myofibres more prone to damage resulting 
from mechanical contraction. This eventually leads to necrosis and failure of myofibre 
regeneration causing replacement of myofibres with fibrous and fatty connective tissue. 
This results in Duchenne muscular dystrophy (DMD) which is characterized by 
progressive muscle weakness and wasting (Whitehead et al., 2006).  
Frame shifting mutations in the dystrophin result in production of shortened 
products that are semi-functional because the open reading frame of the gene is still 
intact (Monaco et al., 1988). The protein thus produced is internally truncated but is still 
partially functional and causes a less severe Becker muscular dystrophy (BMD) (Trollet 
et al., 2009). Expression of small proportions of dystrophin-positive fibres known as 
„revertant‟ fibres in DMD patients as well as in mdx mice (DMD mouse models that 
were derived from naturally occurring C57BL/10 mutants for DMD gene (Collins & 
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Morgan, 2003) that lack the complete DMD gene in both muscle and brain tissue 
(Vaillend et al., 1995)), further provides evidence for the role of exon skipping as a 
mechanism for restoration of frame shift mutation (Sherratt et al., 1993). A Japanese 
Duchene muscular dystrophy patient was demonstrated to have the dystrophin exon 19 
shortened by 52 base pairs due to a deletion such that the pre-mRNA transcript had 
exon 19 missing and exon 18 was directly joined to exon 20 (Matsuo et al., 1991). 
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Figure 1.7  
        
 
 
Figure 1.7: The dystrophin-glycoprotein (DGC) complex. A diagrammatic representation of 
the DGC complex showing dystrophin, dystroglycan complex, sarcoglycan complex, 
dystrobrevin, syntrophins and sarcospan. The extracellular ligand, laminin-2 binds to the α-
dystroglycan which is further linked to a member of sarcolemmal glycoprotein complex, β-
dystroglycan. β -dystroglycan is linked to dystrophin via its cysteine-rich domain. The N-
terminal domain of dystrophin binds to the cytoskeletal actin and the carboxy terminal domain 
is linked to syntrophins. Figure adapted from (Khurana & Davies, 2003) 
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The following strategies have been investigated for their application in muscular 
dystrophy treatment: 
1.8.1. Gene addition therapy  
A number of conventional gene therapy strategies have been employed to 
correct the fatal mutations in dystrophin gene leading to DMD. Due to its large size (14 
kb with 11.5kb coding sequence), replacement of the dystrophin gene with artificial 
cDNA constructs requires large capacity vectors. Adenoviral vectors are quite large in 
size that limits their diffusion into muscle tissue. Myofibre surface does not have many 
receptor molecules for the adenoviral vectors to come and adhere to. Also, the extra 
cellular matrix (ECM) surrounding the myofibres does not let the large sized vectors to 
cross it easily (Chen et al., 1997a; Douglas, 2007). Immunogenicity is another 
disadvantage of adenovirus vectors for their proposed use in gene therapy (Douglas, 
2007). Herpes simplex virus type I vectors have the capacity to carry large inserts but 
they offer limited persistence of gene expression owing to their cytotoxicity and 
immunogenicity (Akkaraju et al., 1999; Huard et al., 1997). Plasmid vectors being 
synthetic are relatively safe and flexible to carry large inserts. However, they need to be 
either tagged to certain lipid formulations for efficient delivery or have to be delivered 
by microtubules, electroporation or ultrasound.  
Recombinant AAV (rAAV) vectors are smaller in size and have lower 
immunogenicity. However, due to their limited capacity, rAAV vectors are unable to 
accommodate full-sized dystrophin cDNA (Wang et al., 2007) and are required in very 
high titers to achieve efficient systemic administration (Gregorevic et al., 2004). 
Dystrophin minigenes with a lower number of centrally located spectrin-like domains 
(with preserved carboxy- and amino- terminal domains) when expressed as transgenes 
in mdx mice, substituted for the wild type gene (Deconinck et al., 1997). As dystrophin-
associated protein complex (DAPC) assembly takes place in the presence of dystrophin 
(Hoffman & Dressman, 2001) which is responsible for linking the extracellular matrix 
and cytoskeleton muscle fibres together (White et al., 2002), microdystrophins 
delivered using AAV vectors have been shown to successfully restore DAPC expression 
as well as the strength and stability of sarcolemmal membrane which further prevents 
degeneration of muscle fibres (Athanasopoulos et al., 2004; Gregorevic et al., 2006; 
Wang et al., 2000). AAV serotype 8 was found to be the most efficient to attain 
systemic transfer of dystrophin gene into skeletal as well as cardiac muscles in mice and 
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hamsters (Wang et al., 2005). Microdystrophins were expressed in dystrophic 
mesoangioblasts of dogs and then transplanted into arterial circulation. This led to a 
widespread microdystrophin expression but there was no maintenance of force of 
contraction (Sampaolesi et al., 2006). Progress in systemic delivery of rAAV 
microdystrophin vectors has been achieved using very high titers of rAAV using 
constitutive viral promoters driving gene expression. However, for clinical applicability, 
it is essential to develop rAAV vectors capable of achieving gene transfer efficiently at 
lower viral titers using a muscle specific promoter (Foster et al., 2008).  
Codon optimisation of microdystrophin can be achieved by inclusion of 
consensus Kozak sequence and codon usage optimisation for efficient translation 
(Garmory et al., 2003; Kozak, 2005) and increased GC content to promote mRNA 
stability (Murray & Schoenberg, 2007). Codon optimisation of microdystrophin under 
the control of a muscle-restrictive promoter has been shown to significantly increase 
levels of microdystrophin mRNA and protein after intramuscular and systemic 
administration of plasmid DNA or (rAAV)2/8 in mdx mice as compared to the 
noncodon-optimized microdystrophins. This was also accompanied by significant 
improvement in specific force and protection from contraction-induced injury (Foster et 
al., 2008).  Nonhuman primate studies involving rhesus macaques using a fusion 
construct of AAV8 and FLAG-tagged microdystrophin have been reported (Rodino-
Klapac et al., 2010). Intramuscular injection of this microdystrophin construct into the 
tibialis anterior of macaques led to a 50-79% muscle transduction that persisted for a 
period of 5 months. Vascular delivery of this construct resulted in up to 80% gene 
expression in muscle fibres without any cellular immune responses (Rodino-Klapac et 
al., 2010). 
 (AAV)2/8 vectors expressing mRNA sequence-optimised canine 
microdystrophin under the control of muscle-specific promoter have been generated. 
When these vectors were injected intramuscularly into canine X-linked muscular 
dystrophy (CXMDj) dog, stable and high levels of microdystrophin along with the 
association with DAPC was observed for at least eight weeks. The treated muscles were 
highly protected from dystrophic damage and there was no immune response (Koo et 
al., 2011). 
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1.8.2. Utrophin 
When dystrophin mRNA was examined in embryonic, newborn and adult mouse 
skeletal muscle, a discrete increase in mRNA size was observed between embryonic and 
adult stages that was nerve-independent. This indicated that a developmentally-
regulated mRNA isoform switch occurs in the dystrophin gene expression in skeletal 
muscle (Dickson et al., 1988). Utrophin is a homolog of dystrophin that maps to human 
chromosome 6 and was identified in 1989 (Love et al., 1989). Utrophin and dystrophin 
show strong homology specifically in the N- and C-terminal ends (Pearce et al., 1993). 
Utrophin is widely expressed in retinal glial cells, vascular endothelia, platelets, various 
kidney cells as well as in skeletal, smooth muscle and cardiac cells and in abundance at 
neuromuscular junctions (Love et al., 1991; Ohlendieck et al., 1991). Utrophin 
expression occurs before dystrophin in developing and regenerating muscle where it is 
detected along the muscle sarcolemma. Dystrophin replaces utrophin along the 
sarcolemma at birth or in mature muscle and therefore utrophin remains confined to 
neuromuscular junctions and vasculature (Ohlendieck et al., 1991; Tinsley & Davies, 
1993). Due to this utrophin has been considered as a foetal dystrophin homologue in 
developing muscle tissues suggesting common functions of the two proteins in muscle 
structure and physiology. A direct relationship between the utrophin expression level 
and the degree of improvement in muscle structure and function in dystrophic mice has 
been demonstrated (Tinsley et al., 1998). In mdx mice, muscle necrosis occurs when 
utrophin expression falls down to adult level that is at the time it should be replaced by 
dystrophin (Khurana et al., 1991).  Exogenous expression of microutrophin using 
recombinant AAV vectors in mdx (Utr-/-) mice has been demonstrated to increase life 
span and improve muscle function but this strategy faces common gene therapy 
obstacles like vector delivery, stability of the construct, poor control of protein 
expression and immunogenicity (Odom et al., 2008). 
1.8.3. Muscle derived stem cells 
Stem cells derived from blood vessels, bone marrow and muscle are capable of 
introducing dystrophin producing cells (Gussoni et al., 1999). Muscle derived stem cells 
(MDSCs) are capable of self renewal as well as regeneration of other tissues. MDSCs 
that readily differentiate into muscle cells are known as CD45- whereas the ones that 
have lower myogenic potential are termed as CD45+ (Peng & Huard, 2004). Skeletal 
MDSCs that exhibit enhanced regeneration ability in different musculoskeletal system 
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tissues have been extensively isolated and characterized. A great focus has been laid on 
improving dystrophic muscle pathology based on investigations of high myogenic 
potential of the stem cells that have vascular or endothelial origin (Crisan et al., 2008; 
Zheng et al., 2007). Regeneration ability of adult skeletal muscle starts to diminish with 
age. Notch signalling is important in triggering satellite cells or muscle stem cells to 
induce muscle tissue regeneration; however, the activation of Notch is largely declined 
in ageing muscle tissue. It has been reported that regenerative capacity of muscle stem 
cells can be rejuvenated by forced activation of Notch (Collins & Partridge, 2005; 
Conboy et al., 2003; Schultz & Lipton, 1982). When bone marrow mesenchymal stem 
cells (with otherwise low myogenic differentiation capacity) were engineered to 
produce higher levels of intracellular Notch protein and transplanted into mdx mice, 
they produced dystrophin in many fibres (Dezawa et al., 2005). Although this approach 
is quite safe, it still requires immune suppression (Gussoni et al., 1999; Sampaolesi et 
al., 2003). 
Transplantation of healthy myoblasts into affected muscles in order to provoke 
synthesis of new muscle fibres that have dystrophin expression has been achieved in 
mdx mice (Acsadi et al., 1991; Hoffman et al., 1987b). Implantation of exogenous 
myoblasts into the muscle for myofibre generation can however provoke immune 
response and has low efficiency due to limited cell migration and poor myoblast 
survival after transplantation (Gussoni et al. 1999).  
1.8.4. Neuronal Nitric Oxide Synthase 
Nitric oxide synthase (NOS) has three different isoforms namely: neuronal nitric 
oxide synthase (nNOS), inducible nitric oxide synthase (iNOS) and endothelial nitric 
oxide synthase (eNOS). nNOS occurs in a variety of cell types including skeletal 
muscle cells and neurons, and synthesizes nitric oxide (NO) which is responsible for a 
number of biological functions like neuromuscular transmission, regulation of 
sarcolemmal ionic pumps and calcium homeostasis among others (Kobzik et al., 1994; 
Meszaros et al., 1996). nNOS is restricted to cytosolic surface of the sarcolemma of fast 
twitch fibres. It is important that nNOS is correctly localized on the sarcolemmal 
membrane in order to prevent blood vessel constriction during muscular activity in 
order to enhance the blood circulation (Lai et al., 2009). nNOS has been reported to be a 
component of dystrophin-associated glycoprotein complex (DGC) (Brenman et al., 
1995). In the absence of dystrophin, assembly of DGC at the sarcolemma fails and 
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therefore functional nNOS also gets displaced (Thomas et al., 1998). nNOS-mediated  
vasodilation is thus hampered leading to necrosis and ischemia that causes very quick 
onset of fatigue in DMD patients (Sander et al., 2000) (Kobayashi et al., 2008). Reports 
suggest that spectrin repeats 16 and 17 (R16/17) on the dystrophin rod domain are very 
crucial in correctly locating nNOS to sarcolemma. When mdx mice were treated with 
mini- and microdystrophin genes containing R16/17, they proved as effective as 
previously reported mini and micro dystrophins in improving muscle pathology and also 
correctly positioned the nNOS on the sarcolemmal membrane which showed significant 
improvement in vasodilation during exercise leading to increase in blood supply (Lai et 
al., 2009). 
1.8.5. Insulin-like growth factor-1 (IGF-1) 
 Insulin-like growth factors are peptide hormones synthesized in the liver which 
are structurally homologous to proinsulin and are responsible for the growth and 
development of various types of cells. Mice carrying a mutation in IGF-1 gene showed 
extreme growth deficiency (Liu et al., 1993). Cultured C2C12 cells when exposed to 
IGF-1 resulted in myotube hypertrophy due to a calcium signalling pathway initiated by 
IGF-1. Mice with continual IGF-1 expression also exhibit hypertrophy in muscles 
(Delaughter et al., 1999; Semsarian et al., 1999). Hypertrophy induced by elevated 
levels of IGF-1 produced as a result of over expression in transgenic mice leads to 
increased force production. When exogenous IGF-1 administration into mdx mice was 
carried out, it showed beneficial effects such as improved resistance to fatigue, 
increased muscle strength and elimination of age-related diaphragm fibrosis (Barton et 
al., 2002; Gregorevic et al., 2002; Schertzer et al., 2006). In another study, when 
recombinant AAV vectors expressing microdystrophin (rAAV-muDys) were delivered 
into mdx muscles, there was an increase in resistance to mechanical injury but no 
increase in muscle mass. AAV vectors expressing muscle-specific IGF-1 (rAAV-mIgf-
1) induced increase in muscle mass but no significant resistance to injury. Co-injection 
of rAAV-muDys and rAAV-mIgf-1 however, resulted in increased muscle mass as well 
as enhanced protection against injury induced by contraction (Abmayr et al., 2005). 
1. 8.6. Exon skipping 
Exon skipping has been proposed as a method of treatment for DMD by using 
antisense oligonucleotides directed against the exons of mutant dystrophin to restore 
reading frame of the gene leading to a milder phenotype of BMD (Graham et al., 2004a; 
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Matsuo, 1996; Popplewell et al., 2009). Antisense oligonucleotides of 2‟OMePS 
chemistry directed against 3‟ splice site of intron 22 and 5‟ splice site of intron 23 in 
primary mdx myotubes resulted in all the dystrophin pre-mRNA transcripts missing 
exon 23 after 24 hours of transfection (Wilton et al., 1999). Further studies 
demonstrated effective dystrophin restoration by exon 46 skipping using AOs in DMD 
patient-derived muscle cells (van Deutekom et al., 2001). An enhanced delivery of the 
AOs of 2‟OMePS chemistry to the TA muscle of adult dystrophic mice resulted in 
dystrophin expression restoration in 20-30% of the fibres (Wells et al., 2003).  
Skipping of exon 51 particularly averts the onset of dystrophic phenotype in the 
vast majority of patient myoblasts (Aartsma-Rus & van Ommen, 2007; Arechavala-
Gomeza et al., 2007). A schematic diagram of exon 51 skipping is shown in Figure 1.8. 
A clinical trial using 2‟OMePS to target exon 51 of dystrophin mRNA involved single 
intramuscular injection of 0.8mg AO into the tibialis anterior (TA) of four DMD 
patients and the biopsy was performed after 4 weeks. The treatment was well tolerated, 
exon skipping was induced and dystrophin expression was restored in 64-97% of the 
myofibres (van Deutekom et al., 2007). In the first UK clinical trial for DMD, 
intramuscular injection of morpholino targeted against exon 51 of dystrophin mRNA 
(AVI-4658) into extensor digitorum brevis (EDB) of seven DMD patients was 
performed. Two patients were injected with 0.09 mg of the AO while the other five 
were injected with 0.9 mg of AO dissolved in 900 μL saline in each case. The muscles 
were biopsied between 3 to 4 weeks and the trial concluded with the results that the 
administration of AVI-4658 was safe and local restoration of dystrophin expression was 
observed in the 44-79% of the treated muscle (Kinali et al., 2009). 
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Figure 1.8 
 
 
 
 
 
Figure 1.8: Illustration of exon 51 skipping therapy in DMD patients. Deletion of exon 50 
from a normal dystrophin pre-mRNA results in disruption of open reading frame resulting in a 
pre-mature stop codon that eventually leads to an unstable and truncated protein. Use of 
antisense oligonucleotides targeted at exon 51 produces a truncated but functional protein (that 
lacks exon 50 and 51) by restoring the reading frame (Figure adapted from (Sugita & Takeda, 
2010).  
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1.9 Therapeutic applications of exon skipping  
Exon skipping applications include following mechanisms of action: 
1.9.1. Exon exclusion/Reading frame restoration 
AOs targeted at specific exons in dystrophin mRNA result in shorter dystrophin 
forms that are still functional. Exon skipping has also been explored as a therapeutic 
application in case of dystrophic epidermolysis bullosa (EB), which is a severe skin 
blistering condition resulting from mutations in type VII collagen, COL7A1 gene (Uitto 
et al., 1995). Patients with in-frame exon skipping have milder symptoms indicating the 
possible use of AO-mediated reading frame restoration as a treatment (McGrath et al., 
1999). AOs targeted against exon 70 of COL7A1 mRNA resulted in exclusion of exon 
70 and therefore resulted in a protein that was short of 16 amino acids encoded by exon 
70. The shortened protein thus restored almost normal function (Goto et al., 2006). Over 
20% of recessive dystrophic EB patients have mutations in exon 70 making this 
approach quite significant for a large number of patients (Aartsma-Rus & van Ommen, 
2007).  
1.9.2. Exon inclusion 
Exon skipping has also been used to induce inclusion of exons that have been 
skipped due to mutations disrupting exon splicing enhancers (ESEs). Spinal muscular 
atrophy (SMA) is caused due to a mutation in survival of motor neuron 1 (SMN1) gene 
(Munsat & Davies, 1992). SMN2 is a paralogous gene which is almost the same as 
SMN1 apart from a mutation in exon 7 which interrupts an SF2/ASF binding site and 
renders SMN2 transcript devoid of exon 7 (Cartegni & Krainer, 2002; Helmken et al., 
2003). Exon 7-specific AOs of 2‟O-methoxy ethyl ribose either with a tail containing an 
ESE motif, or linked to serine-arginine peptide domain to recruit SF2/ASF to disrupted 
ESE, have been reported to promote exon 7 inclusion and an increase in full length 
SMN protein levels. Similar results were obtained with AOs targeting exon splicing 
silencers (ESSs) (Hua et al., 2007; Skordis et al., 2003).  
1.9.3. Isoform switching 
A striking example of use of exon skipping to change the levels of alternatively 
spliced genes is that of Bcl-x gene. The role of anti- and pro-apoptotic factors is 
extremely important in apoptosis. Defective splicing of these factors is one of the 
crucial reasons for development of cancer. Bcl-x gene has two isoforms namely Bcl-xS 
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and Bcl-xL. Bcl-xS is pro-apoptotic and sensitizes cells to chemotherapy whereas Bcl-
xL is anti-apoptotic and induces resistance to chemotherapeutic agents and is over 
expressed in a number of cancers. These two isoforms result from two different 5‟ 
splice sites in exon 2 (Mercatante et al., 2002). Antisense oligonucleotides of 2‟OMePS 
chemistry targeted against the 5‟ splice site of bcl-x exon 2 in a lung carcinoma cells 
increased the bcl-xS to bcl-xL ratio which was not enough to induce apoptosis but it did 
result in sensitization of the cells to inducers of apoptosis like chemotherapy drugs or 
UVB radiation (Williams & Kole, 2006). Similar results have also been shown in the 
case of breast cancer and prostate cancer cell lines by the use of antisense 
oligonucleotides (Mercatante et al., 2002). However systemic delivery of AOs targeting 
Bcl-x induced liver apoptosis in treated mice, thereby limiting the applicability of this 
approach. 
 Use of AOs has also been described for prostate-specific membrane antigen 
encoded by the folate hydrolase gene for isoform switching (Williams & Kole, 2006). 
One of the isoforms of the gene is expressed more than 100-fold higher in malignant 
than the normal prostate tissues and has an extracellular functional domain that 
regulates folate uptake (O'Keefe et al., 2004). Three other prostate-specific membrane 
antigen isoforms exist. Two isoforms result from alternative splicing of exon 6 and 18 
with no enzymatic domain at all or inactive domain respectively. Fourth isoform results 
from alternative donor splice site in first exon that lacks transmembrane domain. 
Individual AOs targeting exons 1, 6 and 18 were successful in inducing isoform 
switching along with lower levels of full length-isoform and decreased enzymatic 
activity (Williams & Kole, 2006).  
1.9.4. Exon exclusion/Destructive exon skipping  
Use of AOs for gene knockdown has been demonstrated by Apolipoprotein B 
(APOB) studies. There exist two isoforms of APOB, APOB100 and APOB48. 
APOB100 acts as a ligand for low density lipoprotein (LDL) receptor and plays central 
role in atherosclerosis (Soutar & Naoumova, 2007). APOB48 plays an important role in 
chylomicron assembly and intestinal fat transport. APOB48 arises from intestine tissue-
specific RNA editing of a CAA into a UAA termination codon in exon 26 and lacks the 
LDL receptor-binding domain (Chester et al., 2000). Due to the lack of this LDL 
receptor-binding domain in APOB48, chylomicrons are unable to bind via this receptor 
and are cleared by interaction between APOE and chylomicron remnant receptor.  AOs 
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directed at exon 27 resulted in shortened and non-functional APOB100 protein 
(APOB87SKIP27) (Khoo et al., 2007). LDL particles containing APOB87SKIP27 show 
greater fractional catabolic rates compared to those containing APOB100 due to greater 
affinity of APOB87-containing particles for LDL receptor and also appear to have 
dominant negative effect on secretion of APOB100. As RNA-editing signal for 
APOB48 is located in exon 26, skipping of exon 27 will not affect this isoform. It will 
however disrupt the APOB100 transcript‟s open reading frame resulting in lower 
amounts of APOB100 and a likely decrease in LDL and cholesterol levels (Khoo et al., 
2007). Gene knockdown by selective exon skipping therefore allows down regulation of 
the disadvantageous isoform of a gene while maintaining the normal levels of the 
desired isoform (Arechavala-Gomeza et al., 2007). 
1.10. Antisense oligonucleotides (AOs) 
AOs are about 11-30 bp long chemically synthesized single stranded nucleic 
acid molecules that are complementary to a specific sequence of the target mRNA 
(Agrawal & Kandimalla, 2000). Based on the mechanism of action, the AOs function in 
the following ways: (i) RNAase H-mediated degradation of the target RNA by 
hydrolysis of RNA strand from the DNA/RNA duplex, (ii) Steric blocking of the target 
mRNA which physically inhibits the pre-mRNA splicing (Dias & Stein, 2002; Larrouy 
et al., 1992). AOs are capable of hybridizing with the target sequence and blocking its 
splicing. They lead to steric hindrance and get in the way of certain proteins essential 
for pre-mRNA splicing and redirect the splicing process. Thus it leads to the formation 
of a truncated product and not the full length transcript This knocks down the 
expression of the gene from which the mRNA was transcribed (Adams et al., 2007a). 
Due to the unstable nature of single stranded DNA molecules, it is important to modify 
the chemistries of AOs in order to provide them stability (Dean et al., 1994; Minshull & 
Hunt, 1986).  
One of the first ever uses of antisense technology was made in 1977 by 
Zamecnik and colleagues to block the circularization of proviral DNA of Rous sarcoma 
virus (RSV) 35S RNA in tissue cultured chick embryo fibroblasts (CEFs) infected with 
the virus (Schwartz et al., 1977). Upon determination of the primary structure of RSV 
35S RNA, a 21 nucleotide segment adjacent to the 3‟ poly-A tail was found to be 
identical to a 21 nucleotide sequence internal to the 5‟ cap in the same molecule 
(Haseltine et al., 1977; Schwartz et al., 1977). These reiterated sequences play a crucial 
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role in provirus DNA circularization prior to integration into cell genome. A 
deoxyribonucleotide complementary to the 13-nucleotide segment of the 21 nucleotide 
reiterated sequence was added to CEF cultures at the same time as RSV infection which 
led to inhibition of RSV production (Zamecnik & Stephenson, 1978).  
Various chemistries of AOs have been developed so far. The mononucleotides 
generated as a result of nuclease degradation of AOs based on phosphodiester (PE) 
chemistry were reported to be cytotoxic and to exert a negative effect on proliferation of 
cells (Vaerman et al., 1997). Methyl phosphonates are modified PE oligomers with the 
substitution of a methyl group for the non-bridging oxygen at each phosphate of the 
oligonucleotide chain. In spite of being very stable, these oligonucleotides have very 
low solubility owing to their uncharged nature (Miller et al., 1981; Miller et al., 1979). 
The phosphorothioate (PS) oligodeoxynucleotides (with a non-bridging oxygen atom of 
the phosphate group substituted with sulphur) were the first generation AOs with two 
important characteristics: resistance to nucleases and ability to direct RNase H-mediated 
degradation of the RNA part of RNA-DNA heteroduplexes. These properties made 
these AOs specifically capable of downregulating the expression of a gene (Crooke, 
1998; Stein, 1998). Modification of the phosphate group of oligonucleotides can result 
in either negatively charged backbone (PS); or positively charged backbone 
(phosphorpiperazidate); or uncharged backbone (phosphormorpholidate; N-butyl-
phosphoramidate). All of these modified compounds have been shown to be more 
effective than the parent phosphodiester compounds (Agrawal, 1996; Agrawal et al., 
1988). Fomivirsen (commercial name: Vitravene) was the first FDA-approved AO 
(phosphorothioate)-based drug for cytomegalovirus (CMV) retinitis that causes 
blindness in acquired immune deficiency syndrome (AIDS) patients. Although, 
Fomivirsen was able to effectively treat the infection, it had some adverse local ocular 
effects like inflammation (Grillone & Lanz, 2001). 
Most of the newly developed AOs do not activate RNase H therefore preventing 
the destruction of pre-mRNA before its splicing, and this is of particular importance 
when using AOs to cause a shift in the aberrant or alternative splicing of the target pre-
mRNA (Kole & Sazani, 2001; Mercatante et al., 2001). For dystrophin skipping, it is 
highly important that the pre-mRNA is not destroyed before splicing so that the 
truncated product generated after splicing is still functional and thereby results in a 
milder Becker‟s muscular dystrophy phenotype rather than severe DMD symptoms.  
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A number of AO chemistries that have been most commonly used  so far include 
2‟O-methyl phosphorothionate (2‟O-MePS), peptide nucleic acid (PNA), locked nucleic 
acid (LNA), ethylene bridged nucleic acid (ENA), phosphorodiamidate morpholino 
oligomer (PMO or morpholino oligomer), peptide linked PMO (PPMO) (Karkare & 
Bhatnagar, 2006; Wilson & Keefe, 2006) and the recently developed dendrimeric 
octaguanidine-conjugated  PMO (Vivo-PMO) (Morcos et al., 2008) (Figure 1.9).  
1.10.1. 2’O-methyl RNA (2’O-MePS) 
 The most frequently used second generation oligonucleotide chemistry in vitro 
is 2‟O-MePS due to its high specificity and affinity to target mRNA, stability, nuclease 
resistance, safety and ease of synthesis. Methylation of the ribose ring of RNA at 2‟-OH 
position results in 2‟O-MePS generation. The additional methyl group at 2‟-O- ribose 
position provides extra stability to the oligo making it resemble RNA rather than DNA 
(Agrawal & Zhao, 1998). Although 2‟OMePS has various advantages, it cannot be used 
at high concentrations due to its low solubility (Lu et al., 2005). Easy and cheaper 
synthesis however, does make 2‟O-MePS a very suitable candidate for testing a 
particular AO sequence in tissue culture prior to in vivo studies (Baker et al., 1997).  
1.10.2. Peptide nucleic acids (PNAs) 
 PNAs consist of a polyamide backbone that is uncharged and contains repetitive 
N-(2-aminoethyl) glycine units to confer better stability. These repeating units have 
nucleobases linked to them by methylene carbonyl linkers. The stability of PNA is due 
to the lack of negative charge present in a regular phosphodiester linkage, which further 
results in absence of electrostatic repulsion (Jensen et al., 1997; Nielsen et al., 1991) 
(Hanvey et al., 1992). 
1.10.3. Ethylene bridged nucleic acids (ENAs)/Locked nucleic acids (LNAs) 
 If the ribose sugar moiety of nucleic acid is locked by an oxyethylene bridge 
that connects C-2‟ and C-4‟ atoms, it is termed as ethylene bridged nucleic acid (ENA), 
whereas if this linkage takes place by an oxymethylene bridge, it is termed a locked 
nucleic acid (LNA). This re-arrangement gives the ENAs or LNAs extremely high 
binding affinity due to a very stable conformation (Koshkin & Wengel, 1998; Kumar et 
al., 1998; Morita et al., 2001) making them a good candidate for antisense technology 
(Kumar et al., 1998).  
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1.10.4. Phosphorodiamidate morpholino oligomers (PMOs) 
 In a PMO, the deoxyribose ring in DNA, or ribose ring in RNA, is replaced by a 
morpholine ring and different morpholine rings are linked together by 
phosphorodiamidate bonds. Due to the non-ionic nature of PMOs, non specific binding 
and protein interactions are reduced. PMOs are highly soluble so they can be used at 
higher dosages compared to 2‟OMePSs (Nakamura & Takeda, 2009). 
1.10.5. Peptide linked PMOs (PPMOs) 
Different peptide-based transporter systems including penetratin, tat and 
polyarginine peptides have been shown to traverse cell membranes and have generated 
interest due to potential therapeutic applications. The limitations however are the 
expensive and laborious synthesis processes and mediocre efficacy (Ferrari et al., 2003). 
Tat conjugated PMOs failed to be delivered efficiently across the cell membrane due to 
the prerequisite of protein folding and rearrangement during translocation (Ferrari et al., 
2003). Penetratin conjugated to PNA has been shown to penetrate the cell membrane 
and reach the cytosol but was not delivered to the nucleus (Richard et al., 2003). 
Delivery across the cell membrane is mainly through endocytosis and the vesicles are 
then permeabilized to release the materials internally. However, it is the incapacity to 
permeabilize the vesicles that render the delivery of peptide conjugated AOs ineffective. 
Also, the lack of ability to get round the electrostatic interactions with the cellular 
heparan sulphates makes the delivery of molecules into the nucleus difficult (Richard et 
al., 2003).  
A peptide-conjugated PMO (PPMO) is a PMO conjugated to a cell penetrating 
peptide (CPP) containing arginine (R), 6-aminohexanoic acid (X), and/or β-alanine (B). 
Conjugation of CPPs to PMOs to form PPMOs has been used in vitro and in vivo for 
blocking the replication of harmful viruses like dengue (Kinney et al., 2005), influenza 
(Ge et al., 2006), SARS (Neuman et al., 2006) and Ebola virus (Enterlein et al., 2006). 
A delivery moiety with 6-9 arginine based peptide in a 6-aminohexanoic structure [(R-
Ahx-R)4] has been reported to deliver PMOs effectively to the cytosol and nucleus in 
vitro as well as in vivo (Wu et al., 2007; Yuan et al., 2006). PMO on its own need to be 
delivered in repeated large doses for measurable functional benefit (Alter et al., 2006). 
PPMOs however are delivered much more effectively and uniformly to myocytes even 
at lower doses in DMD models with delivery to cardiomyocytes as well (Fletcher et al., 
2007; Goyenvalle et al., 2010; Yin et al., 2008). 2µg of PMO or a PPMO for dystrophin 
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exon 23 skipping injected locally into the TA of an mdx mice resulted in 14% and 85% 
restoration of dystrophin-positive fibres respectively (Wu et al., 2008). When 12mg/Kg 
of a peptide conjugated PMO for dystrophin exon 23 skipping was injected into the tail 
vein of mdx mice, it resulted in restoration of dystrophin fibres in almost all the fibres as 
compared to only a small percentage of dystrophin restoration with a 400mg/Kg dose of 
naked PMO (Moulton et al., 2009; Wu et al., 2008).  
P007-PMO is a PPMO that contains alternating non-natural 6-aminohexanoic 
acid and arginine [(RXR)4XB] and B-PMO is another PPMO in which two 6-
aminohexanoic acid residues were substituted with another non-natural amino acid, β-
alanine [(RXRRBR)2XB]. Both these PPMOs have been shown to restore dystrophin 
expression very effectively in skeletal muscle and cardiac tissue in mdx mice following 
single systemic administration (25mg/Kg body weight) (Jearawiriyapaisarn et al., 2010; 
Yin et al., 2008). AVI-5038 is a PPMO developed by AVIBiopharma to skip dystrophin 
exon 50. A PPMO dose of up to 9mg/Kg was well tolerated in pre-clinical studies. 
However a significant level of toxicology was observed in some groups from the 
preliminary data obtained from another pre-clinical study using 12mg/Kg PPMO 
following bolus intravenous injections (http://www.avibio.com/our-programs/rare-
diseases/duchennemusculardystrophy/). A chimeric fusion peptide that consists of a 
muscle-targeting heptapeptide, apart from cell penetrating peptide conjugated PMO, has 
been demonstrated to restore high levels of uniform and widespread dystrophin protein 
expression at very low dose when administered systemically in mdx mice (Yin et al., 
2009). The effect was observed in multiple muscle groups and functional improvement 
was seen in dystrophic pathology without any toxicity or immune response (Yin et al., 
2010).  
The toxicity of the PPMO chemistry is a challenge to overcome in order to 
develop a safe delivery moiety for clinical trials in humans. This is mainly predicted to 
be due to the cationic nature of the CPPs which further relies on the composition of the 
amino acids. Dose frequency also influences the level of toxicity conferred by the 
PPMOs with well spaced dosing regimen taken better by the animals than too frequent 
administration (Moulton & Moulton, 2010). Toxic effects of PPMOs include loss of 
weight and fatigue as well as degeneration of renal tubules (Amantana et al., 2007; 
Moulton & Moulton, 2010). The toxic effects are observed at lower doses in monkeys, 
whereas mice seem to tolerate the same dose quite well so good pre-clinical studies are 
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vital to determine safety (Moulton & Moulton, 2010). Success with the PPMOs thus is 
likely to depend upon pre-clinical studies aimed at designing adequate dosing regimen, 
route of administration as well as frequency of dose in order to develop a safe 
efficiency/toxicity profile of the PPMO treatment across different species (Moulton & 
Moulton, 2010). 
1.10.6. Dendrimeric octaguanidine-conjugated PMOs (Vivo-PMOs) 
A newly developed dendritic transporter structure has a triazine core that acts as 
the centre for eight guanidinium heads arranged around it in such a manner that confers 
effective cell membrane penetration to the PMO that it is linked to. This octaguanidine 
transporter when linked to the PMO, the conjugated molecule is called Vivo-
morpholino or Vivo-PMO (Morcos et al., 2008). Eight guanidinium groups have been 
reported to have the optimal delivery efficiency (Futaki et al., 2002). When eight 
guanidinium head groups were put together in an artificial scaffold and linked to 
flourescin in order to assess delivery efficacy, significantly enhanced delivery was 
observed compared to the arginine peptides (Rothbard et al., 2004; Wender et al., 2008; 
Wender et al., 2005). The guanidinium head groups interact with the phospholipid 
phosphates through hydrogen bonding as well as through electrostatic interaction. 
Transgenic mice harbouring a β-globin splice mutation were injected with Vivo-PMO 
targeting the mutation site at a concentration of 12.5mg/Kg of the body weight for four 
consecutive days and sacrificed on the fifth day. Skeletal muscle, liver, colon and small 
intestine showed nearly complete splice correction as analyzed by RT-PCR. A very 
moderate delivery into the brain, heart, skin and lung was also observed (Roberts et al., 
2006). Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels in 
the liver were also measured to assess the toxicity of the compound, but no significant 
change was recorded (Morcos et al., 2008; Roberts et al., 2006).  
Vivo-PMO targeted against exon 23 of dystrophin at a concentration of 25mg/kg 
of the body weight of mdx mice injected systemically resulted in dystrophin expression 
being restored to normal levels (Morcos et al., 2008). Another study using Vivo-PMO 
for dystrophin exon 23 skipping via intramuscular injections showed 62% to 95% 
increase in dystrophin-positive fibres in mdx mice at a dose of 2µg and 10µg 
respectively (Wu et al., 2009). Vivo-PMO has been used in zebra fish to knockdown the 
level of αIIb involved in primary haemostasis (by complex formation with glycoprotein 
IIIa (gpIIIa) which is an essential step in blood clotting) following injury and thus 
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presents a potential strategy to study thrombocyte biochemistry (Kim et al., 2010).  The 
greater level of activity and effective delivery of Vivo-PMO into a broad range of 
tissues makes this chemistry a suitable candidate for our myostatin skipping study as 
well.  
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Figure 1.9 
 
 
 
Figure 1.9: Different chemistries of antisense oligonucleotides: ENA with the ribose sugar 
moiety of nucleic acid  locked by an oxyethylene bridge that connects C-2‟ and C-4‟ atoms; 
PNA with polyamine backbone instead of ribose-phosphate backbone; LNA with linkage 
through an oxymethylene bridge; 2’OMePS with methylation of ribose ring of RNA at 2‟-OH 
position of RNA; PMO with the deoxyribose ring in DNA or ribose ring in RNA replaced by a 
morpholine ring and different mopholine rings are linked together by phosphorodiamidate 
bonds; PPMO with PMOs linked to peptides that facilitate efficient delivery of the PMOs; 
Vivo-PMO with PMOs linked to dendrimeric octaguanidine moiety. (Image adapted from: 
(Moulton et al., 2009; Sazani et al., 2002b; Takeda, 2009; Wu et al., 2009). 
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1.11. Exon skipping targets: Splicing enhancers and inhibitor elements 
Apart from having a sequence encoding a specific protein, a gene also contains 
information about a number of other signals that affect the expression at the transcript 
level. The splicing information comes from the splicing code comprised of exon 
splicing enhancers (ESEs), exon splicing suppressors (ESSs), Intron splicing enhancers 
(ISE) and Intron splicing silencers (ISS) (Fu, 2004). Exon splicing enhancers (ESEs), 
also called exon recognition sequences are a heterogeneous group of various sequence 
motifs that precisely define exon for an efficient splicing process by acting as the sites 
for binding of Serine/Arginine-rich proteins (SR proteins), a family of conserved 
splicing factors (Liu et al., 1998). A slight disruption in the ESE could lead to the entire 
exon exclusion, thereby resulting in a truncated product (Fairbrother et al., 2004).  
It has been proposed that the choice of target plays a crucial role in skipping 
specificity and efficacy. The acceptor splice site, donor splice site and branch point 
sequences have been demonstrated to successfully induce exon skipping (Dunckley et 
al., 1998; Wilton & Fletcher, 2005b) but they have consensus sequences in common 
with various genes and therefore targeting them has a potential risk of off-target effects 
leading to skipping of exons of other genes (Aartsma-Rus & van Ommen, 2007; Sun & 
Chasin, 2000). ESE sites could therefore be relatively better and more specific skipping 
sites than the acceptor or donor splice sites (Aartsma-Rus et al., 2002; van Deutekom et 
al., 2001). For majority of exons, ESEs have been shown to be the optimal target site 
for precise recognition by the splicing machinery (Cartegni et al., 2002). The RNA-
binding domain of SR proteins binds to the ESEs and this leads to precise recognition of 
exons by recruitment of spliceosomal machinery (Fairbrother et al., 2002; Graveley, 
2000) 
1.12 Aims and objectives of the study 
Muscle mass loss resulting from cachexia, sarcopenia and obesity has a very 
high impact on public health. As myostatin is a negative regulator of muscle mass, 
strategies are being developed to knock down the expression of the myostatin gene in 
order to improve the condition of patients suffering from muscle wasting conditions. 
RNA based modulation therapy has the potential to overcome difficulties 
encountered by conventional gene therapy methods. RNAi system faces a massive 
hurdle in terms of effective delivery of the RNAi molecules into the disease models for 
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clinical studies (Weinstein & Peer). In an alternative approach, antisense-mediated 
modulation of pre-mRNA splicing has been pioneered by Ryszard Kole (Dominski & 
Kole, 1993). The identification of exon/intron boundaries by the splicing machinery and 
therefore inclusion of the exons into the mRNA is extensively thought to depend on 
exonic splicing enhancer (ESE) motifs (Dunckley et al., 1998). By masking these ESE 
sites with sequence-optimised AOs, the targeted exons are no longer recognised as 
exons, and are spliced out with neighbouring introns. Skipping of certain exons by AOs 
has been proposed to partly correct the mutated dystrophin and convert the severe DMD 
phenotype into a milder Becker muscular dystrophy (BMD) phenotype (Cartegni et al., 
2002). Clinical trials to determine the safety profile and the efficacy of single 
intramuscular doses of two different chemistries of AOs, 2'-O-methyl phosphorothioate 
(2‟OMePS) and phosphorodiamidate morpholino oligomers (PMO) in DMD patients 
have been completed (Kinali et al., 2009; van Deutekom et al., 2007).  The treatments 
were well tolerated by all the patients and the injection of AOs induced the production 
of dystrophin. When conjugated with a dendrimeric octaguanidine (Vivo-Morpholino), 
PMOs demonstrate a significantly increased delivery in the case of dystrophin skipping 
in animals (Gebski et al., 2005; Wu et al., 2009).  
The focus of this study was to design specific AOs to utilize a destructive RNA 
exon skipping approach to target myostatin activity, and to investigate the outcome of 
myostatin mRNA disruption. Exon skipping of 374 bp long exon 2 of myostatin leads to 
an out-of-frame fusion of exons 1 and 3 and introduction of a premature stop codon due 
to disruption of the translational reading frame. The objective was to study whether an 
exon skipping approach allows myostatin activity levels to be reduced in vitro and in 
vivo. The study was also aimed at determining whether this antisense-based myostatin 
downregulation approach can be combined with dystrophin rescue by exon skipping 
without any interference, to inhibit myostatin expression and reframe dystrophin 
transcripts simultaneously. Another objective was to try and compare the efficacies of 
AOs when conjugated to cell penetrating peptide or octaguanidine moieties. This 
comparison was to investigate simultaneous exon skipping of myostatin and dystrophin 
to recognize a better chemistry that could be helpful in future experiments to develop an 
effective combination strategy for improvement in dystrophic pathology.  
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CHAPTER 2 
MATERIALS AND METHODS 
2.1. General reagents and buffers   
Acetone (Sigma, 179124) 
Ethylenediaminetetraacetic acid (EDTA) (Sigma, E5134) 
Ethanol (Fischer Scientific, E/0650DF/17) 
Isopentane (BDH, S-7653)) 
Isopropanol (VWR, 102246L) 
Methanol (Fischer Scientific, M/4000/17) 
PBS (Phosphate buffered saline) in water (PBS tablets- Oxoid, BR0014G) 
PBST -1X PBS + 0.05% (v/v) Tween-20 
PBS in 0.02% (w/v) EDTA 
TBE (10X)-108g Tris Base, 55g Boric acid, 9.3g EDTA per litre of water 
Trizma base (tris[hydroxymethyl]aminomethane)-(Sigma, T-1503) 
Tween 20 (polyoxyethylenesorbitan monolaurate)-(Sigma, P-1379) 
2.2. Bioinformatics analysis of the myostatin gene to design anti sense reagents  
Three different bioinformatics algorithms namely ESE Finder, PESX and Rescue ESE 
were used to design antisense reagents. The query sequences were pasted in FASTA 
format in the query box of each program. Results from the three algorithms were 
merged to define exonic splicing enhancer (ESE) sites and used to identify the regions 
of the myostatin exon 2 which are expected to be optimal targets for exon skipping 
antisense reagents. A set of 12 antisense reagents of 2‟O-methyl RNA (2‟OMePS) 
chemistry were designed to target four different ESE-rich regions of exon 2 of 
myostatin.  
2.3. Maintenance, subculture and transfection of C2C12 cells with the designed 
anti sense oligonucleotides 
2.3.1. Materials 
Cell line: C2C12, A204 (ATCC) 
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Dimethyl Sulphoxide (DMSO) (Sigma, D2650) 
Growth medium:  
(i) Antibiotics-100U/ml penicillin and 100µg/ml streptomycin (Sigma, A5955) 
(ii) Dulbecco‟s Modified Eagle Medium (DMEM) (Sigma, D-5671),  
(iii) 10% Fetal Calf Serum (FCS) (Sigma, F7524),  
(iv) 1% Glutamine (Sigma, G7513) 
Lipofectamine™ 2000 (Invitrogen, 11668-019): 1/400 dilution 
Trypsin/EDTA (Sigma, T4049) 
10X PBS (PBS tablets- Oxoid, BR0014G) 
Nuclease-free water (Qiagen, 129114) 
PMO stock (0.3mM) (Gene tools, Philomath) 
2‟OMePS stock (250µM) (Eurofins MWG Operon, Edersberg) 
Leash stock (200µM) (Eurofins MWG Operon, Edersberg) 
Agarose (Bioline, 41026) 
1X TBE buffer 
HyperLadder™ V (Bioline) 
2.3.2. Methods 
2.3.2.1. C2C12 cells- Maintenance and subculture 
C2C12 mouse myoblasts were maintained in DMEM containing 10% fetal calf 
serum, 4mM L-glutamine, 100U/ml penicillin and 100µg/ml streptomycin at 37°C and 
8% CO2. Cells were split/24 hours to prevent differentiation and to maintain less than 
70% confluence. In order to passage the cells, the dishes were given a wash with 1X 
PBS once followed by a wash with 1X PBS/EDTA. Cells were detached by incubating 
them with 0.15% trypsin-PBS for one minute at 37°C. 10ml of full growth medium was 
added to stop the action of trypsin. The cells were then pelleted by centrifugation at 
1,000 rpm for 5 minutes at room temperature. The pellet was re-suspended in growth 
medium (composition as described above) and plated in a six well plate at a density of 
1.5x10
5
cells/well. In order to freeze the cells, 10% DMSO and 9ml full growth medium 
was added to 1 ml of re-suspended cells in a vial. 
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2.3.2.2. Annealing of PMO to an oligonucleotide leash  
 PMOs were leashed to complementary stretches of negatively charged DNA (obtained 
from MWG) for efficient in vitro delivery (Gebski et al., 2005), using Lipofectamine 
2000 as transfection reagent. 50 µM stock of annealed PMO was prepared adding 
12.5µl of 10X PBS, 16.65 µL water, 8.35 µL of 0.3 mM stock of PMO and 12.5 µl of 
200 µM stock of leash and running the program described below. To 1µl of annealed 
PMO, 2µl of sterile PBS (10X) and 1µl water was added and the solution was incubated 
at 37ºC for 30 minutes. Following incubation, 1 µl of 5x loading buffer was added and 
the final solution was run on a 3% agarose gel in 1X TBE with HyperLadder™ V as the 
marker to confirm the annealing. 
ANNEALING PROGRAM 
1. 95ºC, 5 minutes 
2. 85 ºC, 1 minute 
3. 75 ºC, 1 minute 
4. 65 ºC, 1 minute 
5. 55 ºC, 1 minute 
6. 45 ºC, 1 minute 
7. 35 ºC, 5 minutes 
8. 25 ºC, 1 minute 
9. 15 ºC, 1 minute and then Hold at 4 ºC 
2.3.2.3. C2C12 transfection with Antisense oligonucleotides (AOs) 
 The C2C12 cells were plated in 6-well dishes at a density of 1.5x10
5
cells/well 
and after about 48 hours, growth media was removed and replaced with 1600µl media 
that consisted of DMEM and L-Glutamine but no antibiotics and serum. Dilutions of 
Lipofectamine 2000 [5µl in 200µl (DMEM + 4mM L-Glutamine)] as well as 2‟OMePS 
or PMOs (2µl (2‟OMePS) or 10 µl (leashed PMO) in 200µl (DMEM + L-Glutamine) 
per 2ml transfection were prepared  and allowed to stand at room temperature for 20 
minutes. After 20 minutes of incubation, Lipofectamine 2000 and AO dilutions were 
mixed together and the total of 400µl was added to each well already containing 1600µl 
media making the total volume 2 ml (making final dilutions of 1/400 Lipofectamine and 
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1/1000 AOs), and the plates were incubated at 37ºC and 8% CO2 for 4 hours. Then the 
transfection mixture was removed and replaced with 2ml of full growth medium with 
serum and antibiotics and cells were allowed to grow for 24 hours before RNA 
extraction. The transfections were performed in duplicates and the experiment repeated 
twice. Controls contained Lipofectamine 2000 but no antisense reagent.  
2.4. RNA isolation 
2.4.1. Materials 
RNeasy Mini kit (Qiagen, 74104) 
Qiashredder kit (Qiagen, 79654) 
TRIzol reagent (Invitrogen, 15596-026) 
Chloroform (Sigma, 472476) 
Isopropanol (Sigma, 190764) 
75% Ethanol (Absolute ethanol from Sigma, 459844) 
2.4.2. Method 
24 hours after AO transfection of C2C12 cells, RNA was extracted from each 
well using QIAshredder/RNeasy extraction kit. Cells were lysed by adding 350µl of 
lysis buffer to each well and cells scraped using a cell scraper. The cell lysate was then 
transferred to the QIAshredder column in a collection tube. The cell lysate was then 
homogenized through the column by centrifugation at 13,000 rpm for 2 minutes. The 
column was removed and after adding 350µl of 70% ethanol to the homogenized lysate, 
a total of 700µl lysate was transferred to the RNeasy column placed in a collection tube. 
The RNeasy columns were then centrifuged at 10,000 rpm for 15 seconds and the flow 
through was discarded. 700µl of buffer RWI was pipetted onto the column and 
centrifugation carried out at 10,000 rpm for 15 seconds. 500µl of buffer RPE (diluted 
with ethanol as directed by the supplier) was then added to the column and the column 
centrifuged at 10,000 rpm for 15 seconds. The same step was repeated with 500 µl of 
buffer RPE but tubes centrifuged at 10,000 rpm for 2 minutes in order to wash the 
column membrane to prevent ethanol carry over. The RNeasy columns were then placed 
on top of new 1.5 ml collection tubes, 30µl of RNase-free water added directly to the 
column membrane and centrifuged at 10,000 rpm for 1 minute to elute the RNA. The 
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concentration of the sample was then recorded spectrophotometrically using a nanodrop 
and samples stored at -80ºC.  
For in vivo experiments RNA was extracted from tissue blocks using TRIzol reagent. 
1ml TRIzol reagent was added to the tube containing 20µm tissue sections collected 
during cryosectioning. The tissue sections were shredded by syringing the TRIzol in and 
out using 19G as well as 26G needle. The homogenized samples were then incubated at 
room temperature for 5 minutes. 0.2 ml of chloroform was then added to each tube 
followed by vigorous shaking for 30 seconds and then incubation at room temperature 
for 5 minutes. The samples were then centrifuged at 12,000g for 15 minutes at 4ºC. The 
aqueous phase was then transferred to a new tube and RNA was precipitated by adding 
0.5ml of isopropanol and mixing gently with a pipette. This was followed by 10 minutes 
incubation at room temperature. After 10 minutes, the samples were centrifuged at 
12,000g for 10 minutes at 4ºC. The supernatant was then removed and pellet washed 
with 1ml of 75% ethanol for every 1ml of TRIzol reagent used and tubes gently flicked 
for mixing. This was followed by centrifugation at 7500g for 5 minutes. The 
supernatant was removed and pellet dissolved in 20µl of nuclease-free water. 
2.5. Primers and AO sequences 
The sequences of the primers obtained from Eurofins MWG Operon (Edergsberg) used 
for the RT-PCR (mystn_ex1F & mystn_skipR) and nested PCR (mystn_skipF, 
mystn_ex3R) are as following in Table 1. 
Table 1: Sequence of primers used in myostatin nested-RT PCR 
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Antisense oligonucleotide sequences:  
Antisense oligonucleotides- 2‟OMePS (Eurofins MWG Operon, Edersberg) sequences 
are as following in Table 2  
 
Table 2: Sequence of 2’O-methyl RNA oligonucleotides 
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Antisense oligonucleotides- PMO (Gene tools, Philomath) sequences are as following:  
 
Table 3: Sequence of morpholino (PMO) oligonucleotides 
               
            
Octaguanidine dendrimer-conjugated PMO or Vivo-PMO-D (Morcos et al., 2008) 
(Gene tools, Philomath) sequence is as following: 
AG CCC ATC TTC TCC TGG TCC TGG GAA GG  
Peptide conjugated PMO or B-PMO-D (Yin et al., 2008) (conjugated by Amer Saleh 
from Prof Mike Gait‟s group at MRC Laboratory of Molecular Biology, Cambridge) 
sequence is as following: 
AG CCC ATC TTC TCC TGG TCC TGG GAA GG  
2.6. RT-PCR  
2.6.1. Materials 
Gene script RT-PCR System (GeneSys Ltd., GS003) 
2X Master Mix (Genesys Ltd., RM030) 
HyperLadder™ IV (Bioline) 
2.6.2. Method 
1µg of RNA was reverse transcribed and resulting cDNA amplified using specific 
primers obtained from MWG, using the Genescript kit. The preparation of master mixes 
was done as follows: 
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Master Mix I (X1 reaction): 
1. 2µl of 5mM dNTP mix 
2. 1 µl of Primer Ex1F 
3. 1 µl of Primer Skip R 
4. 19µl of nuclease-free water* 
5. 2µl of RNA* 
           * The volume of RNA and water varied depending upon the concentration of 
RNA. 
           Master Mix II (x1 reaction): 
1. 10µl RT-PCR buffer 
2. 0.5µl of enzyme mix 
3. 14.5µl of nuclease-free water 
To the RNA in PCR tubes, 23µl of Master Mix I and 25µl of Master Mix II was added, 
making a total volume of 50µl. The RT-PCR program was run as following: 
2.6.3. RT-PCR Program 
1. 45 ºC, 30 minutes 
2. 92 ºC, 2 minutes 
3. 92 ºC, 30 seconds 
4. 54.5 ºC, 30 seconds 
5. 68 ºC, 2 minutes 
6. Go to step 3, 9 times 
7. 92 ºC, 30 seconds 
8. 54.5 ºC, 30 seconds 
9. 68 ºC, 2 minutes, +5 seconds per cycle 
10. Go to step 7, 24 times 
11. 68 ºC, 10 minutes 
12. END 
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2.7. Nested PCR and analysis of RNA by gel electrophoresis 
2.7.1. Materials 
2X Master Mix (Genesys Ltd., RM030) 
HyperLadder™ IV (Bioline, BIO-33029) 
Nuclease-free water (Qiagen, 129114) 
Ethidium bromide solution (Sigma Aldrich, E1510) 
SYBR® Safe DNA gel stain (S33102) 
Agarose (Bioline, 41026) 
2.7.2. Method 
1µl of PCR products obtained was used as a template for carrying out nested PCR using 
2X Master Mix. The master mix (X1 reaction) was prepared as following: 
1. 12.5µl of 2X Master Mix 
2. 1µl of Primer Skip F 
3. 1µl of Primer Ex3R 
4. 9.5µl of nuclease-free water 
24µl of the above mixture was then added to 1µl of RT PCR products and the following 
program was run using MJ Research PTC-200 thermal cycler: 
2.7.3. Nested PCR program 
1. 92 ºC, 2 minutes 
2. 92 ºC, 30 seconds 
3. 56 ºC, 30 seconds 
4. 68 ºC, 1 minute 
5. Go to step 2, 29 times 
6. 68 ºC, 10 minutes 
7. END 
The products from nested PCR were separated on 1.2% agarose gel with ethidium 
bromide or SYBR® Safe DNA gel stain (5µl for every 50µl of gel) in Tris-
borate/EDTA buffer and HyperLadder™ IV was used as the marker. Densitometric 
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analysis of the agarose gels was carried out using Gene tools 3.05 (Syngene, MD, USA) 
and % skipping expressed as the amount of skipped product intensity relative to total 
PCR products detected. 
2.8. Densitometry  
2.8.1. Materials 
Gene tools software by MW library 
2.8.2. Method: Opened a new file in the software and clicked on spot blot for analysis 
type and chose rectangle as spot type. Image type was selected as fluorescence. Spots 
were created for manual positioning and the size of the rectangle adjusted as 
appropriate. In order to calculate the background, the rectangle was dragged to a 
position where there was no band and just uniform dark area. The table that opens up on 
starting the analysis shows the mean pixel values that were then exported to excel. 
Mean pixel value of the background spot was subtracted from the mean pixel value of 
the full length band and the skipped band to give the corrected full length and skipped 
band mean pixel values respectively. Mean pixel values of corrected full length (F) and 
corrected skipped bands (S) were added together (F+S) and percentage skipping was 
calculated by using the formula:  Percentage skipping = [S/ (F+S)]*100. 
2.9. Proliferation Assay 
2.9.1. Materials 
Cell proliferation assay: Cell Titer 96
®
 Aqueous One Solution Cell Proliferation assay 
(Promega, G3582) 
2.9.2. Method 
A proliferation assay using Cell Titer 96
®
 AQueous One Solution Cell 
Proliferation assay was performed, as reported previously (Cory et al., 1991). Assay 
reagent consists of two components: a tetrazolium compound, [3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; MTS] and 
phenazine ethosulphate (PES), an electron coupling reagent. A very high chemical 
stability of PES enables it to bind to MTS strongly. Bioreduction of the tetrazolium 
compound, MTS results in formation of a coloured product called formazan. This 
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product is soluble in the media the cells are grown in. Therefore, the amount of 
formazan produced and subsequently the absorbance recorded gives a measure of the 
number of viable cells present in each well of the 96-well culture plate.   
C2C12 cells were seeded in full growth media at a density of 2.5x10
3
 cells per 
well of a 96 well plate and transfected with different 2‟OMePS as described before. 
After 24 hours of transfecting the cells, the growth media was replaced with 75µl 
serum-free media and cells incubated at 37°C overnight. After 24 hrs, 15 µl of assay 
reagent was added to each well of the 96-well plate followed by incubation at 37ºC for 
four hours. Plates were read at 490nm after 4 hours. Statistical analysis on the data from 
the proliferation assay was performed using the individual t-test.  
2.10. CAGA assay 
2.10.1. Materials 
pGL3-(CAGA) 12-luc plasmid (Wyeth pharmaceuticals) 
Luria broth (Invitrogen, 12795-027) 
LB-SOC (Invitrogen, 10855-021) 
Lipofectamine™ 2000 (Invitrogen, 11668-019) 
Agar (Invitrogen, 22700-025) 
Ampicillin (Sigma, A0166-5G) 
EndoFree Plasmid Maxi kit (Qiagen, 12362) 
Luminometer (Bio-Rad laboratories) 
QIAprep Spin Miniprep kit (Qiagen, 27104) 
NEB 2 (Biolabs, B7002S) 
Recombinant mouse GDF-8/Myostatin (rndsystems, 788/GD/CF) 
Steady-Glo® Luciferase assay system (Promega, E2520) 
2.10.2. Methods 
2.10.2.1. E.coli transformation with pGL3(CAGA)12 
1ng plasmid pGL3(CAGA)12 was added to 50µl of competent E.coli (Top10F‟, 
Invitrogen) on ice and incubated for 20 minutes on ice. The tube containing the plasmid 
and bacteria was then put on a heat block at 42ºC for 30 seconds, and then back on ice 
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for 2 minutes. 250 µl of LB-SOC was then added to the tube, the components 
transferred to a 20 ml centrifuge tube and left it on a shaker at 37 ºC for 1 hour. After 
the incubation 100 µl of cells were put on an LB/agar plate with Ampicillin (1ml/litre) 
and left overnight in a shaker at 37 ºC. Next day, the colonies were picked from the 
plate and inoculated into 6ml of LB with ampicillin in 8 separate centrifuge tubes. The 
tubes were loosely capped and left overnight in a shaker at 37ºC. 
2.10.2.2. Mini prep 
Tubes with 1.5 ml of the bacterial suspension were centrifuged at 13,000 rpm for 10 
minutes. The pelleted bacterial cells were resuspended in 250µl of resuspension buffer 
P1 and vortexed until the pellet completely dissolved. 250 µl of lysis buffer P2 
(NaOH/SDS) was added and the tube mixed by inverting until the cell suspension 
turned homogeneously blue. This was followed by addition of 350 µl of neutralization 
buffer N3 and mixing the suspension by inverting the tube 4-6 times and then 
centrifugation at 13,000 rpm for 10 minutes. The supernatant was then put into the QIA 
prep spin column which was then centrifuged at 13,000 rpm for 30-60 seconds. The 
flow through was discarded, the column was washed with 0.5 ml washing buffer PB (to 
remove endonucleases) and then centrifuged for 30-60 seconds at 13,000 rpm. The flow 
through was again discarded and the column washed with 0.75ml of buffer P1 followed 
by another centrifugation for 1 minute in order to remove residual buffer. The column 
was then placed in a clean 1.5 ml tube and 50µl of EB buffer (for elution of plasmid 
DNA from QIAprep column) was added to the column. The column was allowed to 
stand for 1 minute and then centrifuged for 1 minute.  
2.10.2.3. Restriction digestion 
For double digestion (10 reactions), a master mix containing 20 µl of 10x NEB 2, 5µl 
Hind III, 5µl Xbal, 20µl of 10x BSA and 50µl of water was prepared. 10µl of this 
master mix was then added to 10µl of plasmid DNA in each of the 8 tubes. For linear 
digestion, 20 µl of 10x NEB 2, 5µl Hind III and 75µl water was used in the master mix 
and 10µl of this was added to another 10µl plasmid from each of the 8 replicates and 
incubated at 37ºC for one hour. The samples were then loaded on a 0.8% agarose gel 
and compared against Hyperladder I. 
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2.10.2.4. Maxi prep 
Two clones were selected from mini prep and 1ml of each added to two separate conical 
flasks containing 200ml of LB with ampicillin. The flasks were incubated overnight in a 
shaker at 37ºC. The cells were centrifuged at 3750 rpm for 30 minutes and the pellet re-
suspended in 10 ml of resuspension buffer P1 and vortexed to dissolve the pellet 
completely. 10ml of lysis buffer P2 was then added and tubes vigorously inverted and 
incubated at room temperature for 5 minutes. 10 ml of chilled neutralization buffer P3 
was then added to the lysate and mixed by vigorous inverting of the tube. The cap of a 
QIA filter cartridge was screwed in and the cartridge placed on a falcon tube. The lysate 
was then loaded on the barrel of the cartridge followed by incubation at room 
temperature for 10 minutes. The cap of the cartridge nozzle was the removed and 
plunger was inserted into the QIA filter cartridge in order to filter the lysate into the 
falcon tube. 2.5 ml of elution buffer EB was added to the filtrate and tube inverted to 
mix well followed by incubation at room temperature for 30 minutes. The QIAGEN tip 
500 was equilibrated by adding 10 ml of equilibration buffer QBT to it and allowing the 
column to empty by gravity flow. The lysate was then applied to the tip and allowed to 
pass through the resin by gravity flow. The column was then washed with 30 ml of 
washing buffer QC. The DNA was then eluted with 15 ml elution buffer QN. The eluate 
was recovered in a falcon and 10.5 ml isopropanol added to it to be followed by 
centrifugation at 15,000xg at 4ºC for 30 minutes. 5ml of endotoxin free 70% ethanol 
was then added and centrifugation carried out at 15,000g for 10 minutes. The 
supernatant was decanted off and pellet air-dried. The pellet was redissolved in 300µl 
TE buffer and stored overnight at 4ºC before recording the OD and storage at -20ºC.  
2.10.2.5. Reporter assay for measuring the biological activity of the cells 
pGl3 luciferase reporter vector backbone has a coding sequence for luciferase 
from a firefly (Photinus pyralis) and this sequence is optimized for transcriptional 
analysis of eukaryotic cells. pGL3 vector with twelve CAGA elements cloned into was 
used as a reporter system for assessing the changes in TGF-β-induced transcriptional 
activity of phosphorylated Smads. Luciferase is a popular choice in reporter assays due 
to rapid reaction and therefore production of functional enzyme immediately upon 
translation. The luciferase reaction involves mono-oxygenation of luciferin in the 
presence of Mg
2+
, molecular oxygen and ATP, catalyzed by luciferase (Kricka, 1988). 
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ATP is used as a cofactor although most of the energy for photon production is provided 
by molecular oxygen (Marques & da Silva, 2008). The Steady-GloTM luciferase assay 
has a very salient feature of high signal half-life which is about 5 hours in mostly used 
cell culture media giving this system high reproducibility under standard laboratory 
conditions (Kurata et al., 2004; Rose et al., 2005). 
 A204 cells were seeded in a 100mm plate at a density of 2.5x10
6 
cells in DMEM 
with L-Glutamine, FCS and antibiotics (100U/ml penicillin and 10µg/ml streptomycin). 
After 48 hours, cells were re-seeded in a 150 mm dish. 24-48 hours later, the cells were 
transfected with pGL3-(CAGA)12-luc (at a concentration of 4µg plasmid for every 
10mm growth area of the culture dish) using Lipofectamine™2000 (1/400) as the 
transfection reagent in DMEM and L-Glutamine and incubated at 37ºC and 5% CO2. 
After 3-4 hours, the media was replaced with full growth media and culture dish put 
back to the 37ºC incubator with 5% CO2 overnight. 24 hours later, the transfected A204 
cells were seeded in a 96-well dish for 24 hours in DMEM and L-Glutamine. The cells 
were transfected in a bigger dish before seeding them in a 96-well plate in order to have 
a uniform plasmid transfection. Next day, the recombinant mouse GDF-8/Myostatin 
was added to the cells at the concentrations (ng/ml): 0, 2.5, 5, 10, 20, 40, 80 diluted in 
serum-free media and the plate incubated at 37 ºC for 4-6 hours. Post incubation, 100µl 
of Steady-Glo® Reagent was added to each well and the plate read in a luminometer 
after 5 minutes.  
 After obtaining the dose response curve for myostatin, the conditioned media 
from C2C12 cells transfected with leashed PMO-D was incubated with A204 cells 
transfected with pGl3-(CAGA)12-luc (media in A204 cells was replaced with serum-free 
media 24 hours before addition of conditioned media from PMO-treated C2C12 cells) 
for 4-6 hours and signal induced on adding the assay reagent was read using a 
luminometer. The control in this case was the supernatant from C2C12 cells transfected 
with leash alone (without PMO) and Lipofectamine™2000. 
2.11. In vivo study 
2.11.1. Materials 
Sterile 0.9% injectable sodium chloride solution (Sigma, S8776)  
Hypnorm (VetaPharma, Vm21757/4000)  
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Hypnovel (Roche, AUST R 46348) 
OCT (Thermo scientific, LAMB-OCT) 
Mice used were: C57BL/10, mdx  
For all the in vivo experiments, animals were bought from Harlan (UK) and in-house 
maintained, and in vivo experimentation conducted under statutory Home Office 
recommendation, regulatory, ethical and licensing procedures and under the Animals 
(Scientific Procedures) Act 1986 (project licence PPL 70/7008).  
2.11.2. Methods 
The desired dilutions of the AOs were prepared in sterile injectable saline. For 
intramuscular injections, animals were anaesthetised via intraperitoneal injection of 
3µl/g body weight of 25% (v/v) fentanyl/fluanisone (Hypnorm) and 25% (v/v) 
midazolam (Hypnovel) in sterile saline and injections carried out into each of the tibialis 
anterior (TA) muscle using 0.5ml insulin syringe with a 28G x 13mm needle. Animals 
were injected with a desired dilution of the AO in sterile saline (25µl) into the TA 
muscle. During recovery, the animals were placed on a heating pad and monitored 
hourly for about 4 hours. Whole body weights were recorded weekly. TAs of treated 
and control mice were excised post mortem and weights were recorded. For intravenous 
injections, animals were placed in a heat chamber at 40ºC for 10 minutes and then 
injected with a desired dilution of the AO in sterile saline (200µl) via the tail vein using 
a 29G needle. Whole body weights were measured weekly and individual muscles were 
weighed on excising the muscles after sacrificing the animals. The muscles were 
embedded in OCT embedding medium and frozen in iso-pentane cooled with liquid 
nitrogen.  Cryosectioning was performed with OTF 5000 cryostat and 10µm transverse 
sections of each muscle were cut at up to 10 levels through the muscle length. The 
tissue cut in the intervening sections between the levels of a block was collected in pre-
cooled 1.5 ml eppendorf tubes for protein and RNA extraction and stored at -80ºC. 
2.12. Immunofluorescence and histological staining 
2.12.1. Materials 
Anti-Laminin (Sigma, L9393): 1/1000 dilution 
Alexa fluor® 568 goat anti-rabbit (Invitrogen, A-11011): 1/200 dilution 
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H12 polyclonal rabbit antibody (Sherratt et al., 1992): 1/400 dilution 
Avidin/Biotin blocking kit (Vector labs, SP-2001) 
Cryostat (Bright, OTF 5000) 
DAB kit (Vector labs, SK-4100) 
DakoCymation pen (Dako, S2002) 
DPX mountant (BDH, 360294H) 
Eosin Y (BDH, 34221HD) 
Ethanol: 50%; 80%; 100% 
Haematoxylin (Sigma, MHS16) 
Dry skimmed milk 
M.O.M kit (Vector labs, PK-2200) 
Mouse IgG Vectastain ABC kit (Vector labs, PK-6102) 
OCT (Optimal cutting temperature) compound (Raymond A Lamb-Labs, Lamb/OCT) 
Rabbit anti mouse kit (Vecor labs, PK-6101) 
Sreptavidin, Alexa fluor® 568 (Invitrogen, S-11226): 1/100 dilution 
Superfrost Plus microslides (VWR, 48311-703) 
Vectashield hard set mounting medium with DAPI (Vecor labs, H-1500) 
Xylene (BDH, 102936H) 
2.12.2 Methods 
2.12.2.1. Haematoxylin and Eosin staining 
10µm thick sections were cut from OCT-embedded muscle blocks using Bright OTF 
5000 cryostat. Sections were placed on superfrost plus microslides and left outside to air 
dry before storing them at -80ºC. Fifteen slides with up to 7-8 levels of muscle sections 
were prepared for each block. For staining, the slides were taken out of the -80ºC 
freezer and left on the bench for about 10 minutes to let them completely dry. The slides 
were then put in ice cold methanol and left in the fridge for 10 minutes. After taking the 
slides out of the fridge they were left to dry on the bench. The slides were then put in a 
coplin jar containing haematoxylin for 10 minutes followed by a quick wash in tap 
water. After the wash, slides were put in a coplin jar containing eosin for 5 minutes. 
This was followed by two quick washes in distilled water and then putting the slides in 
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50% Ethanol for 3 minutes; 80% ethanol for 4 minutes; 100% ethanol for 5 minutes and 
finally in fresh 100% ethanol again for 5 minutes. The slides were then put in xylene for 
10 minutes and mounted in DPX.  
2.12.2.2. Laminin and Dystrophin staining 
Slides were taken out of the -80C and left on the bench for about 10 minutes to let them 
completely dry. The slides were fixed with ice cold acetone at 4ºC for 5 minutes. The 
slides were then taken out and left to dry. An outline was drawn with a liquid blocker 
pen, DakoCymation pen in order to contain the reagents on the sections during 
treatment. The slides were then put in a humid chamber and blocked with 5% marvel 
(dry skimmed milk) in PBST for one hour at room temperature. Following incubation, 
the slides were given a quick wash in a PBST containing coplin jar. 2-3 drops of Avidin 
were then put on the slides for 15 minutes. The Avidin was then drained on a tissue 
paper and slides quickly given a rinse in PBST. 2-3 drops of Biotin were then put on the 
slides for 15 minutes followed by quick rinse in PBST. Primary antibody solution 
(1/1000) was prepared by adding 2µl of anti-laminin rat antibody to 2ml of 2.5% 
marvel. The required amount of the antibody solution was then put on each slide and the 
slide incubated at room temperature for one hour. Three washes for 5 minutes each were 
then given to the slides with PBST. Secondary antibody solution was prepared using 
vectashield rabbit anti rat mouse kit. To 10 ml of PBST, 3 drops of serum and 1 drop of 
anti-rat IgG (biotinylated) were added and the solution mixed well by inverting the tube. 
Equal amount of secondary antibody solution was then put on each slide and incubation 
at room temperature carried out for one hour. The slides were then washed thrice in 
PBST for 5 minutes each time. Tertiary treatment with 2µl Alexafluor® Sreptavidin-
568 (1/100) in 2ml of PBST was done for 6-7 minutes. Again three washes with PBST 
for 5 minutes each was done. The slides were then mounted in vectashield, hard-set 
mounting medium for fluorescence with DAPI. For Dystrophin staining the same 
protocol was followed but the primary antibody used was H12 Polyclonal rabbit 
antibody (1/400) and the secondary antibody used was Alexafluor goat anti-rabbit-568 
(1/200). 
2.13. Microscopy 
The images of stained tissue sections were captured using Leica application suite (Leica 
Microsystems, Germany). For fibre cross-sectional area analysis, the whole tissue 
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section was scanned and different regions were captured at 20X covering the entire 
tissue section making sure no overlaps took place. For the cross sectional area of the 
entire tissue section, images were captured at 5X. The images were recorded and 
processed using identical parameters of exposure, saturation, and gamma between 
differentially treated and untreated specimens. Analysis was performed using 
SigmaScan Pro 5 software as detailed in the next section. 
2.14. Sigma scan analysis 
For fibre cross sectional area analysis, the tissue section with the greatest cross sectional 
area was determined by eye. An image file was opened in SigmaScan Pro 5. F6 was 
then pressed to set intensity threshold (from which the software identifies the areas of 
interest and calls them objects (See the following screen shot representation). Then F2 
was pressed to confirm that „Area‟ is highlighted. In case of missing boundaries of the 
individual fibre, click on MODE on the main menu and then highlight „Overlay draw 
mode‟ and using right click and moving the pointer along the boundary of the individual 
fibres, define the object. Then press F12 to count and identify each object. All the 
counted objects have an individual identifying number and the area represented by the 
number of pixels is determined. This information is saved automatically into a separate 
spreadsheet. Identify the smallest and the biggest fibre and from the individual numbers 
for these fibres, look for the area in pixels against these numbers in the spread sheet. 
One can now disregard all objects that are larger than the largest identified fibre and 
smaller than the identified smallest fibre.  
To calculate the entire tissue area, after opening the image in SigmaScan, click on 
MODE on the menu bar, highlight „Trace measurement mode‟ and use a series of left 
clicks to define the internal edge of the entire tissue and finally a right click when close 
to the starting point to close the area. Press F12 and the program will calculate the 
number of pixels for the gross tissue area. The data in Excel was arranged in descending 
order to eliminate all the values beyond smallest and largest values as determined by 
SigmaScan. The values of area measurement were converted from pixels to µm
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depending on objective used. The fibre CSA values for all treated muscles and all 
control muscles were put together in one column each and frequency distribution was 
calculated using GraphPad Prism software. Statistical analysis was done using Chi-
squared analysis. 
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Representation of SigmaScan analysis (for fibre cross sectional area)  
 
 
 
 
 
2.15. Statistical analysis 
All the in vitro assay data (Proliferation assay and CAGA assay) and the animal tissue 
and gross body weight data was analyzed using two-tailed t-test (with standard error of 
mean). Standard deviation was calculated for percentage skipping of all treatment 
groups (Mean±SD). RT-PCR was performed on individually-treated-tissue bands unless 
otherwise stated that the tissues were pooled together. Densitometric analysis was 
followed by calculation of mean percent skipping and standard deviation. Fibre CSA 
was determined using chi-square test for frequency distributions.  
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CHAPTER 3 
DESIGN OF ANTISENSE OLIGONUCLEOTIDES TO INDUCE 
SKIPPING OF MOUSE MYOSTATIN EXON 2 AND CELL 
CULTURE STUDIES OF THEIR EFFICACY  
3.1 Introduction 
3.1.1. Bioinformatics analysis of myostatin exon 2 to predict AO target sites 
The first step to study AO-based exon skipping as a means of downregulating 
myostatin expression was to select the most amenable splicing motifs as the targets for 
AOs to skip the specific exons (Errington et al., 2003; Popplewell et al., 2009). In the 
case of DMD, different AOs targeted at specific exon(s) of dystrophin mRNA lead to 
restoration of reading frame and the resultant shortened but functional protein due to 
skipping of target exons (Aartsma-Rus et al., 2002; Dickson et al., 2002; Sherratt et al., 
1993). However, targeting one of the three exons of myostatin mRNA would disrupt the 
reading frame and result in downregulation of myostatin expression. It is quite difficult 
to precisely predict potential target ESE sites for AOs, therefore, three different 
computational methods namely, ESE Finder, Rescue ESE and PESX were used in 
conjunction in this study as discussed in the following sections.  
3.1.1.1 ESE prediction using ESE-Finder software 
Nearly 50% of point mutations causing genetic disorders result from aberrant 
splicing which further results either from blockade or creation of a splice site; or cryptic 
site activation; or intervention with splicing regulators (Cartegni et al., 2002). The SR 
protein domain responsible for RNA-binding attaches to the ESEs and further employs 
spliceosomal complex components which eventually leads to precise identification of 
exon boundaries (Fairbrother et al., 2002). An approach called systematic evolution of 
ligands by exponential enrichment (SELEX) has been used to predict putative ESE 
motifs of SR proteins that would bind to an ESE (Cartegni et al., 2002). ESE finder is a 
user-friendly www interface (http://rulai.cshl.edu/cgi-
bin/tools/ESE3/esefinder.cgi?process=home) that recognizes 6-8 nucleotide long 
possible ESE binding sites for SR proteins SC35, SF2/ASF, BRCA1, SRp40 and 
SRp55. ESE finder searches for the possible ESE sites in a given nucleotide sequence 
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based on the matrices relative to different SR protein motifs (Liu et al., 2000; Liu et al., 
1998). The software allows a sequence to be either pasted directly into the query box or 
be uploaded from a file in FASTA format (preceded by „<‟) (Cartegni et al., 2003). 
Multiple sequences can also be analyzed at the same time by separating the two 
sequences by a description for the following sequence in FASTA format. The sequence 
in question should however be in standard DNA notation. All the characters other than 
A, C, G and T will be ignored. Based on the matrices selected by the user, the program 
raises a series of scores. Initially only high score values for each matrix are displayed 
that correspond to the values greater than threshold value which is set in the input page. 
Default threshold values are the median of each sequence‟s highest score. For an easier 
and standardized representation of the results, a graphical output is generated that has 
the exonic sequence on the X-axis. Colour coded bars indicate the scores of different 
motifs above the selected threshold values. The breadth of the bars indicate the position 
and length along X-axis of the motifs whereas, the height represents the motif score 
(Cartegni et al., 2003). It has been demonstrated by using ESE finder matrices that 
interruption of ESEs identified by different SR proteins is capable of inducing exon 
skipping (Caputi et al., 2002; Cartegni & Krainer, 2002; Fackenthal et al., 2002; Smith 
et al., 2002). Importantly, the ESEs predicted using ESE finder, have been shown to be 
gathered in the regions where ESEs have been experimentally positioned (Liu et al., 
1998). Also the frequency of these putative ESEs is higher in exons than in introns (Liu 
et al., 2000; Liu et al., 1998).  At least one of the predicted ESEs was shown to be either 
deleted or diminished in 50 point mutations causing exon skipping in humans (Dance et 
al., 2002). In another bioinformatics tool, RESCUE ESE 
(http://genes.mit.edu/burgelab/rescue-ese/), the potential motifs of ESE are determined 
by frequencies of exon hexamers bound by weak or strong splice sites (Fairbrother et 
al., 2002). Hexamers with weaker splice sites are expected to depend more on the ESEs 
for splicing (Fairbrother et al., 2002) and some outputs from the RESCUE ESE and 
those from ESE Finder have shown overlaps. It is however important to note that ESE 
activity and the numerical scores cannot be strictly correlated. This is due to a number 
of variable factors including the presence of silencer elements or/and splice-site 
strengths. Therefore, the presence of a high score motif does not always mean that there 
is an ESE located at that position and also conversely, absence of a high score does not 
necessarily mean there is no ESE present at that site. This could also be due in part to 
certain redundant ESEs present near the actual ones that do not let the mutation of the 
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actual ESE to exert a significant effect (Cartegni et al., 2003). As these matrices were 
developed in mammalian system, the sequence precision in human SR proteins is 
depicted and the application to other species will depend upon the degree of 
conservation of a particular SR protein across various species (Cartegni et al., 2003). 
3.1.1.2. ESE predictions using the RESCUE ESE (relative enhancer and silencer 
classification by unanimous enrichment) software  
Another computational method to predict ESE activity called RESCUE ESE 
(http://genes.mit.edu/burgelab/rescue-ese/) has been developed. ESEs are recognized 
using this approach by looking up for hexanucleotides that fitted in to the following 
criteria: the hexanucleotides that were significantly more enriched in exons than in 
introns; that are present in exons with non consensus (weak) splice sites at a 
significantly higher rate than in exons with strong (consensus) splice sites. Point 
mutations of these predicted hexanucleotides resulted in more than two folds reduction 
in exon inclusion in 90% of the cases (Fairbrother et al., 2002). Weak exons that have 
nonconsensus splice sites have greater selective pressure to have ESEs as compared to 
the stronger exons, thereby increasing the occurrence of ESEs in weak exons (Graveley, 
2000). The sequence in question is either pasted directly or uploaded in multi-FASTA 
format. Once a vertebrate choice is made and the exon sequence is pasted in the query 
box preceded by “<” symbol, the output is shown in another section at the bottom of the 
page showing all the possible ESE positions along the sequence of the exon being 
investigated. 
3.1.1.3. ESE and ESS predictions using PESX (putative exonic splicing 
enhancers/silencers) software  
PESX (http://cubweb.biology.columbia.edu/pesx/) is an algorithm that focuses 
more on the information from non-protein coding exons. Comparative study of the real 
and pseudo exons (intronic regions that are similar to exons due to being bound by 3‟ 
and 5‟ splice sites and also because of being of same size as a typical exon) helps in 
understanding the distinctive sequence information used by the cellular machinery for 
precise splicing. This splicing information comes from the splicing code comprised of 
exon splicing enhancers (ESEs), exon splicing suppressors (ESSs), Intron splicing 
enhancers (ISE) and Intron splicing silencers (ISS) (Fu, 2004). The focus of this 
algorithm is on ESEs and ESSs. The exons with weak splice sites are expected to have 
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high ESE content for recognition compared to the exons with strong splice sites 
(Fairbrother et al., 2002). Therefore an exon with no protein-coding information would 
have more ESEs than the ESSs. This tool compares the 8-mer (allowing one mismatch) 
frequencies in non-protein-coding exons with those in 5‟untranslated regions (5‟UTRs) 
of intronless genes and pseudo exons. Pseudo exons and 5‟UTRs should therefore have 
more ESSs than the ESEs. The more frequently occurring sequences in non coding 
regions are nominated as alleged ESEs and the ones occurring less frequently are 
termed as putative ESSs (Zhang & Chasin, 2004). 
3.1.2. Assessment of the activity of the designed AOs with C2C12 cells in culture 
C2C12 cell line is an established murine pure myogenic cell line derived from 
C3H mice by injuring the muscle. Due to their proliferative and differentiation activity 
in cell culture, C2C12 cells have been widely used to study skeletal muscle cell growth 
and development, protein expression as well as in various exon skipping studies (Wilton 
et al., 1999; Yaffe & Saxel, 1977). Myogenesis of C2C12 cells has been shown to be 
regulated by myostatin (Rios et al., 2001; Taylor et al., 2001). In order to test the 
efficacy of the AOs designed using different software described above, transfection of 
the C2C12 cells with these AOs was carried out. The transfections were carried out in 
serum-free media to avoid any interference in the results from myostatin present in 
media. The transfection reagent used was Lipofectamine™ 2000 as it is a standard 
transfection reagent for DNA or small RNA-based molecules like siRNA. 2‟OMePS 
were used at 250nM concentration because this concentration has been previously 
reported as minimal effective dose for 2‟OMePS (Graham et al., 2004a) 
3.1.3. Assay for assessment of proliferation of C2C12 cells followed by transfection 
with AOs  
To verify the biological effect of myostatin exon skipping, a proliferation assay 
based on dehydrogenase activity of metabolically-active cells was performed. Cell Titer 
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 AQueous One Solution Cell Proliferation assay kit allows the colorimetric 
quantification of the viable number of cells. The direct relationship between the 
absorbance and number of cells is explained on the basis of dehydrogenase activity of 
the biologically active cells that results in production of NADPH or NADP which are 
responsible for MTS to formazan conversion (Berridge & Tan, 1993; Cory et al., 1991).  
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3.1.4. Delivery of PMOs based on 2’OMePS sequences to induce myostatin exon 2 
skipping in C2C12 cells 
The PMO chemistry has been shown to have high nucleic acid binding, 
nuclease-resistance and high solubility in aqueous solutions (Alter et al., 2006; 
Summerton & Weller, 1997). PMOs have been reported to exhibit higher efficiency and 
better restoration of dystrophin expression in mdx mice (Alter et al., 2006) as well as in 
dystrophic dogs across various skeletal muscles in the body compared to other 
chemistries (Yokota et al., 2009). However, PMOs being neutral in charge are incapable 
of diffusion across the membrane of the cell and therefore need to be administered at a 
much higher concentration to see a reasonable effect (Sazani et al., 2001; Suwanmanee 
et al., 2002). Standard cationic transfection reagents are therefore not sufficient on their 
own for PMO delivery in cell culture. In the case of mouse dystrophin exon 23 
skipping, PMOs were conjugated to different complementary DNA or RNA sequences 
in order to surmount this problem and these sequences were termed „leashes‟ (Morcos, 
2001). When PMOs were delivered complexed with a leash in the presence of a 
standard transfection reagent to induce dystrophin exon 23 skipping in mdx cells, they 
were effective at much lower concentrations as compared to the unconjugated PMO 
(Sazani et al., 2001). Conjugation to a leash has led to effective delivery and nuclear 
uptake of PMO (Popplewell et al., 2010). 
3.1.5. Reporter assay for determining the modulation of myostatin pathway by 
PMO-mediated exon skipping in C2C12 cells  
It has been demonstrated that Smad 2 and Smad 3 are involved in TGF- β and 
activin signalling however Smad1, Smad5 and Smad9 are responsible for bone 
morphogenetic protein (BMP) signalling (Chen et al., 1997b; Liu et al., 1996; Suzuki et 
al., 1997). These pathway-restricted Smad 2 and Smad3 form a heteromeric complex 
with Smad 4 which is a common component of TGF-β, activin and BMP signalling. The 
complexed Smads then move to the nucleus and regulate the transcription of various 
genes (Meersseman et al., 1997). Smad 6 and Smad 7 have been shown to have an 
inhibitory effect on the phosphorylation of Smad 3 and Smad 4 (Hata et al., 1998; 
Hayashi et al., 1997). Several genes responsible for cell cycle regulation like Cyclin 
Dependent Kinase inhibitors (p21, p15) (Elbendary et al., 1994) and also for the 
formation of extra cellular matrix, like Plasminogen activator inhibitor 1 (PAI-1), 
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fibronectin and procollagen are known to be activated by TGF-β (Inagaki et al., 1994; 
Westerhausen et al., 1991). Certain regions in the PAI-1 gene promoter have been 
reported to be responsive to TGF-β as the PAI-1 gene is strongly induced by TGF-β 
(Macias-Silva et al., 1996). A combined over expression of Smad 2, Smad 3 and Smad 
4 resulted in induction of endogenous PAI-1 promoter (Macias-Silva et al., 1996). Short 
repetitive DNA elements in PAI-1 gene have been reported to be responsible for TGF- β 
responsiveness (Dennler et al., 1998). When studies were carried out to identify these 
elements in the TGF-β responsive region of human PAI-1 promoter, three copies of the 
sequence AG(C/A)CAGACA were found at three different positions (Dennler et al., 
1998). The sequence was named as CAGA box and cloned into a transcriptional 
reporter system in order to analyze its role in the induction of PAI-1 by TGF-β.  
When one of the three CAGA sequences was mutated by insertion of a mutant 
sequence (that was not induced by TGF-β), TGF-β induction was reduced compared to 
the wild type promoter. This response was more pronounced with mutations in two 
CAGA sites and PAI-1 promoter almost completely failed to respond to the TGF-β 
when all three sites were mutated. The CAGA elements have been shown to be 
specifically responsive to TGF-β and not to BMP (Dennler et al., 1998). Myostatin 
propeptide has been shown to decrease the transcriptional activity of endogenous Smad 
proteins and therefore reduced TGF-β responsiveness to CAGA elements (Thies et al., 
2001; Whittemore et al., 2003). CAGA assay has also been used to demonstrate 
neutralizing activity of the monoclonal antibody JA16 (Whittemore et al., 2003). In 
another study, the CAGA elements were inserted into a promoter that controls the 
expression of Green fluorescence protein (GFP) in order to show a reduction in the 
transcriptional activity of endogenous Smad 2 in human myoblasts which expressed 
dominant negative form of ActRIIB (Fakhfakh et al., 2011). 
3.2. Aims of the chapter 
In this chapter, design of various AOs targeted at mouse myostatin exon 2 using 
different bioinformatics algorithms has been described. The aim was to validate the use 
of different bioinformatics programs to design various AO sequences followed by 
testing their efficacy to downregulate myostatin mRNA by inducing exon skipping in 
skeletal muscle cell line C2C12. This involved optimising the transfection conditions, 
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testing various different primers and validating the PCR program for amplification of 
mRNA from the treated and control cells.  
The study was also aimed at assessing any changes in the myostatin bioactivity 
following antisense-treatment.  
PMO is one of the desirable chemistries for clinical applications. Use of the best 
2‟OMePS AO sequences to design PMO reagents and testing their efficacy in cell 
culture was another aim of the study in this chapter.  
 
3.3. Results 
3.3.1. Prediction of exon splicing enhancers (ESEs) and suppressors (ESSs) in exon 
2 of mouse myostatin gene  
The myostatin exon 2 pre-mRNA sequence was pasted into the query box of ESE 
Finder software in FASTA format and the output generated showed different coloured bars 
representing different SR protein motifs. This indicates the probability of presence of that motif 
in a particular position. Figure 3.1 shows the result from ESE Finder for the myostatin 
exon 2 mRNA for putative ESEs. An output of the results obtained from pasting the 
myostatin exon 2 pre-mRNA sequence (in FASTA format) in the query box of 
RESCUE ESE and PESX is shown in Figure 3.2 and Figure 3.3 respectively.  
Having analysed mouse myostatin pre-mRNA using different individual 
bioinformatics tools to predict ESE sites as potential targets of exon skipping, the 
results from all the three tools were combined. The predicted sequences which showed 
overlaps using all the three tools were taken into account and 20-mer AO sequences 
were designed around these sites. Four main sites in the whole exonic sequence were 
selected (based on coinciding ESE sites as predicted by at least two algorithms) and a 
set of three overlapping AOs were designed in each of these four regions ( a total of 12 
AOs) as shown in Figure 3.4. The three 20-mer AO sequences in every set were 
designed such that the last ten bases of AO-1 and first 10 bases of AO-2 overlapped, 
and so did the last ten bases of AO-2 and first ten bases of AO-3. Therefore, a total of 
twelve 2‟OMePS AOs were designed for testing their exon skipping efficacy in vitro as 
well as in vivo. Sequences and positions of 2‟OMePS and PMO AOs are shown in 
Figure3.5. 
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Figure 3.1 
 
 
Figure 3.1. The ESE Finder output for myostatin exon 2: Different coloured bars represent different SR protein motifs as labelled in the panel below the 
figure. The width of each column represents the location and length across which a motif is possibly present and the height of each bar depicts the score for 
that particular motif above a set threshold value, which implies the probability of presence of that motif in a particular position.
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Figure 3.2 
 
 
Figure 3.2: RESCUE ESE result for myostatin exon 2 mRNA analysis. Every 50
th
 
nucleotide is shown in red. Laddered green nucleotides are the putative ESEs as predicted by 
RESCUE ESE along the length of the exon sequence (shown in black). 
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Figure 3.3 
CTGACTTTCTAATGCAAGCGGATGGCAAGCCCAAATGTTGC 
TTTTTTAAATTTAGCTCTAAAATACAGTACAACAAAGTAGTAAAAGC
CCA 
ACTGTGGATATATCTCAGACCCGTCAAGACTCCTACAACAGTGTTTG
TGC 
AAATCCTGAGACTCATCAAACCCATGAAAGACGGTACAAGGTATACT
GGA 
ATCCGATCTCTGAAACTTGACATGAGCCCAGGCACTGGTATTTGGCA
GAG 
TATTGATGTGAAGACAGTGTTGCAAAATTGGCTCAAACAGCCTGAAT
CCA 
ACTTAGGCATTGAAATCAAAGCTTTGGATGAGAATGGCCATGATCTT
GCT 
GTAACCTTCCCAGGACCAGGAGAAGATGGGCTG 
 
Figure 3.3: PESX analysis for myostatin exon 2 mRNA: The positions of predicted ESEs are 
shown in green and that of ESSs are shown in red. The first ESS/ESE bases are shown in bold 
letters and are underlined. 
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Figure 3.4: Joint representation of results from all the three different bioinformatics 
algorithms for designing AOs for mouse myostatin exon 2  
Positions of twelve different 20-mer AOs designed relative to the exon 2 pre-mRNA of mouse 
myostatin obtained on combining the outputs of three different bioinformatics programs are 
shown. The ESE Finder analysis shows the location and values above threshold for SR protein 
binding motifs, SF2/ASF, SF2/ASF (BRCA 1), SC35, SRp40 and SRp55 which are shown as 
vertical bars above the sequence of exon 2. The Rescue ESE analysis shows the position of 
possible exonic splicing enhancer sites as black horizontal lines in a box parallel to the sequence 
of exon 2. The PESX analysis shows the location of ESEs as green horizontal lines, and exon 
splicing silencers (ESSs) as red horizontal lines in a different box below Rescue ESE output. 
The black horizontal laddered lines at the bottom represent the sequence of the 20-mer AOs 
which were obtained after aligning the outputs from the three algorithms. 
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    Figure 3.4 
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Figure 3.5a 
 
Figure 3.5b 
                 
Figure 3.5(a) Sequence of AOs targeted at mouse myostatin exon 2 designed using 
bioinformatics analysis. 20-mer Sequences of 2‟OMePS AOs with their positions in the exon 2 
of mouse myostatin. Each 2‟OMePS AO-1 had an overlapping region of 10 bases to AO-2 and 
each AO-2 had an overlapping region of 10 bases to AO-3. (b) Sequence of PMOs.  30-mer 
AOs of PMO chemistry designed based on the sequences of 2‟OMePSs. The 2‟OMePS 
sequences of AO-2 and AO-3 of each of the four sets were merged together to make a 30-mer 
PMO sequence. Comparison of vertebrate myostatin mRNA sequence (3‟ to 5‟) against which 
AO-3 (used for all PMO experiments in vivo) was designed is also shown. Human, mouse and 
rat sequences have 100% homology for this AO whereas rat sequence has a mismatch of single 
base. Although PMO study is discussed later, the sequences are shown here for a better 
comparison and positioning relative to 2‟OMePS sequences.  
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3.3.2. Myostatin exon 2 skipping in C2C12 cell culture following treatment with a 
range of AOs targeting ESEs 
In order to verify the exon skipping potential of the designed AOs, C2C12 
myoblast cultures were transfected (using Lipofectamine™ 2000)  separately with all 
the twelve 2‟OMePS (250nM) in serum-free media. After 4 hours of transfection, the 
media was replaced by full growth media containing 10% serum to let the cells 
proliferate under normal growth conditions. RNA was then extracted from the cells 24 
hours after transfection and nested RT-PCR for skipping of myostatin performed on the 
RNA from transfected and control cells. The primers for the RT-PCR were designed to 
yield a full length product of 587 bps. Nested PCR primers were designed to give a full 
length product of 532 bps. Skipping of myostatin exon 2 (374 bps) results in the 
production of a product that is 158 bps long. A representative horizontal agarose gel 
(1.2%) electrophoresis separation of products obtained is shown in Figure 3.6. The 
level of skipping produced by each AO at 250nM was semi-quantified by densitometric 
analysis using the image analysis software, Gene Tools. All twelve 2‟OMePSs induced 
myostatin exon 2 skipping to different levels. A2 and A3 induced almost complete 
skipping; B3, C3, and D3 induced 74%, 41% and 48% skipping. The nature of putative 
antisense-induced exon1-exon3 splicing product was confirmed by sequencing the 
products. 
 
 
 
 
 
 
 
 
 
 
101 
 
Figure 3.6        
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6: Comparison of efficacy of different 2’OMePS AOs to induce myostatin exon 2 
skipping in C2C12 cell cultures. RT PCR was performed on 1µg mRNA from C2C12 cells 
treated with twelve different 2‟OMePS AOs at 250nM concentration. Transfections were 
performed in duplicates and the nested RT PCR products were loaded on 1.2% agarose gel as 
follows: Tracks 1 and 2: oligomer A1; Tracks 3 and 4: oligomer A2; Tracks 5 and 6: oligomer 
A3; tracks 9 and 10: oligomer B1; Tracks 11 and 12: oligomer B2; Tracks 13 and 14: oligomer 
B3; Tracks 15 and 16: oligomer C1; Tracks 17 and  18: oligomer C2; Tracks 19 and 20: 
oligomer C3; Tracks 23 and 24: oligomer D1; Tracks 25 and 26: oligomer D2; Tracks 27 and 
38: oligomer D3; Tracks 7, 8, 21 and 22: controls with transfection reagent Lipofectamine 2000 
alone, but no AO; Size Marker used was HyperLadder IV.       
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3.3.3. Assessment of level of proliferation of C2C12 cells transfected with 
myostatin exon-skipping 2’OMePS AOs  
The assay reagent was added to the cultured C2C12 cells which were 
transfected with the AOs (A3, B3, C3 and D3; based on the best RT-PCR results) using 
Lipofectamine™ 2000 as well as to the control cells without any AOs in a 96-well plate. 
The plates were incubated at 37ºC for 4 hours. Following incubation the plate was read 
at 490nm. The results of the proliferation assay showed a significant difference in cell 
proliferation in transfected C2C12 cells, compared to the untreated control cells (Figure 
3.7). Statistical analysis of the data using individual t-test showed that the 2‟OMePS A3 
(p=0.0031), B3 (p=0.0055) and D3 (p=0.0115), induced a significant increase in cell 
proliferation, as compared to untransfected control cells. C3 (p=0.0534) did not produce 
a statistically significant change. The experiment was done in six replicates per 
condition. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
103 
 
Figure 3.7 
 
 
 
 
 
 
 
 
 
 
Figure 3.7: Proliferation assay for the C2C12 cells treated with myostatin exon skipping 
AOs. C2C12 cells were treated with four of 2‟OMePS oligomers (A3, B3, C3 and D3) using 
Lipofectamine™ 2000 (LF2000), and assayed 24h later for determining the cell proliferation by 
lactic dehydrogenase assay. The transfections were performed in 6 replicates for each condition 
(6 wells transfected with each AO as well as controls, a total of 30 wells). t-test analysis with 
standard error of the mean,*: p<0.05; **: p<0.01.  
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3.3.4 Myostatin exon skipping efficacy of PMOs designed based on the most 
efficient 2’OMePS sequences in C2C12 cells  
PMOs were designed on the basis of the sequences of the most efficient 
2‟OMePS AOs (A3, B3, C3 and D3) and initially tested in C2C12 cells after linking to 
a complementary stretch of DNA (leash) to improve delivery. The sequence and 
position of different leashes are shown in Figure 3.8. Nested RT PCR analysis of 
mRNA harvested from PMO-treated C2C12 cells demonstrated that exon skipping was 
induced by all the PMOs tested as shown in Figure 3.9.  
3.3.5. Reporter assay for modulation of the myostatin signalling pathway in C2C12 
cells by PMO-mediated exon skipping 
The reporter vector used for the reporter assay was a modification of basic pGL3 
luciferase vector which is highly flexible in allowing cloning of putative regulatory 
sequences due to the absence of promoter and enhancer sequences. pGL3 luciferase 
reporter vector backbone has a coding sequence for luciferase from a firefly (Photinus 
pyralis) and this sequence is optimized for transcriptional analysis of eukaryotic cells. 
Twelve CAGA elements were cloned into the pGL3 vector in order to develop a 
reporter system for assessing the changes in TGF-β-induced transcriptional activity of 
phosphorylated Smads (Diagrammatic representation Figure 3.10). Mini preps and 
maxi preps were carried out for pGL3(CAGA)12-luc and the purified plasmid was used 
to transfect the human rhabdomyosarcoma A204 cells. Figure 3.11 shows the products 
of restriction digestion using different restriction enzymes to confirm the structure of 
the plasmid.  
Myostatin dose response curve was prepared by assaying different 
concentrations of myostatin onto the A204 cells transfected with pGL3-(CAGA)12-luc. 
A204 cells were transfected with the plasmid pGL3-(CAGA)12-luc in a 100mm dish 
first and 24 hours later seeded into 96-well dish in order to ensure uniform transfection 
in each well. Serum-free media was added to A204 cells 24 hours prior to adding 
myostatin dilutions to them. Dilutions of recombinant myostatin ranging from 2.5, 5, 
10, 20, 40 and 80 ng/ml were assayed on to the transfected A204 cells and a standard 
curve obtained (as shown in Figure 3.12). The assay was performed in eight replicates 
per dose of treatment as well as for control. 
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Figure 3.8 
 
 
 
                                      
                                         
 
                     
                                                                                         
 
 
 
 
 
 
Figure 3.8: Position of the “leashes” relative to PMO sequence: The sequence of the PMO is 
shown in 5‟ to 3‟ orientation while leash sequence is shown in the complementary orientation. 
The complementary leash sequence is shown in blue while the non-complementary overhangs 
are shown in red colour.  
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Figure 3.9  
 
 
                
 
 
 
 
Figure 3.9: Demonstration of myostatin exon 2 skipping in C2C12 cell culture following 
treatment with a range of leashed PMO lipoplexes. C2C12 cell cultures treated with a range 
of leashed PMOs in lipoplex form with Lipofectamine™ 2000 exhibited skipping of exon 2 in 
myostatin mRNA. RT PCR was performed on 1µg mRNA from C2C12 cells treated with 
250nM PMOs (designed on the basis of the most effective 2‟OMePS sequences: A3, B3, C3 and 
D3) for a period of 24 hours. Transfections were performed in triplicate and RT PCR products 
were loaded on 1.2% agarose gel as follow: Tracks 1-3: PMO-A; Tracks 4-6: PMO-B; Tracks 7-
9; PMO C; Tracks 10-12; PMO-D; Tracks 13-15 : Lipofectamine™ 2000-treated control; Track 
marked „M‟: Size marker, HyperLadder IV 
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Figure 3.10 
                                 
                                                        
Figure 3.10: A diagrammatic representation of a Smad2 dependent reporter with a 12 
times repetition of Samd2-binding site (CAGA) that further controls the expression of a firefly 
luciferase (Adapted from (Sartori et al., 2009)).  
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Figure 3.11 
 
 
Figure 3.11: Restriction digestion for confirmation of CAGA plasmid structure. For 
purification of pGL3 plasmid DNA containing (CAGA)12-luc, E.coli transfections were carried 
out with the reporter plasmid and ampicillin selection was performed. The competent colonies 
were then picked and a mini prep carried out for the same. In order to verify plasmid structure, 
restriction digestion was performed. For linear digestion only Xba1 was used whereas for 
double digestion, HindIII and Xba1 were used. The expected length of the PCR product for 
linear digestion with Hind III was 4926 bps and that for double digestion were 3237 bps and 
1689 bps. Wells 1 to 8 in both the cases were loaded with eight different clones whereas ninth 
well was loaded with the uncut plasmid. Marker used was HyperLadder I. 
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C2C12 cells were treated with leashed PMO-D in serum-free media and 
incubated at 37ºC for 24 hours and 48 hours in different 6-well culture dishes. As 
controls, C2C12 cells were treated with just the leash in the presence of 
Lipofectamine™ 2000. The conditioned media from the cells was harvested after 24 
hours and 48 hours. A204 cells were transfected with pGL3-(CAGA)12-luc and after 48 
hours were plated in opaque 96-well plates compatible for luminometer. Conditioned 
media from treated and control C2C12 cells was added to the pGL3-(CAGA)12-luc-
transfected A204 cells and plates incubated for 4-6 hours at 37ºC. After the incubation, 
the assay reagent from the Steady-Glo™ luciferase kit was added to the cells and plates 
read in a luminometer. The results depicted no significant change in the biological 
activity of the treated cells compared to the control cells after 24 hours measured as the 
Relative Light Units (RLU) although there was a trend towards decrease in luciferase 
signal in case of PMO-treated cells compared to the control cells. After 48 hours, the 
luciferase expression was significantly decreased for treated cells (p=0.0111) compared 
to the control cells as shown in Figure 3.13. Therefore, myostatin exon skipping in a 
mouse muscle cell line resulted in reduced biological activity of the treated cells 
compared to the control cells as shown by lower luciferase expression due to decrease in 
the TGF-β responsiveness.  
The amount of myostatin present in the cells after PMO-treatment compared to 
the control cells was calculated from the myostatin standard curve (Figure 3.14). The 
PMO sequence used for this study (PMO-D) induced efficient skipping in vitro and also 
resulted in a significant increase in proliferation of treated cells. It also maps in a region 
totally conserved between mouse and human myostatin. The mean value of Relative 
light units (RLUs) obtained for PMO-D-treated cells was 289 and for control cells was 
453. From the standard curve equation (y = 18.62x + 215.2), the amount of myostatin 
for PMO-treated cells was calculated to be 3.96 ng/ml and for control cells was 
calculated to be 12.77 ng/ml. Therefore, the AO-treated cells showed a 68.9% decrease 
in the biological activity dependent upon TGF-β signalling pathway after AO-induced 
exon skipping of myostatin. Controls had no myostatin treatment and the mean RLU 
values from controls were subtracted from the mean RLU values of treated cells. 
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Figure 3.12 
 
 
 
 
Figure 3.12: Myostatin dose response curve: A204 cells were transfected with pGL3-
(CAGA)12-luc and put in serum-free media 24 hours prior to the addition of myostatin. 
Transfected A204 cells were incubated with different myostatin dilutions (2.5 ng/ml; 5 ng/ml; 
10ng/ml; 20 ng/ml; 40 ng/ml and 80 ng/ml) for 4 hours in serum-free media. After 4 incubation, 
luciferase assay was performed using Steady-Glo luciferase kit by adding 100μL of assay 
reagent to each well including the controls with no myostatin. After five minutes following the 
addition of assay reagent, the plate was read using a luminometer and mean of the background 
from the wells without any myostatin was subtracted from the mean of luminescence from 
different myostatin dilution replicates. A standard curve after subtracting background was then 
plotted for relative light units (RLU) against myostatin concentration. The assay was done in 
eight replicates for each myostatin dilution. 
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Figure 3.13 
   
                                
 
 
 
 
 
 
 
 
 
Figure 3.13: Reporter assay for estimation of biological activity of C2C12 cells after 
treatment with leashed-PMO-D to skip myostatin exon 2. C2C12 cells were transfected with 
leashed PMO-D and the conditioned C2C12 media was assayed on pGL3-(CAGA)12-luc-
transfected A204 cells after 24 hours and 48 hours of transfection. Each transfection was done 
in eight replicates; p=0.0111; two-tailed t-test with standard error of  mean. 
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 Figure 3.14 
 
 
 
Figure 3.14: Estimation of the reduction in the amount of myostatin following PMO 
treatment. The mean RLU values for conditioned media from PMO-D-treated and control 
C2C12 cells (for the 48 hours time point) assayed on the reporter plasmid-transfected A204 
cells were substituted in the equation obtained from the myostatin standard curve and amount of 
change in myostatin concentration was calculated.  
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3.4. Discussion 
This part of the study was aimed at designing antisense oligonucleotides 
targeting myostatin exon 2 and verification of the feasibility of this approach to 
downregulate the expression of myostatin mRNA in cell culture. Although targeting 
donor splice site, acceptor splice sites and branch point sequences has successfully led 
to exon exclusion including DMD exon skipping (Graham et al., 2004b; Wilton & 
Fletcher, 2005a; Wilton et al., 2002), some studies have suggested that targeting splice 
sites does not always induce exon skipping (Wilton et al., 2006). These contain some 
consensus sequences common to many other genes; therefore there lies a possible risk 
of disrupting the splicing of non-specific genes (Aartsma-Rus et al., 2009). Exon 
splicing enhancers (ESEs) motifs form the binding sites for SR-protein RNA domains 
and thus help the splicing machinery in exon recognition (Stojdl & Bell, 1999). As SR 
protein binding to ESEs is very crucial for exon inclusion, blocking the ESEs with 
antisense oligonucleotides is expected to result in exon skipping. Different software 
including  RESCUE ESE (Burge et al., 2002; Burge et al., 2004), ESEFinder (Krainer 
et al., 2003) and PESX (Chasin & Zhang, 2004) have been widely used to predict 
possible ESE sites for different SR domains in order to assist in designing AOs 
(Aartsma-Rus et al., 2004a; van Deutekom et al., 2002; van Deutekom et al., 2003) and 
therefore the same programs were used for this study.  
The results predicting the presence of ESEs and ESSs along the myostatin exon-
2 pre-mRNA using the above mentioned three bioinformatics programs were aligned 
together. ESE finder generates different coloured bars based on the probability of 
presence of different SR protein domains in a particular region defining its location and 
score. An emphasis was laid on regions with clusters of various SR binding domains 
rather than isolated higher peaks. The regions picked up by ESE finder, Rescue ESE 
and PESX were overlapped to narrow down and identify common regions of ESE sites 
as predicted by each program. Therefore, four different regions were chosen in exon 2 
mRNA of myostatin where there was a coincidence of overlapping output from all the 
three programs avoiding the areas of putative ESS as predicted by PESX. A set of three 
overlapping AOs in each of these four regions were designed.  
2‟OMePS chemistry was used for the preliminary tissue culture studies because 
of the advantages of cheap and easy synthesis and ease of use due to charged backbone 
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over the uncharged PMO chemistry (Agrawal, 1999; Sazani et al., 2002b). RNA from 
all the C2C12 cells transfected with twelve different 2‟OMePS AO sequences showed 
skipped myostatin exon 2 as demonstrated by RT-PCR (Figure 3.6) along with the full 
length product. A study to test the AO sequences which seem to have weaker or no 
biological activity at all from these algorithm predictions would be able to validate 
further the integrity of our method of AO sequence selection. As myostatin has been 
established to be a negative regulator of muscle mass growth and differentiation (Grobet 
et al., 1997; McPherron et al., 1997; Szabo et al., 1998), a decrease in its level is 
expected to result in enhanced proliferative capacity of muscle cells (Thomas et al., 
2000; Zhu et al., 2000). Therefore, a colorimetric proliferation assay based on the 
principle of bioreduction of a tetrazolium compound by viable cells gives a quantitative 
measure of living cells present in a system (Berridge & Tan, 1993). On performing this 
assay on cells treated with four different AOs (one from each of the four sets based on 
RT PCR results), it was observed that the cells treated with AO-A3 showed increased 
proliferation compared to control cells (p<0.01), treatment with AOs B3 and D3 also 
showed an increased cell proliferation (p<0.05), whereas AO-C3 did not lead to a 
significant increase in level of proliferation compared to the control cells.  
Exon skipping is dependent upon the AO‟s ability to reach nucleus and interfere 
with the spliceosome machinery. PMO chemistry has high nuclease resistance 
(Summerton & Weller, 1997) but due to uncharged background they cannot be 
delivered efficiently across cells using cationic liposomes. Therefore, they need to be 
used at very high concentrations (Sazani et al., 2001; Suwanmanee et al., 2002). Thus, 
an anionic single-stranded nucleic acid molecule called „leash‟ was annealed to the 
PMO in order to mediate complex formation of PMO with the cationic transfection 
reagent. Various parameters including length of the annealing leash, extent and position 
of non-complementary overhangs and chemistry have been studied by other researchers. 
It is important for the leash to have enough stability to be delivered to the nucleus and 
also to retain some nuclease liability to liberate PMO from PMO: leash duplex. In order 
to maintain a balance between resistance and susceptibility to degradation, various 
chemistries have been studied (Gebski et al., 2003). Presence of non-complementary 
overhangs particularly at 5‟end has been shown to increase accessibility of nucleases 
which liberate the PMO from the leash (Morcos, 2001).  Out of all the different leashes 
tested, the one with phosphodiester complementary region and phosphorothioate 
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overhangs performed much better than the others to induce exon skipping. Therefore, 
we used the same leash chemistry in our studies. Four different 20-mer 2‟OMePS AO 
sequences were used as the basis for design and synthesis of four PMO sequences. All 
the PMOs linked to their respective leashes resulted in induction of exon 2 skipping of 
myostatin mRNA and therefore showed the feasibility of the approach with two 
different AO chemistries.  
A luciferase reporter assay has been used to study the myostatin inhibition effect 
of myostatin propeptide as well as that of myostatin neutralizing antibody JA16 in terms 
of a decrease in Smad binding to TGF-β responsive elements called CAGA boxes 
(Dennler et al., 1998); (Thies et al., 2001; Whittemore et al., 2003). A dose-response 
curve was prepared using different dilutions of recombinant mouse myostatin using 
human rhabdomyosarcoma cell line, A204 transfected with pGL3-(CAGA)12-luc. When 
conditioned media from C2C12 cells treated with PMO-D was assayed on the A204 
cells transfected with reporter plasmid containing Smad-binding site (CAGA) and 
luminescence was recorded, there was found to be a significant decrease (p=0.011) in 
the luciferase read out after 48 hours in case of medium from treated C2C12 cells 
compared to the control cells. This indicates a decrease in the transcriptional activity of 
endogenous Smad proteins which are crucial for TGF-β-mediated signal transduction 
(Dennler et al., 1998). Therefore, inhibition of myostatin by exon skipping results in 
reduced biological activity related to modulation of myostatin pathway. This study thus 
confirms the reported results for myostatin blockade using dominant negative ActRIIB 
in human myoblasts (Fakhfakh et al., 2011), myostatin-neutralizing antibody, JA16 
(Whittemore et al., 2003) and myostatin propeptide (Thies et al., 2001) showing a 
decrease in Smad2 transcriptional activity and thus antagonizing biological activity. 
When the mean RLU values from the reporter assay for PMO-D treated cells were 
substituted in the myostatin standard curve equation, there was found to be a decrease in 
myostatin concentration in treated samples relative to the control cells by 68.9%. All 
these results were evident of skipping of myostatin exon 2 in vitro using two different 
chemistries along with modulation of proliferative capacity as well as alteration of 
myostatin signalling pathway of AO-treated cells.  These results paved a path for the 
progression of this study in vivo in order to confirm the applicability of antisense-
mediated exon skipping of myostatin in animals and for studying various aspects that 
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would determine the use of this strategy for therapeutic use in human musculoskeletal 
disorders. 
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CHAPTER 4 
ANTISENSE OLIGONUCLEOTIDE-MEDIATED MYOSTATIN 
EXON SKIPPING IN WILD TYPE MICE 
4.1. Introduction 
Having demonstrated the capability of the designed AOs to induce myostatin 
exon 2 skipping in cell culture, it was important to investigate and establish their 
efficacy in vivo to determine their therapeutic potential. As an in vivo proof-of-concept 
study, intramuscular injection of 2‟OMePS AOs targeting exon 23 mutation in mdx 
mouse (dystrophin-deficient mouse with a nonsense mutation in exon 23) resulted in 
dystrophin expression restoration for three months along with restoration of dystrophin-
associated proteins and improvement in function of the treated muscle (Gebski et al., 
2003).  
Selecting two AOs from in vitro studies based on efficacy and availability, an 
experiment was set up to test these sequences for their potential to induce myostatin 
exon skipping in wild type mice and to demonstrate the feasibility of this approach in 
vivo. PMOs have been proposed to have better stability in biological systems along with 
efficient exhibition of exon skipping (Hudziak et al., 1996; Summerton et al., 1997) but 
in their unmodified form, have not been very successfully delivered into normal muscle 
but only into damaged leaky muscle (Alter et al., 2006). As discussed before, the 
delivery of naked PMO in a tissue culture system requires the use of complementary 
charged sequences  and specific low-serum growth conditions (Morcos, 2007). Among 
several issues that pose difficulty in using unconjugated PMOs in an animal disease 
model is the inability of the PMOs to enter the cells and therefore they are rapidly 
eliminated from the circulation by the kidneys (Alter et al., 2006). In a 7-week 
Dystrophin PMO study in mice, 100mg/Kg per week yielded only a restricted 
improvement in muscle function (Liang et al., 2004). The doses required were even 
more for functional improvement as well as for the restoration of dystrophin to wild 
type levels in case of another study in dogs (Yokota et al., 2009). Therefore, repeated 
large dose life-long treatment would be required for a therapeutic benefit. Variable exon 
skipping in different muscles and inconsistent dystrophin restoration from one section to 
the other of a muscle and also within the same section leads to a prediction that PMO is 
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taken up by leaky muscles only (Alter et al., 2006; Wu et al., 2008). Therefore, it 
becomes a necessity to look at a delivery system that along with being effective and safe 
also eliminates the need of high levels of dose and frequency. The conjugation of PMO 
with a dendrimeric octaguanidine (Vivo-PMO) significantly increases its delivery and 
efficiency compared to unmodified PMO (Morcos et al., 2008);(Wu et al., 2009). 
Restoration of dystrophin reading frame and expression of the protein in skeletal and 
cardiac muscles has been reported in mdx mice using Vivo-PMOs (Wu et al., 2009).  
When Vivo-PMO designed to correct the β-globin splice mutation was assessed 
for cytosolic and nuclear delivery efficiency, it was found that an intravenous dose of 
12.5mg/Kg of body weight for four consecutive days in transgenic mice followed by 
sacrifice on fifth day led to almost complete splice correction in various tissues 
including skeletal muscle, diaphragm, liver and small intestine without any liver toxicity 
(Morcos et al., 2008). Use of Vivo-PMO for dystrophin exon 23 skipping for a single 
intravenous injection at a dose of 6mg/Kg of the body weight resulted in higher level of 
dystrophin expression restoration compared to the same treatment with 300mg/Kg of 
body weight of unmodified PMO in mdx mice (Wu et al., 2009). The same study 
showed that there was no toxicity conferred with the dosing regimen used.  
In a repeated dose systemic study for dystrophin exon 23 skipping, 6mg/Kg of 
body weight of Vivo-PMO for exon 23 was injected intravenously into mdx mice for 
five times at biweekly intervals and muscles were harvested two weeks after last 
injection (Morcos et al., 2008). Level of dystrophin expression was restored to normal 
levels in most of the fibres in skeletal muscle and about 40% restoration of dystrophin 
expression was also observed in cardiac muscle (Morcos et al., 2008). 
4.2 Aims of the chapter 
The main aim of the study elaborated in this chapter was to determine the 
efficacy of designed and cell culture-tested AOs in animal system. 
It was very crucial to investigate the time point at which the optimum effect of 
an antisense oligomer could be observed. Vivo-PMO was used with an aim of 
improving the delivery efficiency over unmodified PMO as previously reported 
(Morcos et al., 2008; Wu et al., 2009). Apart from looking at the optimum time point, it 
was also important to find out that once the Vivo-PMO has been administered at a 
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particular dose, how long does it take until any significant change is seen in the muscle 
weight and also to investigate how long does the effect last in terms of mRNA 
downregulation. This experiment was also aimed at determining the right dosing 
regimen to understand how frequently the Vivo-PMO needs to be administered in order 
to have a persistent effect.  
Another objective of this study was to do a comparative analysis of the delivery 
efficiency of the recently developed PMO-conjugation systems with naked 
unconjugated PMO for targeting myostatin for exon skipping. Systemic delivery of 
conjugated myostatin PMO in wild type mice was another objective in this part of the 
study in order to treat the whole body rather than a specific muscle.  
4.3. Results 
4.3.1. Intramuscular treatment of wild type mice with the 2’OMePS AO effective 
in cell culture to induce myostatin exon skipping 
On the basis of results obtained from the in vitro studies, two of the 2‟OMePS 
(A2 and B3) were selected to verify their skipping efficacy in vivo. Each 2‟OMePS was 
administered by single intramuscular injection (3nmol) into both tibialis anterior (TA) 
muscles of two 6 weeks old MF-1 mice (four muscles). As controls, normal saline was 
injected into both the TAs of two control animals. Two and four weeks after the single 
injections, TA muscles were recovered, pooled and analysed for the presence of 
myostatin exon 2 skipping in triplicates (of pooled RNA) by nested RT-PCR. RNA 
from control muscles was also pooled and nested RT-PCR was performed in duplicates. 
Both the 2‟OMePS induced skipping after 2 weeks which persisted even after 4 weeks 
(Figure 4.1). A densitometric analysis of full-length and skipped products from nested 
RT-PCR analysis of RNA was performed to detect the efficacy of the tested 2‟OMePS 
AOs. A2 produced 25.6% skipping and B3 showed 54.6% skipping after 2 weeks time 
point. However, after 4 weeks, A2 showed 48.6% skipping while B3 showed 24.5% 
skipping. From previous work on exon skipping for dystrophin, it is well established 
that the IM injections of AOs in undamaged muscles are not very efficient (Wu et al., 
2009). Although the skipping of myostatin exon 2 was evident, the effect was not 
sufficient to see any significant change in TA mass. 
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Figure 4.1 
 
   
 
                   
Figure 4.1: Exon skipping in mice following intramuscular injection of 2’OMePS AOs 
targeting myostatin exon 2. Oligomers A2 and B3 (3nmol) were administered by a single 
intramuscular injection into the tibialis anterior (TA) muscles of mice. Two and four weeks 
later, muscles were recovered, and RNA was extracted and analysed for the presence of 
myostatin exon 2 skipping by RT-PCR. Agarose ethidium bromide gel electrophoresis is shown 
for the products of RT PCR analysis. The upper and lower bands correspond to the normal full 
length product (532bp) and the exon 2 skipped product (158bp) respectively. Tracks 1 and 2:  
14 days control (duplicates of two pooled samples); Tracks 3-5: 14 days A2-treated (triplicates 
of two pooled samples); Tracks 6-8: 14 days B3-treated (triplicates of two pooled samples); 
Tracks 9-11; 28 days A2-treated (triplicates of two pooled samples); Tracks 12-14: 28 days B3-
treated (triplicates of two pooled samples); Tracks 15 and 16: 28 days control (duplicates of two 
pooled samples). The marker used is HyperLadder IV which was loaded in track marked „M‟. 
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4.3.2. Time course analysis for the treatment of wild type mice with octaguanidine 
linked PMOs (Vivo-PMO) for myostatin exon skipping by intramuscular injection 
The aim of this experiment was to determine the level of myostatin mRNA 
down regulation at four different time points of one week, two weeks, four weeks and 
eight weeks (n=6 for treated and control mice for each time point). 6 weeks old wild 
type mice (C57BL/10) were injected into the TA with single intramuscular injection of 
10µg (3nmol) of Vivo-PMO-D (PMO-D conjugated to octaguanidine dendrimer). 
Contralateral TA muscles were injected with same volume of normal saline as controls. 
Six mice were sacrificed after week 1, 2, 4 and 8 and both their TAs were weighed and 
embedded in OCT prior to being flash frozen in liquid nitrogen-cooled isopentane. 
Myostatin exon skipping was observed in the very first week which was still persistent 
after 8 weeks. There was no significant change in the weight of TA of treated and 
control muscles after week 1 and week 2. However, after 4 weeks, the treated muscles 
showed an increase in weight relative to the control muscle (p=0.0404). After 8 weeks 
as well there was a significant increase in the weight of treated TAs compared to the 
control TAs (p=0.005) as shown in Figure 4.2. In this figure, X-axis represents the time 
point, whereas, Y-axis represents the weight of TA muscles in milligrams. As each 
mouse had a contralateral control, normalizing the weight of treated as well as of 
control TA against the body weight would have given the same amount of change in 
muscle weight, so absolute muscle weights were used in the figure.  
Myostatin skipping was observed in the very first week (Figure 4.3) which was 
still persistent after 8 weeks (Figure 4.4 (a).   The level of skipping as quantified by 
densitometric analysis after week 1 was: 58.1% (±8.7 SD); week 2: 63.1% (±25.5 SD); 
week 4: 72.3% (±24.0 SD); week 8: 41% (±4.94 SD) (Figure 4.4 (b). Cross-sectional 
area (CSA) of the TA muscle fibres treated with Vivo-PMO-D and control muscles was 
calculated by staining tissue sections with laminin antibody and using SigmaScan Pro 5 
software. Statistical analysis was performed using Chi-squared analysis for frequency 
distributions. No significant change in cross sectional area of the muscle fibres was 
observed (for week 4, p>0.99; week 8, p>0.90) (Figure 4.5). There was no significant 
change in the gross TA area of the treated and control muscles (two tailed t-test, for 
week 4, p=0.124; Week 8, p=0.381).  
 
122 
 
 
Figure 4.2 
 
 
 
Figure 4.2: Change in the weight of TA muscles of wild type mice following single 
intramuscular injection of Vivo-PMO-D. Intramuscular injection of 10µg of Vivo-PMO-D 
was administered into the TA of four groups of six C57BL/10 mice each. The muscles were 
harvested after 1 week, 2 weeks, 4 weeks and 8 weeks. Contralateral control TA muscles were 
injected with same volume of normal saline. N=6 for control as well as for Vivo-PMO-D 
treatment. *p = 0.0404; **p = 0.005; two-tailed t-test with standard error of mean 
 
 
 
 
 
 
 
 
123 
 
Figure 4.3 
 
 
Figure 4.3: RT PCR analysis for time course study of intramuscular Vivo-PMO-D 
treatment in wild type mice for one and two weeks. Demonstration of myostatin exon 2 
skipping following single intramuscular injection of 10µg of Vivo-PMO-D into the TA muscles 
of C57BL/10 mice. 6 mice were sacrificed after both week one and week two. A nested RT 
PCR was performed on 100ng mRNA from treated as well as control muscles (injected with 
normal saline) and the products were loaded on a 1.2% agarose gel. Different gel tracks were 
loaded with following samples: Tracks 1-4: Week 1 control TAs; Tracks 5-8: Week 1 Vivo-
PMO-D treated TA; Tracks 9-12: Week 2 control TAs; Tracks 13-16: Week 2 Vivo-PMO-D 
treated TA. Tracks marked „M‟ were loaded with the size marker HyperLadder IV. The faint 
shadow band of intermediate migration in some tracks was found upon sequencing to 
correspond to a product containing a partial sequence of exon 2 due to a cryptic 3‟ splice site 
downstream of the correct one. Percent skipping was calculated as Mean ± SD. 
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Figure 4.4 (a) 
 
 
Figure 4.4 (a): RT PCR analysis for time course study of intramuscular Vivo-PMO-D 
treatment in wild type mice for four and eight weeks. The nested RT PCR products from 
mRNA of TA muscles treated with Vivo-PMO-D for four and eight weeks time points were 
loaded on a 1.2% agarose gel. The loading pattern of different samples was as following: Tracks 
1-4: Week 4 control TAs; Tracks 5-8: Week 4 Vivo-PMO-D treated TAs; Tracks 9-12: Week 8 
control TAs; Tracks 13-16: Week 8 Vivo-PMO-D treated TAs. Tracks marked „M‟ were loaded 
with the size marker HyperLadder IV.  
Figure 4.4 (b) 
                  
 
Figure 4.4(b): Scatter plot for time course study: Representation of level of myostatin exon 
skipping induced by Vivo-PMO in each mice of individual time point group (week1, week2, 
week4 and week8). Horizontal bars running through different ponts indicates mean values and 
the vertical bars represent mean±SD 
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Figure 4.5 
Week 4 
 
Week 8 
 
Figure 4.5: Distribution of myofibre sizes in Vivo-PMO-D-treated TA muscles of wild type 
mice after four and eight weeks. Cross-sectional area (CSA) of the TA muscle fibres treated 
with Vivo-PMO-D (Blue bars) and saline (Green bars) after 4 weeks and 8 weeks time points; 
n=6 for treated and control muscles. 
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4.3.3. Comparison of efficacies of myostatin exon 2 skipping induced by peptide 
conjugated PMOs (B-PMOs), Vivo-PMOs and unconjugated naked PMOs 
delivered by IM injection in wild type  mice 
The time-course study showed that a single intramuscular injection of Vivo-
PMO-D into TA of wild type mice induced sustained myostatin exon 2 skipping from 
one week after the treatment up to the eighth week with a significant increase in muscle 
weight after four weeks. Therefore, a comparison of myostatin exon skipping efficacies 
of both arginine-rich cell penetrating peptide-conjugated PMO (B-PMO) which is 
abbreviated as (RXRRBR)
2
XB-PMO; R= Arginine; X= 6-aminohexanoic acid; B= β-
alanine (Yin et al., 2009; Yin et al., 2008) as well as dendrimeric octaguanidine 
conjugated morpholino (Vivo-PMO) (Wu et al., 2009; Wu et al., 2008) was done 
relative to the naked unconjugated PMO for a time point of eight weeks following 
single intramuscular injection.  
Idividual TA muscles of twelve 6 weeks old wild type C57BL/10 mice were 
injected with saline (control) or with 3nmol (~10µg) of B-PMO-D, Vivo-PMO-D and 
unconjugated PMO-D, whereas the controls were treated with the same volume of 
normal saline into the TA muscle. Therefore, six muscles had each type of treatment 
Mice were weighed and sacrificed after eight weeks and TAs were weighed and 
embedded in OCT prior to being flash frozen in liquid nitrogen-cooled isopentane. 
Myostatin mRNA exon skipping was confirmed in the treated muscles by nested-RT-
PCR. Densitometric analysis of the skipped and full length bands showed that there was 
12.5% (±5.1 SD)   myostatin exon 2 skipping in case of unconjugated PMO-D; 33.8% 
(±4.6 SD)  exon skipping in case of Vivo-PMO-D and 43.5% (±9.5 SD)  exon skipping 
in case of B-PMO-D (Figure 4.6 (a)). There was found to be a significant increase in 
the weights of TAs treated with B-PMO-D (p=0.04) compared to saline-treated controls. 
A significant increase in muscle weights was also recorded in case of Vivo-PMO-D 
treatment (p=0.01) compared to saline-treated controls as shown in Figure 4.7. 
However, unconjugated PMO-D did not lead to any significant change in the TA 
weight. The cross sectional area (CSA) of TA muscle fibres in Vivo-PMO-D-treated 
animals significantly increased (0.04<p<0.05) relative to the fibre CSA of control 
animals as shown in Figure 4.8 (χ2= 26.71; df =16). There was however no significant 
change in the fibre CSA of unconjugated PMO-D or B-PMO-D-treated muscles. 
Standard H&E (haematoxylin and eosin) staining was performed on transverse 10µm 
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sections of the muscles obtained using a cryostat. No changes in histology of control 
and treated muscles were revealed (Figure 4.9). 
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Figure 4.6 (a) 
 
Figure 4.6 (a): Comparative analysis of myostatin exon 2 skipping efficacy of 
unconjugated PMO-D, Vivo-PMO-D and B-PMO-D. Different groups of C57BL/10 mice 
(three mice [six muscles] each group) were injected by an intramuscular injection of 3nmol of 
unconjugated PMO-D, Vivo-PMO-D and B-PMO-D into the TA muscles. Different treatment 
groups of mice were sacrificed after eight weeks time point and a nested RT PCR was 
performed on 100ng mRNA from treated as well as control muscles (injected with normal 
saline). The nested PCR products were loaded on a 1.2% agarose gel as following: Tracks 1-3: 
Control TAs; Tracks 4-6: Unconjugated PMO-D-treated TAs; Tracks 7-9: Vivo-PMO-D-treated 
TAs; Tracks 10-12: B-PMO-D-treated TAs. Tracks marked „M‟ were loaded with the size 
marker HyperLadder IV. The faint shadow band of intermediate migration in some tracks was 
found upon sequencing to correspond to a product containing a partial sequence of exon 2 due 
to a cryptic 3‟ splice site downstream of the correct one. The figure shows some representative 
samples. 
Figure 4.6(b) 
 
 
 
 
 
 
 
Figure 4.6 (b): Scatter plot for myostatin exon skipping analysis of unconjugated PMO, 
Vivo-PMO and B-PMO eight weeks following single IM injection (10µg each) into the TA 
of 6 weeks old C57BL/10 mice. Horizontal bars running through different ponts indicates mean 
values and the vertical bars represent mean±SD 
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Figure 4.7 
                       
Figure 4.7: Effect of single intramuscular injection of unconjugated PMO-D, B-PMO-D or 
Vivo-PMO-D on the weight of the TA muscles in wild type mice. Single intramuscular 
injection of 3nmol (~10µg) of unconjugated PMO-D, B-PMO-D or Vivo-PMO-D was 
administered into the TA of C57BL10 mice and the mice were sacrificed after 8 weeks. Control 
TA muscles were injected with same volume of normal saline. N=6 for control as well as for 
treated muscles; ns= non significant change for Saline (Control) vs. Unconjugated PMO; *p for 
Saline (Control) vs. B-PMO-D = 0.04; *p for Saline (Control) vs. Vivo-PMO-D= 0.01. Two-
tailed t-test was performed with standard error of mean. 
 
 
 
 
 
 
 
 
130 
 
Figure 4.8: Distribution of TA fibre diameter in wild type mice treated with unconjugated 
PMO-D, Vivo-PMO-D and B-PMO-D. The TA muscles of different groups of C57BL/10 
mice were treated with 3nmol (~10µg) of unconjugated PMO-D, B-PMO-D and Vivo-PMO-D; 
Controls were treated with same volume of saline (n=6 for each treatment group) and mice were 
sacrificed after eight weeks. TA muscles were sectioned and immunostained with laminin in 
order to calculate fibre size distribution using SigmaScan Pro 5 software. In the top panel, green 
bars represent TA muscles treated with unconjugated PMO-D and blue bars represent TA 
muscles treated with normal saline; in the middle panel, red bars represent TA muscles treated 
with B-PMO-D and blue bars represent TA muscles treated with normal saline; in the bottom 
panel, yellow bars represent TA muscles treated with Vivo-PMO-D and the blue bars represent 
TA muscles treated with normal saline. p(unconjugated PMO-D vs. Saline) > 0.7; p(B-PMO-D 
vs. Saline) > 0.7; p(Vivo-PMO-D vs. Saline)<0.05 
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Figure 4.8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
132 
 
Figure 4.9: Histological staining of TA muscle cross sections from myostatin AO (Vivo-
PMO-D, B-PMO-D and unconjugated PMO-D)-treated C57BL/10 mice. C57BL/10 mice 
injected with unconjugated PMO-D, B-PMO-D and Vivo-PMO-D were sacrificed after eight 
weeks and their TAs were cut into 10µm transverse sections using a cryostat. The slides with 
these sections were stained with haematoxylin and eosin. Scale bar represents 500µm. 
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Figure 4.9 
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4.3.4. Systemic delivery of Vivo-PMO-D into wild type mice by IV injection 
In order to determine the efficacy of Vivo-PMO-D by systemic delivery, weekly 
intravenous injections of Vivo-PMO-D for 5 weeks were administered into the tail vein 
of 6 weeks old C57BL/10 mice at 6mg/Kg of the body weight. The injections were 
performed by Dr Alberto Malerba. The whole body weight and weights of TA, Soleus 
and EDL were recorded 10 days after the last injection. Vivo-PMO-D induced 79.1% 
exon skipping of myostatin exon 2 in Soleus as determined by densitometric analysis on 
nested-RT PCR results of mRNA from treated muscle. A very low level of skipping was 
observed in EDL muscle (9%) (Figure 4.10). In accordance with the exon skipping 
data, treated soleus muscles showed a statistically significant increase in the weight 
(p=0.0335) as compared to the controls (Figure 4.11) whereas no significant change in 
weight of Vivo-PMO-D-treated EDL muscle was observed compared to the controls. 
The cross sectional area (CSA) of soleus muscle fibres in treated animals significantly 
increased (p<0.0001; with a significant shift on the distribution of CSA (χ2= 38.34; df 
=12) (Figure 4.12 and Figure 4.13), while no change was observed in the fibre CSA of 
EDL muscle. 
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Figure 4.10 
 
 
 
 
 
                               
 
Figure 4.10: RT PCR analysis of mRNA from soleus and EDL muscles of wild type mice 
treated intravenously with Vivo-PMO-D. A nested RT-PCR was carried out on 1µg mRNA 
from soleus and EDL muscles of C57BL/10 mice treated intravenously with five weekly Vivo-
PMO-D injections, and the products were resolved on a 1.2% agarose gel.  Track 1: Vivo-PMO-
D- treated soleus; Track 2: control soleus; Track 3: Vivo-PMO-D- treated EDL; Track 4: 
control EDL 
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Figure 4.11 
 
 
                             
 
Figure 4.11: Effect of systemic delivery of Vivo-PMO-D on muscle mass of wild type mice. 
C57BL/10 mice were treated with 6mg/Kg of Vivo-PMO-D3 by five weekly intravenous 
injections and muscles were harvested for RNA extraction and immunohistology after 10 days 
of last injection. Weights of soleus muscles were significantly increased (p=0.034; n=6) whereas 
weights of EDL muscles showed no significant change.  
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Figure 4.12 
 
                    
Figure 4.12: Distribution of myofibre sizes in soleus muscle of wild type mice treated 
intravenously with Vivo-PMO-D. Cross-sectional area (CSA) of the soleus muscle fibres of 
the C57BL/10 mice treated intravenously with Vivo-PMO (black bars) and control (open bars) 
was calculated by staining tissue sections with dystrophin antibody and using SigmaScan Pro 5 
software. Statistical analysis was performed using Chi-squared analysis for frequency 
distributions. 
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Figure 4.13  
 
                     
Figure 4.13: Immunohistological staining for soleus fibre cross sectional area analysis. 
Representative dystrophin immunohistology indicating increased myofibre CSA in Vivo-PMO-
D-treated soleus muscle compared to control soleus muscle cryo-sections.  Magnification bar 
represents 500 µm. 
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4.4. Discussion 
With an aim of in vivo testing of the AO sequences successful in inducing 
myostatin exon 2 skipping in C2C12 cell culture, 2‟OMePS AO were injected 
intramuscularly into the TAs of C57BL/10 mice. Although, 2‟OMePS RNA sequences 
used were successful in bring about skipping of myostatin exon 2 in wild type mice, 
they did not have enough effect after four weeks following the single intramuscular 
injection into the TA of animals to result in any change in muscle mass. PMOs have 
been reported as more effective AO chemistry for exon skipping induction with longer 
lasting dystrophin expression restoration in mdx mice following intramuscular as well as 
intravenous administration compared to 2‟OMePS chemistry (Fletcher et al., 2006; 
Heemskerk et al., 2009; Sazani et al., 2002a). It is also reported in case of dystrophin 
exon skipping that intramuscular injections of unconjugated AOs are not quite efficient 
(Wu et al., 2009). It has been shown that the level of dystrophin expression restoration 
and exon skipping induction in case of DMD by unconjugated AO chemistries is quite 
variable and therapeutic levels are attained only in skeletal muscle by the PMO 
chemistry (Alter et al., 2006). Unconjugated PMO chemistry has not been able to 
induce effective dystrophin expression restoration in cardiac muscle, which has a 
massive direct impact in context of DMD due to death resulting mainly from cardiac 
and respiratory failure (Eagle et al., 2007; Wagner et al., 2007). Therefore, one of the 
most commonly used approach to enhance the effect of AOs and therefore the 
efficiency of exon skipping to have a reasonable therapeutic effect is to use certain 
delivery moieties which are capable of high charge-charge interactions with the 
membrane phospholipids (Futaki et al., 2002; Wender et al., 2000; Wu et al., 2007). 
Administration of a single intravenous injection of octaguanidine-linked 
morpholino oligomers (Vivo-PMO) targeting dystrophin exon 23 (VivoME23) led to a 
better expression restoration compared to the effect induced by unconjugated PMO 
(even at a concentration almost 50 times that of Vivo-PMO) in mdx mice (Wu et al., 
2009). In order to have a precise time line of efficient exon skipping induction a time 
course study was carried out to see how long does it actually take to induce a 
pronounced myostatin exon skipping following a single intramuscular Vivo PMO-D 
injection and for what duration does the effect of this single treatment persist. A 10µg 
injection of Vivo-PMO-D into the TA of C57BL/10 mice for a time course of one week, 
two weeks, four weeks and eight weeks was performed. The controls were treated with 
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an equal volume of normal saline. As shown by densitometric analysis, 58±8.7% 
myostatin exon 2 skipping was seen right after first week, followed by 63±25.5% 
skipping after two weeks, 72±24.0% skipping after four weeks and 41% skipping after 
eight weeks. There was however no change in the muscle weights after first and second 
week compared to the controls. A significant increase in TA weight was recorded after 
fourth week (p=0.04) and eighth week (p=0.005). When frequency distribution of TA 
fibre diameter was analyzed, there was no significant change in cross sectional area 
(CSA) of the fibres. Haematoxylin and Eosin staining was carried out to see if there was 
any influx of immune cells leading to inflammation resulting in an increase in Vivo-
PMO-treated muscle weights. There was no significant change in the histology of 
treated as well as control muscles. Myostatin mRNA downregulation using antisense-
mediated exon skipping in animals was demonstrated for the first time in these studies. 
Out of the available PMO conjugation systems, Vivo-PMO and B-PMO both 
have been recently reported to have restored almost normal levels of dystrophin 
expression in skeletal muscle of mdx mice using different dosing regimens and routes of 
administration (Morcos et al., 2008; Wu et al., 2011; Yin et al., 2008). It has been 
reported that B-PMO as well as Vivo-PMO have been used in repeated dose study for a 
period of three months without any obvious toxic effects (Wu et al., 2009; Wu et al., 
2008; Yin et al., 2008). Therefore, a comparative analysis of these two myostatin PMO-
conjugations along with unmodified PMO was done as a key step for future myostatin 
exon skipping work. A single intramuscular injection of 10µg of Vivo-PMO-D, B-
PMO-D and unconjugated naked PMO-D into the TA of different groups of C57BL/10 
mice resulted in a significant increase in TA weights of the animals treated with B-
PMO-D as well as with Vivo-PMO-D compared to controls following eight weeks of 
the treatment. Vivo-PMO-D treatment also resulted in a significant increase in the TA 
fibre diameter compared to the controls. There was, however, no change in the 
distribution of fibre CSA of muscles treated with B-PMO-D. H&E staining did not 
show any damage caused due to an immune response in the treated tissues by any of the 
treatments. It is likely that the dose used may have not been high enough to show a 
consistent significant effect in the case of unmodified PMO. These findings confirm 
better targeting and higher uptake of B-PMO and Vivo-PMO compared to unconjugated 
PMO.  
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A reported study of repeated biweekly injections of dystrophin exon 23-vivo-
PMO (6mg/Kg of body weight) for five weeks resulted in dystrophin expression 
restoration to nearly normal levels with a pronounced effect in cardiac muscles as well 
(Morcos et al., 2008). Based on these studies, a systemic study was undertaken with 
C57BL/10 mice using 6mg/Kg of body weight of Vivo-PMO-D targeted at myostatin 
exon 2 every week for five weeks. Conjugation of PMO to dendrimeric octaguanidine 
was successful in inducing exon skipping as well as in increasing the mass of Soleus 
muscle. This effect was however not seen in other muscles apart from EDL which 
showed a very low level of skipping and there was no change in the weight of the 
muscle. The reason for this could be anything ranging from dosing regimen, route of 
administration to time point at which the maximal effect can be seen. Perhaps it seems 
the dose and frequency of the Vivo-PMO for myostatin required to achieve significant 
level of change in weight of different muscles could probably be very different from 
dystrophin exon skipping system that was followed. Dystrophin is established to have 
longer half-life whereas myostatin seems to be more likely to need repeated dose of 
AOs to induce persistent exon skipping (Ghahramani Seno et al., 2008). Also, the leaky 
muscles as in mdx mice would perhaps have a better effect compared to healthy muscle 
of wild type mice with a lack of porosity. Also, it has been proposed that a greater 
amount of ActRIIb are expressed on the surface of EDL muscle and that the intrinsic 
level of myostatin is greater in fast (myosin type IIb positive) myofibres (Foster et al., 
2009; Matsakas et al., 2009). 
A study has been reported to downregulate the expression of myostatin receptor 
AcRIIb using sh-RNA and restoration of quasi-dystrophin using a vectorized U7 exon 
skipping (U7-DYS). Co-expression of U7-DYS/sh-AcRIIb to restore quasi dystrophin 
expression and downregulate the expression of myostatin receptor in mdx mice showed 
force development comparable to C57BL/6 and much more enhanced as compared to 
U7-DYS or sh-AcRIIb expressed alone (Dumonceaux et al., 2010). Therefore, it is quite 
crucial to determine the efficacy of a dual approach targeting myostatin and dystrophin 
to study the effects of myostatin inhibition and dystrophin restoration simultaneously in 
mdx mice from DMD point of view. U7-DYS/sh-AcRIIb study also suggests that in 
order to have a better understanding of how myostatin inhibition affects muscle force 
and strength, in situ contractile properties of the treated muscle need to be studied in 
future.  
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CHAPTER 5 
ANTISENSE OLIGONUCLEOTIDE-MEDIATED MYOSTATIN 
AND DYSTROPHIN DUAL EXON SKIPPING IN mdx MICE 
5.1. Introduction 
As described before, mdx mice are murine models that have been widely used 
for DMD research (Coulton et al., 1988; Hoffman et al., 1987a; Morgan et al., 1989). 
They were derived from C57BL10 colony resulting from spontaneous mutation leading 
to loss of dystrophin protein and very high levels of serum creatine kinase (Bulfield et 
al., 1984). The use of AOs to induce exon skipping in dystrophin in order to restore its 
reading frame exhibited therapeutic potential of this approach for Duchenne muscular 
dystrophy in vitro (Aartsma-Rus et al., 2002; Aartsma-Rus et al., 2004b) as well as in 
vivo using mdx mice (Mann et al., 2002). This led to subsequent clinical trials using 
2‟OMePS (van Deutekom et al., 2007) and PMO (Kinali et al., 2009) chemistries. 
However, due to severe DMD pathology including fibrosis and exhaustion of muscle 
regeneration capacity in DMD patients because of vigorous myoblast division in 
response to early degeneration of muscle cells (Blau et al., 1985; Yoshida et al., 1998), 
some sort of additional therapy is required along with dystrophin restoration. An 
example of such a combination therapy is the use of altered U7 snRNA for dystrophin 
restoration together with shRNA targeted against myostatin receptor, ActRIIb in AAV 
vector (Dumonceaux et al., 2010). This study showed that there was an additional 
improvement in muscle physiology of mdx mice when myostatin pathway was inhibited 
along with restoration of dystrophin. However, there is the limitation of immune 
response related to viral vector system. Blocking myostatin signalling pathway with 
dominant negative ActRIIb (dnActRIIb), also added value to myoblast transplantation 
by increasing the proliferation of myoblasts and thus resulted in improvement of 
transplantation success (Fakhfakh et al., 2011). AOs of 2‟OMePS chemistry have 
recently been used to illustrate successful simultaneous induction of exon skipping of 
both myostatin and dystrophin (Kemaladewi et al., 2011). 
5.2 Aims of the chapter 
In this chapter, simultaneous exon skipping of both myostatin and dystrophin 
was studied to determine the feasibility of this combination strategy to downregulate 
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myostatin expression and to correct dystrophin transcript in mdx mice. It is particularly 
important to use this combined approach because in DMD patients, severe muscle 
wasting and defective muscle regeneration can hamper the efficacy of dystrophin 
restoration on its own. Due to enormous muscle degeneration, myoblasts in DMD 
patients go through rigorous division in order to regenerate leading to saturation of 
muscle regeneration capacity (Blau et al., 1985; Yoshida et al., 1998). Different 
additional therapies have therefore been studied to accompany dystrophin expression 
restoration to surmount these issues. Myostatin inhibition being one of these strategies 
that can help reduce the muscle mass loss, an attempt was made to carry out dual exon 
skipping targeting dystrophin and myostatin genes at the same time. Two of the recently 
developed PMO conjugation systems namely B-PMO and Vivo-PMO were used and 
results were compared to see the effect in mouse model of DMD. A well established 
PMO sequence to target murine dystrophin exon 23 was used (Alter et al., 2006; 
Fletcher et al., 2006; Gebski et al., 2003) along with PMO-D for myostatin exon 2 
skipping, both in a B-PMO conjugation as well as in a Vivo-PMO complex.  
5.3. Results 
5.3.1. B-PMO-induced dual exon skipping of dystrophin and myostatin RNA in 
mdx mice following intramuscular injections of PMO combinations 
Six weeks old mdx mice were treated with 3nmoles (~10µg) of single 
intramuscular injection of B-PMO-Dys (B-PMO for dystrophin exon 23 skipping) 
alone, B-PMO-D [named as B-PMO-Myo in this chapter to avoid confusion, so B-
PMO-D and B-PMO-Myo are used interchangeably in this thesis for the same sequence 
of myostatin AO] alone and a cocktail of B-PMO-(Dys+Myo) (a total of 20µg) into the 
TA muscles. The control muscles were treated with the same volume of normal saline. 
There were six muscles per treatment and no contralateral controls. These injections 
were performed by Dr Graham McClorey at the Department of physiology, anatomy 
and genetics, University of Oxford. Mice were weighed and sacrificed after eight weeks 
and TAs were weighed and embedded in OCT prior to being flash frozen in liquid 
nitrogen-cooled isopentane. Efficiency of B-PMO AOs to induce exon skipping 
resulting in decrease in the level of myostatin expression at transcript level and 
reframing dystrophin was tested by RT-PCR. Myostatin exon skipping was confirmed 
in the treated muscles by nested-RT-PCR on the mRNA from treated samples as shown 
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in Figure 5.1. RT-PCR for dystrophin skipping induced by B-PMO-Dys is shown in 
Figure 5.2. Dual exon skipping induced by using a cocktail of both B-PMO-Myo and 
B-PMO-Dys is shown in Figure 5.3 (a). Densitometric analysis of the skipped and full 
length bands showed that B-PMO-Myo alone induced 33% (±9.1 SD) skipping and B-
PMO-Dys alone induced 56% (±14.4 SD)   skipping. In case of animals treated with a 
cocktail of B-PMO-Myo and B-PMO-Dys, 65% (±11.3 SD)   dystrophin skipping and 
40% (± 6.0 SD)   myostatin skipping was observed. These results showed the feasibility 
of the dual myostatin and dystrophin exon skipping mediated by B-PMO AOs without 
the possibility of interference with each other rather than their respective targets.   
5.3.2. Effect of dystrophin and myostatin exon skipping induced by single 
intramuscular injection of B-PMOs on muscle weights of mdx mice 
The muscle weights were normalized against the whole body weight for 
individual animals as there were no contralateral but separate controls. There was found 
to be a significant increase in the weights of TAs treated with B-PMO-Myo alone 
(p=0.03) compared to saline-treated controls as well as in the weights of TAs treated 
with a cocktail of B-PMO (Myo+Dys) (p=0.006) compared to saline-treated controls as 
shown in Figure 5.4, however, B-PMO-Dys on its own did not lead to any significant 
change in the TA weight.  
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Figure 5.1                                                     
 
 
 
 
 
 
Figure 5.1: RT-PCR results from mRNA of B-PMO-treated TA muscle of mdx mice for 
myostatin exon skipping. Myostatin exon 2 skipping induced by B-PMO-Myo following 
single (10µg) intramuscular injection into the TA of mdx mice is shown. Mice were sacrificed 
after eight weeks and a nested RT PCR was performed on 100ng mRNA from treated as well as 
control muscles (injected with normal saline). The nested PCR products were loaded on a 1.2% 
agarose gel as following: Tracks 1-3: Control TAs; Tracks 4-6: B-PMO-Myo treated TAs. 
Tracks marked „M‟ were loaded with the size marker HyperLadder IV. An intermediate faint 
band represents a cryptic 3‟ splice site downstream of the correct one as verified by sequencing. 
The figure shows some representative samples. Percent skipping was calculated as Mean±SD. 
MSTN represents myostatin. 
Figure 5.2 
 
 
 
 
Figure 5.2: RT-PCR results from mRNA of B-PMO-treated TA muscle of mdx mice for 
dystrophin exon skipping. Dystrophin exon 23 skipping induced by B-PMO-Dys following a 
single (10µg) intramuscular injection into the TA of mdx mice is shown. Eight weeks post-
injection, the mice were sacrificed and the TAs were harvested. The nested RT-PCR products 
were run on a 1.2% agarose gel as following: Tracks 1-3: Control TAs (injected with normal 
saline); Tracks 4-6: B-PMO-Dys-treated TAs. A shorter band apart from the exon 23-skipped 
band represents a transcript with exon 22/23 deletions as verified by sequencing. Pictures of 
gels with representative samples are shown. DMD represent dystrophin.                                          
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 Figure 5.3 (a)                        
                            
 
 
 
 
 
 
 
 
 
 
Figure 5.3 (a): Dual myostatin and dystrophin exon skipping in mdx mice. Myostatin exon 
2 skipping and dystrophin exon 23 skipping induced by a cocktail of B-PMO-Myo (10µg) and 
B-PMO-Dys (10µg) following single intramuscular injection into the TA of mdx mice is shown. 
Mice were sacrificed after eight weeks and a nested RT PCR was performed on 100ng mRNA 
from treated as well as control muscles (injected with normal saline). The nested PCR products 
were loaded on a 1.2% agarose gel. In the top panel, Tracks 1-3: Controls; Tracks 4-6: B-PMO-
Myo-treated TAs. In the bottom panel, Tracks 1-3: Controls; Tracks 4-6: B-PMO-Dys-treated 
TAs. Tracks marked „M‟ were loaded with the size marker HyperLadder IV. The figure shows 
gels with representative samples; Densitometric analysis was performed on all the samples and 
average was calculated. 
 
 
 
 
147 
 
 Figure 5.3 (b)                        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3 (b): Scatter plot for B-PMO-induced myostatin and dystrophin exon skipping 
levels eight weeks after single IM injections 3nmol (~10µg each) in the TA of mdx mice. A 
total of six muscles were treated per group. Multiple replicates (3-4) for each sample were 
loaded on the gel and then mean ± SD was calculated from the densitometric analysis. „D+M‟ 
denotes cocktail of B-PMO-myostatin and B-PMO-dystrophin. Horizontal bars running through 
different ponts indicates mean values and the vertical bars represent mean±SD 
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Figure 5.4 
 
 
                   
                       
 
 
 
 
 
 
 
 
Figure 5.4: Effect of exon skipping induced by B-PMO-Myo and/or B-PMO-Dys on TA 
muscle weights of mdx mice following single intramuscular injection. Single intramuscular 
injection of 3nmol of each of B-PMO-Dys, B-PMO-Myo and B-PMO-(Dys+Myo) was 
administered into the TAs of different groups of mdx mice. Control TA muscles were injected 
with same volume of normal saline. Mice were sacrificed eight weeks after the injections were 
performed. N=6 for control as well as for treated muscles; ns= non significant change for Saline 
(Control) vs. B-PMO-Dys; *p for Saline (Control) vs. B-PMO-Myo = 0.03; **p for Saline 
(Control) vs. B-PMO-(Dys+Myo) = 0.006. Two-tailed t-test was performed with standard error 
of mean. 
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5.3.3. Dystrophin expression restoration in mdx muscles following intramuscular 
B-PMO injections 
Immunofluorescence staining of transverse TA muscle tissue sections was 
performed to detect the dystrophin protein expression and localization in mdx mice 
treated with B-PMO-Dys and a cocktail of B-PMO-Myo+Dys. Enhanced dystrophin 
expression detected by immunofluorescence in B-PMO-treated muscle sections 
compared to the control muscle sections can be seen as in Figure 5.5. 
5.3.4. Effect of B-PMO induced myostatin and dystrophin dual exon skipping on 
size distribution of muscle fibres  
The TA sections from each treatment group were stained with laminin and CSA 
of the fibres was calculated using SigmaScan Pro5 software followed by a chi-squared 
analysis on the data from different treatment groups. There was found to be no 
significant change in the TA fibre CSA distribution with either B-PMO-Myo or B-
PMO-Dys or B-PMO-(Myo+Dys) (Figure 5.6); p (B-PMO-Dys vs. saline) >0.99; p (B-
PMO-Myo vs. Saline) >0.99; p [B-PMO-(Dys+Myo) vs. Saline] >0.99.  
5.3.5. Histological analysis of B-PMO-treated mdx muscles 
Standard H&E (haematoxylin and eosin) staining was performed on transverse 
10µm sections of the harvested muscles using a cryostat. The staining of the sections of 
tissue treated with B-PMO-Myo, B-PMO-Dys and a cocktail of B-PMO-Dys+Myo 
showed no damage to the muscle compared to untreated mdx mice (Figure 5.7).  
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Figure 5.5 
 
Figure 5.5: Dystrophin expression restoration in B-PMO-treated TA muscles of mdx mice. 
Immunohistochemical detection of dystrophin (red) in TA of the mdx mice treated with B-
PMO-Dys and a cocktail of B-PMO-(Dys+Myo) is shown. Mdx mice treated with B-PMO-Myo 
alone and the ones with normal saline are the negative controls. Magnification bar represents 
500µm. 
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Figure 5.6: TA fibre diameter distribution following B-PMO-Myo or/and B-PMO-Dys 
treatment in mdx mice. The TA muscles of mdx mice were treated with 3nmol (~10µg) of B-
PMO-Myo; B-PMO-Dys; a cocktail of B-PMO-Dys+Myo (total 20µg); Controls were treated 
with same volume of saline and mice were sacrificed after eight weeks (n=6 each treatment). 
TA muscles were sectioned and immunostained with laminin in order to calculate fibre size 
distribution using SigmaScan Pro 5 software. In the top panel, green bars represent TA muscles 
treated with B-PMO-Myo and blue bars represent TA muscles treated with normal saline; in the 
middle panel, yellow bars represent TA muscles treated with B-PMO-Dys and blue bars 
represent TA muscles treated with normal saline; in the bottom panel, pink bars represent TA 
muscles treated with a cocktail of B-PMO-(Dys+Myo) and the blue bars represent TA muscles 
treated with normal saline. p (B-PMO-Dys vs. Saline) >0.99; p (B-PMO-Myo vs. Saline) >0.99; 
p [B-PMO-(Dys+Myo) vs. Saline] >0.99. 
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Figure 5.6 
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Figure 5.7: Histological analysis of B-PMO-treated and saline-treated TA muscle sections 
of mdx mice. Haematoxylin and eosin staining of TA muscle transverse sections from mdx mice 
injected with  B-PMO-Dys,  B-PMO-Myo; a cocktail of B-PMO-(Dys+Myo) –a total of ~20 µg 
was performed. Representative pictures are shown. Magnification bar represents 500µm. 
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Figure 5.7 
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5.3.6. Vivo-PMO-induced dual exon skipping of dystrophin and myostatin RNA in 
mdx mice following intramuscular injections of PMO combinations  
Single intramuscular injections of 3nmol (~10µg) of Vivo-PMO-Dys alone, 
Vivo-PMO-Myo alone and Vivo-PMO-(Myos+Dys) cocktail (a total of 20µg) were 
performed into the TAs of different groups of six weeks old mdx mice (no contralateral 
controls, 6 muscles per treatment). The controls were injected with the same volume of 
normal saline into the TA muscle. Mice were weighed and sacrificed after eight weeks 
and TAs were weighed and embedded in OCT prior to being flash frozen in liquid 
nitrogen-cooled isopentane. Myostatin exon skipping was confirmed at transcript level 
in the treated muscles by nested-RT-PCR as shown in Figure 5.8. RT-PCR for 
dystrophin skipping induced by Vivo-PMO-Dys is shown in Figure 5.9 (a). 
Densitometric analysis of the skipped and full length bands showed that Vivo-PMO-
Myo alone induced 46.9% (±28.3 SD) skipping and Vivo-PMO-Dys alone induced 
37.4% (±7.2 SD)    skipping. In case of animals treated with a cocktail of Vivo-PMO-
(Myo+Dys), 30.6% (±3.5 SD) dystrophin skipping and 66.4% (±35.2 SD)    myostatin 
skipping was observed. Table 4 shows the percentage skipping induced by each 
treatment using both B-PMO as well as Vivo-PMO. 
5.3.7. Effect of dystrophin and myostatin exon skipping induced by single 
intramuscular injection of Vivo-PMOs on muscle weights of mdx mice  
The TA weights were normalized against body weight of the individual animals. 
Vivo-PMO-Dys led to a significant decrease in the muscle weight compared to saline 
treatment as did the cocktail of Vivo-PMO-(Dys+Myo) compared to saline control 
treatment. There was however no significant change in the weight of TAs treated with 
Vivo-PMO-Myo alone compared to saline-treated controls; as shown in Figure 5.10.  
 
 
 
 
 
156 
 
Figure 5.8 
 
  
 
 
Figure 5.8: Myostatin exon skipping following Vivo-PMO-treatment in mdx mice. 
Myostatin exon 2 skipping induced by Vivo-PMO-Myo following single 3nmol intramuscular 
injection into the TA of six weeks old mdx mice is presented. Mice were sacrificed after eight 
weeks and a nested RT PCR was performed on 100ng mRNA from treated as well as control 
muscles (injected with normal saline). The nested PCR products were loaded on a 1.2% agarose 
gel. Different gel tracks were loaded with following samples: Tracks 1-3: TAs treated with 
Vivo-PMO-Myo alone; Tracks 4-6: TAs treated with saline; Tracks 7-9: TAs treated with a 
cocktail of Vivo-PMO-(Myo+Dys). Tracks marked „M‟ were loaded with the size marker 
HyperLadder IV. Percent skipping was calculated as Mean±SD. The figure shows some 
representative samples. 
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Figure 5.9 (a) 
 
Figure 5.9 (a): Dystrophin exon 23 skipping in mdx mice induced by Vivo-PMO-Dys. Six 
weeks old mdx mice were treated with a single intramuscular injection of 3nmol of Vivo-PMO-
Dys and a cocktail of Vivo-PMO (Dys+Myo) -a total of ~20µg.  Controls were treated with 
same volume of normal saline. Mice were sacrificed after eight weeks and a nested RT-PCR 
was performed on 100ng mRNA from treated as well as control muscles. The nested PCR 
products were loaded on a 1.2% agarose gel. Tracks 1-6: TAs treated with a cocktail of Vivo-
PMO-(Dys+Myo); Tracks 7-11: TAs treated with saline; Tracks 12-17: TAs treated with Vivo-
PMO-Dys. Tracks marked „M‟ were loaded with the size marker HyperLadder IV; n=6 for each 
group. The figure shows gel with representative samples; Densitometric analysis was performed 
on all the samples and average was calculated. 
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Figure 5.9 (b) 
 
Figure 5.9 (b): Scatter plots for Vivo-PMO-induced myostatin and dystrophin exon 
skipping levels eight weeks after single IM injections (3nmol each) in the TA of mdx mice. 
Six muscles received each treatment. „D+M‟ represents a cocktail of Vivo-PMO-myostatin and 
Vivo-PMO-dystrophin. Horizontal bars running through different ponts indicates mean values 
and the vertical bars represent mean±SD 
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Figure 5.10 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.10: Change in weight of TA following single intramuscular Vivo-PMO treatment 
in mdx. Single intramuscular injections of 3nmol (~10µg) Vivo-PMO-Myo; Vivo-PMO-Dys; a 
cocktail of Vivo-PMO-(Dys+Myo) (total ~20µg) were administered into the TAs of six weeks 
old mdx mice. Controls were treated with same volume of normal saline. Mice were sacrificed 
and muscles harvested for RNA extraction and immunohistology after 8 weeks.  Weights of TA 
muscles were normalized against whole body weight. There was no significant change in 
weights of Vivo-PMO-Myo-treated TAs compared to the controls. TAs treated with Vivo-
PMO-Dys and with a cocktail of Vivo-PMO-(Dys+Myo) showed a significant decrease in 
weight compared to the controls. **p(Vivo-PMO-Dys vs. Control) = 0.009; **p(Vivo-PMO-
(Dys+Myo) vs. Control) = 0.002; n=6 for each treatment; two-tailed t-test was performed with 
standard error of mean. 
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Table 4. 
 
Table 4: Percentage skipping of myostatin exon 2 and dystrophin exon 23 and change in 
TA weight induced by B-PMO and Vivo-PMO in mdx mice. Table showing the percentage 
(Mean±SD) of myostatin exon 2 skipping induced by B-PMO as well as Vivo-PMO along with 
dystrophin exon 23 skipping induced by both the PMO conjugations in the TA muscle of 
dystrophic mice. Also shown are the values for percent exon skipping of myostatin and 
dystrophin when a dual treatment of PMOs for both myostatin and dystrophin using B-PMO as 
well as Vivo-PMO conjugations were administered intramuscularly.  
   
 
 
 
 
 
 
       AO (10µg each)  Myostatin 
Skipping (%) 
Dystrophin 
Skipping (%) 
p value for weight change 
      B-PMO-Myostatin                        
33.0±9.1 
      ----   0.03 (increase in weight) 
     B-PMO-Dystrophin    ----                    
56.0±14.4 
                  ns 
     B-PMO-Myo/Dys                  
40.0±6.0 
                
65.0±11.3 
  0.006 (increase in weight) 
   Vivo-PMO-Myostatin                  
46.9±28.3 
     ----                   ns 
  Vivo-PMO-Dystrophin    ----                 
37.4±7.2 
  0.009 (decrease in weight) 
  Vivo-PMO-Myo/Dys                  
66.4±35.2 
                
30.6±3.5 
  0.002 (decrease in weight) 
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5.3.8. Dystrophin expression restoration in mdx muscles following intramuscular 
Vivo-PMO injections 
10µm transverse TA sections were stained with fluorescent dystrophin antibody 
and mounted in medium for fluorescence with DAPI. Restoration of dystrophin 
expression was evident from immunofluorescence detection of dystrophin on transverse 
TA sections as shown in Figure 5.11. 
5.3.9. Effect of Vivo-PMO induced myostatin and dystrophin dual exon skipping 
on size distribution of muscle fibres in mdx mice 
TA muscles of different treatment groups were cryosectioned and 10µm sections 
were stained with laminin antibody. Fibre cross sectional area was calculated using 
SigmaScan Pro5 software and chi squared analysis was performed on the data. There 
was no significant change in the fibre CSA with either of the treatment (trends of fibre 
CSA change shown in Figure 5.12), p (Vivo-PMO-Dys vs. Saline) >0.2; p (Vivo-PMO-
Myo vs. Saline) >0.90; p [Vivo-PMO-(Dys+Myo) vs. Saline] >0.90. 
5.3.10. Histological analysis of Vivo-PMO-treated mdx muscles  
 Standard H&E (haematoxylin and eosin) staining was performed on transverse 
10µm sections of the muscles using a cryostat. There was no noticeable muscle damage 
caused by the treatment with either of the Vivo-PMO compared to untreated mdx mice 
(Figure 5.13). 
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Figure 5.11 
 
Figure 5.11: Immunohistochemical detection of dystrophin in TA sections of Vivo-PMO-
treated mdx mice. Detection of dystrophin by immunohistochemical staining (red) in TA of the 
mdx mice treated with Vivo-PMO-Dys and a cocktail of Vivo-PMO-(Dys+Myo) is shown. Mdx 
mice treated with Vivo-PMO-Myo and the ones treated with normal saline are the negative 
controls. Dystrophin-positive fibres seen in the negative controls correspond to the revertant 
fibres. Magnification bar represents 500µm. 
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Figure 5.12: Fibre diameter distribution in mdx TA muscles following different Vivo-PMO 
treatments. The TA muscles of mdx mice were treated with 10µg of Vivo-PMO-Myo; Vivo-
PMO-Dys; a cocktail of Vivo-PMO-Dys and Vivo-PMO-Myo (total 20µg); Controls were 
treated with same volume of saline and mice were sacrificed eight weeks post-injections. TA 
muscles were sectioned and immunostained with laminin and fibre size distribution was 
calculated using SigmaScan Pro 5 software. In the top panel, green bars represent TA muscles 
treated with Vivo-PMO-Myo and blue bars represent TA muscles treated with normal saline; in 
the middle panel, red bars represent TA muscles treated with Vivo-PMO-Dys and blue bars 
represent TA muscles treated with normal saline; in the bottom panel, yellow bars represent TA 
muscles treated with a cocktail of Vivo-PMO-(Dys+Myo) and the blue bars represent TA 
muscles treated with normal saline. For change in fibre CSA distribution, p (Vivo-PMO-
dystrophin vs. Saline) > 0.2; p (Vivo-PMO-Myo vs. Saline) > 0.9; p [Vivo-PMO-(Dys+Myo) 
vs. Saline] > 0.9. 
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Figure 5.12 
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Figure 5.13: Histological staining of TA muscle of mdx mice treated with different Vivo-
PMOs. Haematoxylin and eosin staining of  TA muscle cross sections from mdx mice injected 
with 10µg Vivo-PMO-Dys, 10µg Vivo-PMO-Myo; a cocktail of Vivo-PMO-(Dys+Myo)- total 
of 20 µg. Animals were sacrificed after two months and their TAs were cut into 10µm 
transverse sections using a cryostat; n=6; representative pictures are shown. Magnification bar 
represents 500µm. 
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Figure 5.13 
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5.4. Discussion 
AO-mediated dystrophin exon skipping is potentially a very promising approach 
for correcting the underlying gene defect in DMD patients but it does not particularly 
aim at improvement in muscle regeneration and decreasing the level of fibrosis. In order 
to have an overall enhancement in the muscle development and function it is important 
to look at a combined therapy that along with restoring the expression of mutated gene, 
also addresses the issue of muscle loss. Therefore, in this study the aim was to 
investigate the potential of a combined approach of inhibiting the expression of 
myostatin, which is a negative regulator of muscle mass and at the same time reframing 
the dystrophin transcripts using antisense reagents.  
A commonly used dystrophin AO sequence targeting exon 23 along with our 
myostatin exon 2 AO sequence linked to two different conjugations namely Vivo-PMO 
and B-PMO were used for the study in six weeks old mdx mice. Intramuscular B-PMO 
treatment targeted against myostatin alone resulted in a significant increase in muscle 
weight whereas B-PMO-dystrophin did not result in any significant change in muscle 
weight. A combination of both the AOs also resulted in an increase in muscle weight 
confirming the synergistic effect of both individual AOs. This has not been reported 
before although a 2‟OMePS AO study has been conducted that showed induction of 
dual exon skipping of myostatin as well as dystrophin in mdx mice (Kemaladewi et al., 
2011) but there was no change in muscle weights. The studies reported in this chapter 
confirmed the previous results (Kemaladewi et al., 2011) that myostatin and dystrophin 
AOs can be used simultaneously to induce exon skipping of pre-mRNAs of both the 
genes without any possible interference with each other. It was observed that B-PMO-
Myo administration on its own induced exon skipping however when a combination of 
B-PMO-(Dys+Myo) was administered the level of myostatin exon skipping was higher 
as estimated by densitometric analysis. Similarly, dystrophin skipping level was 
enhanced when a cocktail of B-PMO-(Dys+Myo) was injected compared to B-PMO-
Dys alone. An enhanced effect of a combination treatment of myostatin inhibition and 
dystrophin expression restoration on absolute and specific muscle maximal force 
compared to each treatment alone has been shown in a U7-DYS/shAcRIIb study to 
inhibit AcRIIb and skip dystrophin exon 23 (Dumonceaux et al., 2010). These results 
suggest that myostatin inhibition and reframing dystrophin transcripts simultaneously 
could be crucial to have a better effect in terms of muscle weight and strength.  
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TA fibre diameter of the treated and control muscles was estimated to determine 
any change in the cross sectional area distribution of individual fibres of the tissue but 
there was no significant change with either of the treatment. Histological staining was 
performed on the tissue sections to see if there was any damage caused by the B-PMO 
treatment but it was observed that either of the treatment did not seemed to cause 
necrosis or infiltration of immune cells that could lead to inflammation. The treated 
tissue sections appeared normal thereby negating the possibility of inflamed muscles 
causing an increase in the weight. Dystrophin expression was checked by dystrophin 
immunostaining and dystrophin restoration was observed in case of B-PMO-Dys alone 
as well as in B-PMO-(Dys+Myo) cocktail.  Overall, the increase in muscle weight and 
level of exon skipping seems to be more enhanced when the mRNA transcripts of both 
the genes are skipped simultaneously which could be due to restoration of fibre integrity 
resulting in protection from fibre damage.  
A study for Vivo-PMO along the same lines as mentioned above was carried out 
for B-PMO. Six weeks old mdx mice were treated intramuscularly in the TA with a 
single 10µg injection of either Vivo-PMO-Myo alone or Vivo-PMO-Dys alone or with 
a cocktail of Vivo-PMO-(Myo+Dys) for eight weeks. Although an increased level of 
myostatin skipping induction was observed with the combined treatment of Vivo-PMO-
(Dys+Myo) compared to Vivo-PMO-Myo alone, the percentage of dystrophin skipping 
with Vivo-PMO-(Dys+Myo) was found to be less than that observed with Vivo-PMO-
Dys alone (Table 4). Contrary to the previous studies in wild type mice, Vivo-PMO 
alone did not lead to any increase in the muscle weight compared to the controls. 
However, a significant decrease in muscle weight was observed with the treatment of 
Vivo-PMO-Dys alone (p=0.009) and also with the Vivo-PMO cocktail (Myo+Dys) 
(p=0.002). This could be accounted for by the stabilization of muscle integrity because 
of a decrease in constant cycles of cell necrosis and renewal thereby, reversing the 
typical phenotype of „pseudohypertrophy‟ in mdx muscles. As it has been shown in 
whippet dog breed, that dogs with one copy of two-base pair deletion in myostatin exon 
3 are more muscular and faster than wild type as well as the ones with two copies of 
deletions, incomplete maintenance of the pathway could actually be more useful 
(Mosher et al., 2007).  
The analysis of fibre cross sectional area did not show any significant change 
despite a significant decrease in the weights of TAs treated with Vivo-PMO-Dys and 
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Vivo-PMO-(Dys+Myo). Therefore, the data on increase in muscle weight and its 
proportionality to hypertrophy following myostatin exon skipping treatment as observed 
in these intramuscular studies is not entirely consistent. It is likely that there are changes 
in the fibre diameter distribution of the treated muscles over the entire range of CSA 
values considered but it is distributed in such a way that it is well dispersed across the 
whole range of values that a significant change in any specific region is not observed. 
Increasing the number of animals used in future studies could possibly enhance the 
chances of producing a clearer and more precise trend of effects of myostatin exon 
skipping on muscle fibre CSA. Perhaps studies to determine the effect of myostatin 
exon skipping on muscle strength need to be done. The combined approach to 
downregulate the expression of myostatin receptor AcRIIb using sh-RNA and 
restoration of quasi-dystrophin using a vectorized U7 exon skipping (U7-DYS) showed 
that although no significant increase in muscle hypertrophy was observed with down 
regulation of AcRIIb although resulting in myostatin inhibition, a significantly 
enhanced muscle maximal strength was observed with the both the treatments together 
(Dumonceaux et al., 2010).  
 H&E staining did not show any damage to the treated muscle compared to the 
control mdx muscles and dystrophin expression restoration was observed with Vivo-
PMO-Dys as well as Vivo-PMO-(Dys+Myo) treatments by dystrophin 
immunohistological staining. Therefore, in order to have a better understanding of how 
a combination of myostatin inhibition and dystrophin expression restoration affects the 
strength, force and its functional properties, contractile properties of the muscle need to 
be analyzed. Thus from these studies so far, myostatin exon skipping does show a great 
potential to be a part of a combination therapy alongside dystrophin expression 
restoration. The next step from here would be to try different conjugation systems and 
carry on systemic studies to deliver the AOs to the entire body so that all the tissues can 
be treated. At the same time, it is very crucial to do some analysis of contractile 
properties of the muscle in order to understand how the treatment affects the absolute 
and specific muscle force as this will give important information for the studies to 
follow regarding different dosing regimens as well as routes of administration for a 
combined treatment with myostatin and dystrophin AOs. 
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CHAPTER 6 
GENERAL DISCUSSION AND FUTURE WORK 
Apart from being a characteristic feature of muscular disorders, skeletal muscle 
wasting also goes together with ageing-related immobility and cachexia resulting in 
fatal conditions like kidney failure and cardiac arrest. Therefore, treating the main 
causative agent of the muscular disorder along with the enhancement of muscle 
development could form a potent strategy to counter various muscle wasting conditions 
including Duchenne muscular dystrophy. It has been well established that myostatin is a 
negative regulator of skeletal muscle mass (Carnac et al., 2006) and several approaches 
have been used to knock down this factor to induce an increase in skeletal muscle 
growth (Patel & Amthor, 2005). This could have important implications in disease 
conditions including cancer and HIV/AIDS which are accompanied by tremendous 
muscle mass loss. Sarcopenia, muscle atrophy, obesity-related metabolic disorders and 
insulin resistance can also be ameliorated by inducing myostatin inhibition. In context 
of Duchenne muscular dystrophy, although dystrophin restoration can be achieved using 
different approaches including over-expression of mini/microdystrophin and dystrophin 
exon skipping, it is likely to be less effective if the disease has already progressed to a 
state where there is tremendous muscle wasting and damage.  
As myostatin has conserved function in humans there are immense expectations 
that muscle regeneration resulting from myostatin inhibition in animal models can be 
reproduced in humans. Inhibition of intracellular signal transduction, blockade of 
extracellular activity of myostatin and decrease in signalling of myostatin are various 
strategies that can be explored for inhibiting myostatin expression. Myostatin 
neutralizing antibody was prepared by immunizing myostatin-null mice with 
recombinant myostatin and its treatment resulted in improved muscle mass and function 
in pre-clinical studies (Enzmann et al., 2003). Monoclonal neutralizing antibody to 
myostatin, MYO-029 was studied in a clinical trial which showed good safety but no 
improvement in muscle function of strength (Wagner et al., 2008). A modified 
myostatin propeptide that is resistant to proteolytic cleavage has been shown to bind 
myostatin and inhibit its signal transduction that resulted in increase in skeletal muscle 
mass of adult mice (Wolfman et al., 2003). Although follistatin, a secreted glycoprotein 
binds very strongly to myostatin, its inhibitory effects are not specific to myostatin 
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suggesting that it inhibits other TGF-β family members as well during muscle growth 
(Lee & McPherron, 2001). Myostatin inhibition by ACE-031, soluble form of activin 
receptor type IIB (AcRIIB) showed a significant increase in muscle mass independent 
of fibre type (Cadena et al., 2010). A clinical trial to assess the safety profile of ACE-
031 and for dose optimization was initiated in 2010 but was terminated in 2011 due to 
minor nosebleeds, gum bleeding and/or slightly dilated blood vessels in the skin of the 
patients under trial. All these issues were completely resolved on discontinuation of the 
treatment. Another trial by the same companies, Acceleron and Shire has been 
suspended and will start under extra safety monitoring to ensure patient safety in near 
future (http://www.muscular-dystrophy.org/research/news/3862).  
The use of AOs to induce exon skipping and thereby downregulate the 
expression of myostatin presents several advantages over the other currently used gene 
therapy approaches. Firstly, there is no risk of uncontrolled insertion into the genome 
with AOs as in case of virus-mediated approaches (Amantana & Iversen, 2005). 
Moreover, with an appropriate dosing regimen, exon skipping levels can be regulated 
and, if necessary the treatment can be interrupted. Importantly AOs have not been 
reported to produce any toxic effects or immune response so far in animal models as 
well as when used in clinical application (Arora et al., 2004).  
In this study it is shown that AOs of 2‟OMePS chemistry, designed using three 
bioinformatics algorithms (ESE Finder, PESX and Rescue ESE) resulted in a substantial 
level of myostatin exon 2 skipping in vitro. These bioinformatics programs have been 
successfully used in previous studies to design AOs for dystrophin exon skipping 
studies (Arechavala-Gomeza et al., 2007; Popplewell et al., 2009). The truncated 
transcript can be expected to undergo nonsense mediated decay but we observed a well 
defined skipped band that was sequenced and found to be of the right size. Although the 
shortened transcript is possibly stable but due to the lack of entire mature domain and a 
substantial segment of propeptide domain resultant of a premature stop codon, 
downstream signalling will eventually abolish. Myostatin being an inhibitor of 
myogenic differentiation controls the proliferation of myoblasts (Langley et al., 2002b). 
Therefore, myostatin down regulation is expected to increase the cell proliferation. The 
AOs designed were biologically active and induced an increase in C2C12 cell 
proliferation. The efficacy of knock down by exon skipping in vivo has proved to be 
more challenging to establish than in vitro. The efficiency of myostatin skipping was 
172 
 
verified by injecting 2‟OMePS intramuscularly, however, a significant change in 
muscle mass was not observed. Therefore it was necessary to carry out a time course 
analysis using single intramuscular administration of AO in wild type mice in order to 
have a clear time line that is needed to see an evident effect in the muscle weight. It was 
also important to estimate how long is the AO capable of inducing efficient exon 
skipping following single treatment of a specific dose. PMO chemistry was chosen for 
this experiment due to its better stability compared to the 2‟OMePS and also because 
PMOs have been reported to have a longer effect in vivo (Iversen, 2001). This is 
particularly important for knocking down proteins with a very fast turnover like 
myostatin. The PMO sequence used for this study induced the most efficient skipping in 
vitro. It also maps in a region totally conserved between mouse and human myostatin 
paving the way to test the same PMO for clinical applications in humans.  
In order to achieve a reasonable effect in undamaged muscles, a PMO 
conjugated to a delivery moiety has to be used (Morcos et al., 2008). Vivo-PMO is 
commercially available and has been reported to be effective in normal healthy mice 
(Wu et al., 2009). After four weeks of single treatment of Vivo-PMO-D in wild type 
mice, a significant increase in TA weight was observed and the effect was further 
evident after eight weeks as well. No histological signs of any damage to the tissue was 
observed neither was there any indication of general illness in the Vivo-PMO-treated 
mice during the experiment. Keeping this time frame in mind, a comparative study was 
done to see how efficiently a PMO targeted at myostatin is delivered when conjugated 
to delivery moieties like octaguanidine dendrimer (Vivo-PMO) and B-peptide (B-PMO) 
compared to a naked unconjugated PMO. As expected, a single intramuscular treatment 
of 10µg Vivo-PMO-D as well as B-PMO-D resulted in efficient skipping and a 
significant increase in TA muscle weight after four weeks and eight weeks whereas, 
unconjugated PMO did not lead to any significant change in TA weight.  
Having tested the efficiency of these PMO conjugates, the aim of the study was 
to use these conjugation systems to target biologically active myostatin supplied to the 
injected muscle by the bloodstream. Moreover, in a hypothetical clinical approach, the 
whole body needs to be treated. Therefore, the next experiment was to administer wild 
type mice with AOs by systemic tail vein injections. By injecting Vivo-PMO-D, a 
significant increase in muscle size and the change of CSA fibre distribution has been 
obtained, but only in the soleus muscle. This was probably due to the lack of porosity of 
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vessels and fibres in the normal healthy mice used in this experiment. Also, the 
differential response in EDL and Soleus may be due in part to a greater amount of 
ActRIIb being expressed on the surface of EDL muscle, or because the intrinsic level of 
myostatin is greater in fast (myosin type IIb positive) myofibres (Foster et al., 2009; 
Matsakas et al., 2009). Alternatively, it can be speculated that the dosing regimen used 
which has been reported to be optimal for Vivo-PMO for exon skipping of dystrophin 
gene (Wu et al., 2009), does not achieve sufficient skipping of myostatin gene. In the 
case of dystrophin skipping, the half life of dystrophin protein and mRNA is extremely 
long and therefore relatively smaller dosage of AO gives more sustained exon skipping 
(Ghahramani Seno et al., 2008). However, in myostatin skipping, it is perhaps likely 
that more frequent re-dosing is required, to have a more sustained presence of AOs. 
This may explain the transient and weak effect in terms of whole body weight change 
observed in vivo. Differential effect seen if soleus and EDL is in compliance with some 
previously published data showing that soleus is the most affected muscle following a 
systemic approach to knock down myostatin (Foster et al., 2009).  
As discussed before in the case of DMD, along with dystrophin expression 
restoration, myostatin inhibition is equally important to take care of any muscle wasting 
and fibrosis that has already taken place. A study involving the use of U7-DYS/sh 
AcRIIb constructs to restore dystrophin expression as well as to inhibit myostatin 
receptor Activin receptor IIb (AcRIIb) simultaneously showed that downregulation of 
AcRIIb on its own was not sufficient to improve muscle strength of treated TA. Mdx 
mice were injected into their TAs with AAV vector carrying U7-DYS construct alone, 
shAcRIIb construct alone or the combination construct, U7-DYS/shAcRIIb. The 
controls were injected with either PBS or vector harbouring control sh-RNA. Animals 
were sacrificed after three months and the TA muscles were harvested and weighed 
followed by dystrophin expression analysis. The combined U7-DYS/shAcRIIb 
treatments led to a significant improvement in absolute and specific maximal muscle 
strength that was better than U7-DYS treatment on its own (Dumonceaux et al., 2010). 
Another double strategy combining the dystrophin restoration and myostatin inhibition 
by exon skipping has been reported. 5-6 weeks old mdx mice (n=6) were injected into 
the gastrocnemius muscle with cocktails of 2‟OMePS AOs (40µg each) for myostatin 
exon 2 and dystrophin exon 23 for four consecutive days with 48 hours resting time 
between second and third injection. The mice were sacrificed after 6 hours, one day and 
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two days of last injection (Kemaladewi et al., 2011). Using 2‟OMePS AOs for skipping 
dystrophin exon 23 and myostatin exon 2 concurrently, this study showed feasibility of 
inducing exon skipping using AOs for two different transcripts without any possible 
interference but the skipping levels were not quite high. 
As a next step, the efficacy of simultaneous myostatin and dystrophin exon 
skipping induced by respective PMO sequences conjugated both as B-PMO as well as 
Vivo-PMO in mice with dystrophic pathology was studied. Single 10µg intramuscular 
B-PMO-myostatin administration to the mdx mice resulted in a significant increase in 
TA weight compared to control muscles as expected but when the same dose of B-
PMO-dystrophin was administered, there was no significant change in the weights of 
the treated muscles. A combined B-PMO-myostatin/dystrophin treatment resulted in a 
significant increase in muscle weight and exon skipping was demonstrated by nested 
RT-PCR. It is likely that a higher dose of B-PMO-dystrophin is required to see a 
prominent effect. In the case of Vivo-PMO treatment, a significant decrease in the 
weight of TA muscle with Vivo-PMO-dystrophin treatment on its own was observed, 
whereas Vivo-PMO-myostatin did not cause any significant change in muscle weight. 
Vivo-PMO-myostatin/dystrophin treatment led to a significant decrease in muscle 
weight. The decrease in the muscle weight following Vivo-PMO-dystrophin can be 
described due to stoppage of degeneration/regeneration cycles in dystrophic muscle as a 
result of dystrophin restoration. As only a minimum standard dose was used, there is a 
likelihood of getting more pronounced effect in terms of change in muscle weight and 
dystrophin expression restoration if repeated injections are administered via systemic 
route for myostatin as well as dystrophin exon skipping together.  
Future work needs to involve comparative studies of different systemic delivery 
routes. Direct evaluation of intravenous and intraperitoneal routes in mdx mice will be 
highly important in order to determine which method is more effective in better 
distribution of the AOs to the target tissues and therefore in inducing beneficial exon 
skipping.  An optimal dosing regimen for myostatin exon skipping still needs to be 
determined. In one of our studies, five weekly intravenous injections of 6mg/Kg of body 
weight did not induce enough exon skipping in all the muscles of wild type mice except 
soleus but the weak effect could be due to intact healthy muscles of these animals 
compared to dystrophic animals. Consequently, a comparison of fortnightly and 
monthly dosing regimen needs to be studied over a longer time course. As it is clear 
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from the time course analysis in this study that once injected locally into the TAs of a 
wild type mice, PMO conjugated to octaguanidine dendrimer exhibited exon skipping 
until eight weeks. Therefore it may not be necessary to repeat the treatment as often as 
every week. Also in context of dystrophin/myostatin combination exon skipping 
approach, electrophysiological analyses would give an insight into how the muscle 
strength is affected by either myostatin skipping alone or dystrophin skipping alone or 
simultaneous dystrophin/myostatin skipping as it has been shown that dystrophin 
expression restoration and myostatin inhibition induced simultaneously have a better 
effect on improvement of maximal muscle strength (Dumonceaux et al., 2010). Serum 
creatine kinase levels of mdx mice treated with PMO for dystrophin exon 23 skipping 
with seven intravenous treatments were reported to drop significantly compared to the 
controls (Alter et al., 2006). Systemic studies to induce simultaneous 
dystrophin/myostatin exon skipping therefore need to be followed by an estimation of 
serum creatine kinase levels and examination of any immune response developed to the 
newly expressed dystrophin in treated and control mdx mice. Analysis of different 
markers from the serum including urea, alkaline phosphatase and aspartate transaminase 
can help to assess the toxicity level of the AOs used and is very important in a pre-
clinical or clinical set up (Khajavi et al., 2005).  
A series of western blots were attempted during the course of this study to 
determine any changes in myostatin protein expression following AO-treatment using 
various antibodies but with no success. Rabbit anti-myostatin (GDF-8) polyclonal 
antibody (AB3139) by Chemicon International inc., rabbit anti-gdf8 polyclonal 
antibody by Bethyl laboratories (A300-401A) and a self-prepared monoclonal myostatin 
antibody from Markus Scheulke‟s lab in Berlin, were tested at different dilutions. 
Protein was extracted from cells and also conditioned media from cell culture were 
harvested for myostatin protein detection. The conditioned media were also 
concentrated using centrifugal filter units (Centricon® by Millipore) and conventional 
TCA (Trichloroacetic acid) method but still none of the antibodies showed a protein 
band for myostatin in the western blotting experiments. As a future study, a well-
optimized qPCR study to quantify not only myostatin expression but also Smad2, 
Smad3, Smad7, myogenin, myoD etc following myostatin AO-treatment would give 
another very interesting insight into the modulation of signalling pathway resulting from 
myostatin inhibition.  
176 
 
This study represent a proof of principle that myostatin can be down regulated 
by skipping an exon from the transcript using antisense oligonucleotides. In case of 
DMD, development of an optimal strategy to counter muscle wasting requires 
correcting the genetic defect combined with enhanced muscle regeneration. 
Applications of dual myostatin/dystrophin exon skipping will depend upon further 
optimizations and investigations including different delivery routes, dosing regimens 
and electrophysiological studies to ensure effective in vivo knock down of myostatin 
expression and restoration of dystrophin expression for maximal therapeutic benefit. 
This work has the potential to be developed into part of an efficient treatment for age- 
and disease-related muscle wasting and various neuromuscular disorders including 
muscular dystrophies. 
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